<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">1765</journal-id><journal-id journal-id-type="pmc-domain">hvi</journal-id><journal-title-group><journal-title>Human Vaccines &amp; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10913723</article-id><article-id pub-id-type="pmcid-ver">PMC10913723.1</article-id><article-id pub-id-type="pmcaid">10913723</article-id><article-id pub-id-type="pmcaiid">10913723</article-id><article-id pub-id-type="pmid">39693178</article-id><article-id pub-id-type="doi">10.1080/21645515.2024.2317439</article-id><article-id pub-id-type="publisher-id">2317439</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors</article-title><alt-title alt-title-type="left-running-head">M. JUNG ET AL.</alt-title><alt-title alt-title-type="right-running-head">HUMAN VACCINES &amp; IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8124-8945</contrib-id><name name-style="western"><surname>Jung</surname><given-names initials="M">Myunghwan</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hongmin</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choi</surname><given-names initials="E">Eunsol</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1782-5351</contrib-id><name name-style="western"><surname>Shin</surname><given-names initials="MK">Min-Kyoung</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0854-4582</contrib-id><name name-style="western"><surname>Shin</surname><given-names initials="SJ">Sung Jae</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0002" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label>Department of Microbiology, Institute of Medical Science, Department of Convergence Medical Science, BK21 Center for Human Resource Development in the Bio-Health Industry, <institution-wrap><institution>Gyeongsang National University College of Medicine</institution></institution-wrap>, <city>Jinju</city>, <country>South Korea</country></aff><aff id="aff0002"><label>b</label>Department of Microbiology, Institute for Immunology and Immunological Diseases, Graduate School of Medical Science, Brain Korea 21 Project, <institution-wrap><institution>Yonsei University College of Medicine</institution></institution-wrap>, <city>Seoul</city>, <country>South Korea</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Min-Kyoung Shin <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:mkshin@gnu.ac.kr">mkshin@gnu.ac.kr</email> Department of Microbiology, Institute of Medical Science, Department of Convergence Medical Science, BK21 Center for Human Resource Development in the Bio-Health Industry, <institution-wrap><institution>Gyeongsang National University College of Medicine</institution></institution-wrap>, <city>Jinju</city><postal-code>52727</postal-code><country>South Korea</country>.</corresp><corresp id="an0002">Sung Jae Shin <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:sjshin@yuhs.ac">sjshin@yuhs.ac</email> Department of Microbiology, Institute for Immunology and Immunological Diseases, Graduate School of Medical Science, Brain Korea 21 Project, <institution-wrap><institution>Yonsei University College of Medicine</institution></institution-wrap>, <city>Seoul</city><postal-code>03722</postal-code><country>South Korea</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>4</day><month>3</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><volume>20</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">452148</issue-id><elocation-id seq="86">2317439</elocation-id><pub-history><event event-type="pmc-release"><date><day>04</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>05</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-20 12:25:25.727"><day>20</day><month>12</month><year>2024</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>28</day><month>2</month><year>2024</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>28</day><month>2</month><year>2024</year></date></event><event event-type="received"><date><day>31</day><month>10</month><year>2023</year></date></event><event event-type="revised"><date><day>24</day><month>1</month><year>2024</year></date></event><event event-type="accepted"><date><day>07</day><month>2</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KHVI_20_2317439.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KHVI_20_2317439.pdf"/><abstract><title>ABSTRACT</title><p>Vaccines are an effective way to prevent the emergence and spread of antibiotic resistance by preventing diseases and establishing herd immunity. However, the reduced effectiveness of vaccines in the elderly due to immunosenescence is one of the significant contributors to the increasing antibiotic resistance. To counteract this decline and enhance vaccine effectiveness in the elderly, adjuvants play a pivotal role. Adjuvants are designed to augment the effectiveness of vaccines by activating the innate immune system, particularly through pattern recognition receptors on antigen-presenting cells. To improve vaccine effectiveness in the elderly using adjuvants, it is imperative to select the appropriate adjuvants based on an understanding of immunosenescence and the mechanisms of adjuvant functions. This review demonstrates the phenomenon of immunosenescence and explores various types of adjuvants, including their mechanisms and their potential in improving vaccine effectiveness for the elderly, thereby contributing to developing more effective vaccines for this vulnerable demographic.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Vaccines</kwd><kwd>adjuvants</kwd><kwd>elderly</kwd><kwd>effectiveness</kwd><kwd>pattern recognition receptors</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Gyeongsang National University Fund for Professors on Sabbatical Leave</institution></institution-wrap></funding-source><award-id>2023</award-id></award-group><award-group><funding-source><institution-wrap><institution>Korean Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare</institution></institution-wrap></funding-source><award-id>HV22C0079 and HV23C0090</award-id></award-group><funding-statement>The work was supported by the&#160;Gyeongsang National University Fund for Professors on Sabbatical Leave [2023]; Korean Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare [HV22C0079 and HV23C0090]; Ministry of Food and Drug Safety in 2022 [22202MFDS173].</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="2"/><ref-count count="289"/><page-count count="1"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><sec disp-level="2" id="s0001-s2001"><title>Antibiotic resistance and its burden</title><p>The &#8216;2019 Antibiotic Resistance Threats Report&#8217; from the Centers for Disease Control and Prevention of the USA reported that in 2019 alone, at least 1.27 million people worldwide were killed by Superbugs infections. In the USA, there were more than 2.8 million Superbug infections, killing more than 35,000 people in 2019. &#8220;Superbugs&#8221; refer to bacteria that are resistant to antibiotics.<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup> The UK government has also predicted that if antibiotic-resistant bacteria are not controlled, 10 million people could be killed annually by antibiotic-resistant bacteria, resulting in an associated economic loss of US$100 trillion by 2050.<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup> According to the World Health Organization (WHO)&#8217;s priority list of antibiotics resistant bacteria, it is mainly Gram-negative bacteria such as carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> and carbapenem-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>, but Gram-positive bacteria such as vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic>, methicillin-resistant, and vancomycin resistant <italic toggle="yes">Staphylococcus aureus</italic> is also causing problems.<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup> Antibiotic resistance evolution has been primarily attributed to the overuse of antibiotics, and it can be easily transferred to other bacteria, thereby threatening global public health.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref></sup> In addressing antibiotic resistance, the urgent development of new antibiotics is necessary; however, it is a challenging task. Specifically, the speed at which antibiotic resistance emerges and disseminates surpasses the pace at which new antibiotics are developed.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> This implies that diverse strategies must be explored to effectively prevent the occurrence and transmission of antibiotic resistance.</p></sec><sec disp-level="2" id="s0001-s2002"><title>Vaccines as potential arms against antibiotic resistance</title><p>Vaccines play a pivotal role in preventing the emergence of antibiotic resistance and curbing its transmission.<sup><xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref></sup> Vaccination can prevent specific bacterial infections, thereby reducing the need for antibiotics in infection treatment.<sup><xref rid="cit0009" ref-type="bibr">9&#8211;11</xref></sup> Beyond bacterial infections, virus vaccines can prevent viral infections, consequently lessening the need for antibiotics in both the prevention and treatment of secondary bacterial infections.<sup><xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0008" ref-type="bibr">8</xref></sup> Additionally, vaccines exert an indirect influence by diminishing resistant infections in unvaccinated populations through the establishment of herd immunity.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Furthermore, vaccines offer long-term protective immunity without inducing resistance, thereby reducing reliance on antibiotics.<sup><xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref></sup> All these contributions of vaccines against antibiotic resistance are documented in the WHO-led value attribution framework.<sup><xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0016" ref-type="bibr">16</xref></sup></p></sec><sec disp-level="2" id="s0001-s2003"><title>Low vaccine effectiveness by immunosenescence in the elderly</title><p>With the increase in life expectancy, there has been a significant rise in the proportion of the elderly population. High-income countries are experiencing a rapid aging of the population, and it is expected that between 2015 and 2050, the global population over 60&#8201;y old will nearly double from 12% to 22%.<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> This demographic shift has negative implications for both public health and antibiotic resistance, particularly considering the diminished effectiveness of vaccines in the elderly.<sup><xref rid="cit0018" ref-type="bibr">18&#8211;22</xref></sup> In a study led by Kim C. et al., vaccination was found to be effective in reducing the burden of antibiotic resistance in infections caused by <italic toggle="yes">Mycobacterium tuberculosis</italic> (Mtb), <italic toggle="yes">Streptococcus pneumoniae</italic>, and <italic toggle="yes">Haemophilus influenzae</italic> type B (Hib). Notably, they demonstrated that the reduced effectiveness of vaccines in the elderly contributes to a lesser alleviation of the burden of antibiotic resistance through vaccination in this demographic.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> The compromised vaccine effectiveness in the elderly is associated with an increase in antibiotic use.<sup><xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0024" ref-type="bibr">24</xref></sup> For instance, tuberculosis, caused by Mtb, demands extensive antibiotic use for treatment.<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> Tuberculosis treatment necessitates continuous administration of antibiotics, significantly elevating the risk of antibiotic resistance and its potential spread.<sup><xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0026" ref-type="bibr">26</xref></sup> While vaccination has the potential to mitigate the need for antibiotics in treating tuberculosis, the currently approved tuberculosis vaccine (Bacille Calmette-Guerin, BCG) only exhibits a preventive effect in childhood, not in the elderly.<sup><xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0027" ref-type="bibr">27</xref></sup> To address the excessive use of antibiotics in the elderly due to tuberculosis,<sup><xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0028" ref-type="bibr">28</xref></sup> strategies to enhance the effectiveness of the tuberculosis vaccine in this demographic must be explored.<sup><xref rid="cit0026" ref-type="bibr">26&#8211;29</xref></sup> Moreover, many studies have also reported a decrease in viral vaccine effectiveness in the elderly, such as vaccines for SARS-CoV-2 and influenza, which contribute to a high risk of antibiotic resistance by compelling antibiotic use for the prevention and treatment of secondary bacterial infections.<sup><xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0026" ref-type="bibr">26</xref></sup></p><p>The decline in vaccine effectiveness in the elderly is attributed to immunosenescence &#8211; a phenomenon characterized by a diminished immune response, typically observed in individuals over 60&#8201;y of age.<sup><xref rid="cit0019" ref-type="bibr">19&#8211;22</xref></sup> Immunosenescence induces an ineffective immune response to new antigens, reducing the effectiveness of vaccines. The utilization of adjuvants is considered the most effective approach to enhance vaccine effectiveness in the elderly population.<sup><xref rid="cit0022" ref-type="bibr">22&#8211;30</xref>&#8211;<xref rid="cit0032" ref-type="bibr">32</xref></sup> Therefore, extensive research is underway on adjuvants as a strategy to overcome immunosenescence in the elderly and enhance vaccine effectiveness.<sup><xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0032" ref-type="bibr">32</xref></sup></p></sec><sec disp-level="2" id="s0001-s2004"><title>Scopes and aims</title><p>This review addresses the phenomenon of immune senescence, which reduces the effectiveness of vaccines in the elderly. Furthermore, we will explore adjuvants that can be integrated into vaccines for the elderly to improve their effectiveness by counteracting immune senescence. While numerous adjuvants are currently under development for various vaccine applications, including those targeting young adults, neonates, and cancer, this review exclusively focuses on adjuvants with the potential to enhance the effectiveness of vaccines for infectious diseases in the elderly population. This review primarily discusses results observed in humans, and findings exclusively from animal experiments were specified by a statement indicating the kind of laboratory animals. A comprehensive understanding of immune aging and the mechanisms by which adjuvants function can form the basis for enhancing the effectiveness of existing vaccines and developing new ones. This endeavor ultimately contributes to preventing the emergence and spread of antibiotic resistance by bolstering the effectiveness of vaccines in the elderly.</p></sec></sec><sec disp-level="1" id="s0002"><title>Immunosenescence</title><p>As life expectancy increases, the proportion of adults over 60&#8201;y old in the population is growing.<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> The elderly population is vulnerable to various diseases, imposing a substantial burden on the healthcare system. Representative infectious diseases in the elderly include seasonal influenza, pneumococcal infection, and the reactivation of the varicella-zoster virus.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> The high susceptibility of the elderly to infectious diseases results in an increased use of antibiotics, posing a significant challenge in preventing the emergence of antibiotic resistance.<sup><xref rid="cit0018" ref-type="bibr">18&#8211;22</xref></sup> Vaccination is an effective way to address this issue. Nonetheless, the effectiveness of vaccines is compromised by immunosenescence in the elderly. Therefore, it is imperative to explore ways to increase the effectiveness of vaccines in the elderly, and to achieve this, an understanding of immunosenescence is crucial.<sup><xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0033" ref-type="bibr">33</xref></sup></p><p>Immunosenescence is characterized by the diminished ability to respond effectively to either new or previously encountered pathogens, due to a range of declines in immune functions associated with aging.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> Immunosenescence is induced by various causes such as alcohol, smoking, pollution, tissue damage, persistent antigen stimulation, cellular senescence, and epigenetic remodeling.<sup><xref rid="cit0034" ref-type="bibr">34&#8211;38</xref></sup> Antigens, introduced via pathogen infection or vaccination, are recognized by the innate immune system, initiating the activation of adaptive immunity through antigen presentation. Following this, memory immunity is established for previously encountered antigens. However, in the elderly, efficient immune responses are hampered by persistently low levels of nonspecific induced inflammatory responses. This phenomenon, called &#8216;inflammaging,&#8217; describes the tendency of aging organisms to experience distinct pro-inflammatory states due to increased levels of pro-inflammatory markers in cells and tissues, and was first introduced by Claudio Franceschi in 2000.<sup><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0040" ref-type="bibr">40</xref></sup> Furthermore, reduced functionality of B and T lymphocytes, and the formation of memory cells with diminished function could hamper efficient immune responses.<sup><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref></sup> This immunosenescence renders individuals more susceptible to infections and diminishes vaccine effectiveness.<sup><xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0043" ref-type="bibr">43</xref></sup> Immunosenescence shares numerous functional and phenotypic features with T cell exhaustion. However, given their independent regulatory mechanisms and distinct developmental signatures, this section addresses only the characteristics of immunosenescence that contribute to reduced vaccine effectiveness.<sup><xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0045" ref-type="bibr">45</xref></sup> Numerous adjuvants employ a strategy targeting professional antigen-presenting cells (APCs), such as dendritic cells (DCs), to enhance vaccine effectiveness.<sup><xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0047" ref-type="bibr">47</xref></sup> In light of this approach, this section provides a description of immunosenescence of human, with a specific focus on DCs, while also addressing the fundamental immunosenescence of T and B cells.</p><sec disp-level="2" id="s0002-s2001"><title>Immunosenescence of innate immunity</title><p>The innate immune system serves as the first line of defense, responding nonspecifically to pathogens or vaccine antigens. Among the various roles of innate immunity, critical functions related to vaccination include the induction and regulation of immune responses through antigen recognition, antigen presentation, and the secretion of various cytokines.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> Representative characteristics of immunosenescence in innate immunity include inflammaging due to chronically elevated levels of pro-inflammatory cytokines, diminished activity of antigen recognition, and decreased ability to prime T cells.<sup><xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0035" ref-type="bibr">35</xref></sup></p><p>Inflammaging is characterized by an antigen-nonspecific inflammatory response, driven by an elevation in pro-inflammatory cytokines such as basal unstimulated levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-&#945; in the elderly.<sup><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0050" ref-type="bibr">50</xref></sup> Importantly, this increase in pro-inflammatory cytokines is not a response to antigens of innate immunity. Instead, it is induced by pro-inflammatory senescence-associated secretory phenotype factors, including IL-1, IL-6, IL-8, IL-13, IL-18, metalloproteinases, miRNAs, ROS, metabolites, and extracellular vesicles. These factors are linked to cell stress caused by chronic infectious diseases and senescence.<sup><xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0051" ref-type="bibr">51</xref></sup> The activities of nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) increases with aging, and this has been reported as one of the causes of inflammaging in humans.<sup><xref rid="cit0052" ref-type="bibr">52</xref></sup> NLRP3 is a type of pattern recognition receptors (PRRs) in the innate immune system that recognizes pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Upon activation, NLRP3 triggers the activation of caspase 1, leading to the release of inflammatory cytokines.<sup><xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0054" ref-type="bibr">54</xref></sup> It has been reported that NLRP3 signals increase with aging in both humans and mice.<sup><xref rid="cit0053" ref-type="bibr">53&#8211;55</xref></sup> Additionally, it has been reported that dysbiosis of the gut microbiome in the elderly has detrimental effects on intestinal permeability and the translocation of bacterial components into the bloodstream, contributing to sustained inflammation.<sup><xref rid="cit0056" ref-type="bibr">56</xref></sup> These alterations in bacterial components in the bloodstream have been confirmed to cause continuous damage to lung tissue, leading to chronic inflammation.<sup><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0057" ref-type="bibr">57</xref></sup> The increased basal level of TNF-&#945; during inflammaging accelerates the differentiation of premature monocytes in the bone marrow. Consequently, immature monocytes secrete more TNF-&#945; upon antigen stimulation.<sup><xref rid="cit0058" ref-type="bibr">58</xref></sup> It is established that the elevated basal TNF-&#945; level in an inflammaging environment suppresses CD28 expression in CD8<sup>+</sup> T cells<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> and diminishes the activity of B cells.<sup><xref rid="cit0060" ref-type="bibr">60</xref></sup> These effects ultimately contribute to a reduction in vaccine effectiveness in the elderly.<sup><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0060" ref-type="bibr">60</xref></sup></p><p>DCs play a crucial role in recognizing antigens and presenting them to the adaptive immune system, thereby initiating T cell immune responses.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> The immunosenescence characteristics of DCs remain a topic of debate.<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> While the total cell number of DCs in older adults generally shows no significant change compared to young adults, studies showed different results concerning the decline in the number of circulating plasmacytoid DCs or myeloid DCs.<sup><xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;66</xref></sup> In addition, DCs isolated from elderly individuals exhibit decreased expression of toll-like receptor (TLR) 1, TLR3, and TLR8, pivotal for cognitive function.<sup><xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0062" ref-type="bibr">62&#8211;65</xref></sup> Consequently, the antigen recognition ability and activation level of DCs are diminished. In contrast, there is no observed change in the expression levels of TLR2 and TLR4 with age.<sup><xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></sup> It has been reported that the expression of TLR7 and TLR9 in DCs is reduced in older adults.<sup><xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0067" ref-type="bibr">67</xref></sup> However, for TLR9, it remains unclear whether the expression levels are decreased or conserved.<sup><xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0067" ref-type="bibr">67</xref></sup> The compromised TLR function leads to a reduction in the production of type I and III interferons (IFN), interleukins (IL-6, IL-10, IL-12), and TNF-&#945; in DCs.<sup><xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0064" ref-type="bibr">64</xref></sup> For instance, in response to vaccination with Fluzone&#174;, an influenza vaccine, DCs from older adults exhibited lower levels of IL-6, IL-12, and TNF-&#945; expression than DCs from young adults, resulting in lower hemagglutination antibody inhibition (HAI) titers.<sup><xref rid="cit0064" ref-type="bibr">64</xref></sup> In addition, a non-human primate study showed that a protein vaccine using TLR7 and TLR8 ligands as adjuvants induces a high frequency of multifunctional T cell responses producing multiple cytokines simultaneously, indicating that DC activation by TLRs is critical for vaccine efficacy.<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup></p><p>DCs isolated from the elderly exhibit reduced responses of co-stimulators (CD80, and CD86) following antigen uptake compared to DCs from young adults.<sup><xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0069" ref-type="bibr">69</xref></sup> Aged DCs also exhibit decreased migratory level to lymph nodes after antigen uptake, leading to an impaired capacity to present antigens to T cell.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0070" ref-type="bibr">70</xref></sup> These reduced antigen presentation functions of DCs results in impaired T cell priming and activation.<sup><xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0063" ref-type="bibr">63</xref></sup> It&#8217;s worth noting that DCs isolated from older individuals tend to induce the development of aberrant effector CD8<sup>+</sup> memory T cells (CD45RA<sup>&#8722;</sup> CCR7<sup>&#8722;</sup>), which differs from the responses induced by DCs from young adults.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> Furthermore, the diminished activation of CD4<sup>+</sup> T cells contributes to reduced levels of T cell-dependent antibody responses, leading to less effective antibody production.<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup> Inflammaging, characterized by pro-inflammatory cytokines that are unrelated to TLR activation by antigens, along with the decreased function of DCs, collectively contribute to the negative impact on immune responses and vaccine hyporesponsiveness in the elderly (<xref rid="f0001" ref-type="fig">Figure 1</xref>).
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Immunosenescence affects various immune cell functions in response to infection or vaccination. Functions that are reduced due to immunosenescence are indicated by red downward arrows, increased functions are represented by red upward arrows, conserved functions are denoted by green circles with a &#8220;C&#8221; inside, and functions with unclear changes are marked by black circles with question marks. Inflammaging, characterized by heightened basal inflammation, leads to decreased activation of immune cells. Specifically, CD28 expression on T cells decreases due to the inflammaging. While many functions of dendritic cells (DCs) decline with immunosenescence, the functions of TLR2 and TLR4 are conserved, and NLRP3 functions are increased. Reduced expression and signaling of TLRs, exposure to chronic inflammation, and decreased co-stimulator expression levels of DCs impact the impaired functions of B and T cells. T cells show reduced functionality due to immunosenescence. Decreased co-stimulator expression on DCs and reduced CD28 expression on T cells result in diminished T cell activation. An increased TCR threshold leads to reduced TCR signaling, and a decreased TCR repertoire contributes to the decline in T cell function. A reduced BCR repertoire and decreased BCR signaling negatively affect antigen recognition and differentiation functions of B cells. In particular, decreased CD40L expression on CD4 T cells and reduced CD40 expression on B cells induce diminished activation of B cells, leading to a reduction in antibody production in response to vaccines. These functional declines in DCs, B, and T cells, result in reduced immune responses, making the elderly more susceptible to infections and diminishing the effectiveness of vaccines. Abbreviations: DCs, dendritic cells; TLR, toll-like receptor; NLRP3, nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 3; TCR, T cell receptor; BCR, B cell receptor.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_2317439_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_2317439_F0001_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="s0002-s2002"><title>Immunosenescence of T cells</title><p>T cells are pivotal components of cellular immunity within the adaptive immune system, primarily categorized into CD4+ and CD8<sup>+</sup> T cells. CD4<sup>+</sup> T cells coordinate immune responses by secreting cytokines, while CD8<sup>+</sup> T cells differentiate into cytotoxic T lymphocytes (CTLs), responsible for eliminating infected cells and producing proinflammatory cytokines in response to infections.<sup><xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></sup> Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells are the main targets for vaccines due to their crucial role in defending against infections.<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup> Consequently, the decline in T cell function observed in the elderly significantly contributes to the reduction in vaccine effectiveness.<sup><xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></sup></p><p>One of the characteristics of immunosenescence of T cells is the loss of surface CD28 expression.<sup><xref rid="cit0076" ref-type="bibr">76</xref>,<xref rid="cit0077" ref-type="bibr">77</xref></sup> As a co-stimulator molecule, CD28-mediated signaling is essential for responses of na&#239;ve T cells; in the absence of this signal, antigen recognition by the T cell receptors (TCRs) is insufficient for T cell activation.<sup><xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></sup> CD8<sup>+</sup>CD28<sup>null</sup> T cells exhibit reduced activity of perforin and granzyme, essential enzymes for CTL function.<sup><xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0078" ref-type="bibr">78</xref></sup> CD4<sup>+</sup>CD28<sup>null</sup> T cells lack the display of CD40L and demonstrate inadequate capacity to promote B cell proliferation and antibody production.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0079" ref-type="bibr">79</xref></sup> The high frequency of the CD8<sup>+</sup>CD28<sup>null</sup> phenotype within the T cell subpopulation isolated from influenza vaccine non-responders, often observed in the elderly, suggests a decline in vaccine effectiveness attributable to the reduction in CD28 expression on T cells.<sup><xref rid="cit0078" ref-type="bibr">78</xref></sup></p><p>Another prominent characteristic of T cell immunosenescence is the reduction in the number of na&#239;ve T cells and an increase in the number of differentiated memory T cells.<sup><xref rid="cit0076" ref-type="bibr">76</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></sup> Hematopoietic stem cells (HSCs) are responsible for generating both T and B cells.<sup><xref rid="cit0081" ref-type="bibr">81</xref></sup> With aging, HSCs exhibit a bias toward the myeloid cell lineage, leading to decreased lymphoid cell generation.<sup><xref rid="cit0081" ref-type="bibr">81</xref></sup> Additionally, the thymus undergoes degeneration (atrophy) as individuals age.<sup><xref rid="cit0082" ref-type="bibr">82</xref></sup> These factors may contribute to the reduction in the number of na&#239;ve T cells. Studies have reported that homeostatic proliferation of CD4<sup>+</sup> T cells is insufficient in the elderly, and CD8<sup>+</sup> T cells experience significant reduction with aging.<sup><xref rid="cit0083" ref-type="bibr">83</xref></sup> On the other hands, despite changes in HSCs, the number of T cell precursors in the bone marrow does not significantly decrease. Furthermore, thymus atrophy is largely completed in adulthood, and the number of na&#239;ve T cells in young adults does not substantially differ from that in adolescence.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;86</xref></sup> These findings suggest that the alteration of HSCs to the myeloid cell lineage and thymus involution may not be the only causes of the decrease in the number of na&#239;ve T cells.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0085" ref-type="bibr">85</xref></sup> Recently, a decrease in the expression of Bim, the proapoptotic molecule, has been identified as a factor contributing to the decline in the number of na&#239;ve T cells. Immunosenescent CD4<sup>+</sup> T cells exhibit reduced Bim expression, extending the longevity of na&#239;ve CD4<sup>+</sup> T cells and leading to the phenomenon known as &#8216;semi-memory.&#8217; This indicates that na&#239;ve CD4<sup>+</sup> T cells have entered the differentiation pathway, resulting in a decrease in the number of na&#239;ve T cells.<sup><xref rid="cit0087" ref-type="bibr">87</xref></sup></p><p>The reduction in the number of naive T cells leads to a decrease in the TCR repertoire.<sup><xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></sup> Healthy adults have been shown to possess 2&#8211;5 times more TCR repertoire compared to aged individuals.<sup><xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0088" ref-type="bibr">88</xref></sup> The aging-induced limited TCR repertoire reduces the variety of TCRs available to recognize and respond to different pathogens. With this limited repertoire, the immune system&#8217;s adaptability to novel threats might weaken, potentially hindering its capacity to mount robust and effective responses against various pathogens. Consequently, this age-related constraint in TCR diversity could impact overall immune function, raising concerns about the body&#8217;s resilience against a broad range of infection risks. While the exact mechanisms behind this reduction in TCR repertoire are not entirely clear, studies using mice have confirmed that a limited TCR repertoire can contribute to reduced immune responses to vaccine antigens.<sup><xref rid="cit0089" ref-type="bibr">89</xref></sup> Immunosenescence also leads to a decrease in TCR signaling in T cells.<sup><xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref></sup> One contributing factor is an increase in the threshold for low TCR signaling. In CD4<sup>+</sup> T cells affected by immunosenescence, there is an elevated intracellular concentration of dual-specific phosphatase (DUSP) 6, which dampens the activation of the extracellular signal-regulated kinases (ERKs). These diminished ERK responses result in an increase in the TCR threshold, making it more challenging for TCR stimulation to generate a productive signal. This, in turn, reduces TCR signaling and impairs the function of CD4<sup>+</sup> T cells.<sup><xref rid="cit0090" ref-type="bibr">90</xref></sup> Furthermore, some senescent-like T cells express natural killer (NK) cell receptors with reduced TCR function. These NK cell receptors expressing T cells can lead to significant tissue damage, functioning via NK cell receptors rather than specific killing through TCRs.<sup><xref rid="cit0091" ref-type="bibr">91</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></sup> This alteration in TCR repertoire and signaling, along with the emergence of T cells with NK cell receptor-like activity, has negative implications for immune responses, including responses to vaccines, in the elderly population.</p><p>The response of regulatory T cells (Tregs) also plays a critical role in immune regulation. Tregs are responsible for returning immune responses to their basal levels after pathogens are cleared, and they also help regulate excessive immune responses and induce immune tolerance.<sup><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref></sup> However, it has been reported that the number of Tregs gradually increases with age, and their activity decreases.<sup><xref rid="cit0093" ref-type="bibr">93&#8211;95</xref></sup> This Treg dysfunction results in the ineffective secretion of IL-10, contributing to another cause of inflammaging.<sup><xref rid="cit0093" ref-type="bibr">93&#8211;95</xref></sup> After the clearance of pathogens or the completion of the immune response to vaccine antigens, memory T cells are formed. Memory T cells generated during young adulthood are reported to maintain their function even as individuals age.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0087" ref-type="bibr">87</xref></sup> However, memory T cells generated in old age experience a decline in function due to immunosenescence.<sup><xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></sup> In the case of memory CD4<sup>+</sup> T cells generated during old age, an increase in phosphorylated AMPK is observed, leading to elevated levels of DUSP4. This results in reduced expression of ERK and c-Jun N-terminal kinase (JNK), leading to decreased expression of CD40L, CD28, and cytokines. Consequently, memory CD4<sup>+</sup> cells fail to adequately activate B cells, leading to a reduction in vaccine effectiveness.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0079" ref-type="bibr">79</xref></sup> The changes in memory T cell function due to immunosenescence are more significant in CD8<sup>+</sup> T cells.<sup><xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref></sup> Changes due to immunosenescence result in reduced CD28 expression in memory CD8<sup>+</sup> cells, leading to decreased T cell activity.<sup><xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></sup> Overall, the impact of immunosenescence on naive, memory effector, and regulatory T cells eventually leads to diminished vaccine effectiveness in the elderly<sup><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0097" ref-type="bibr">97</xref></sup> (<xref rid="f0001" ref-type="fig">Figure 1</xref>).</p></sec><sec disp-level="2" id="s0002-s2003"><title>Immunosenescence of B cells</title><p>In the context of the immune response to vaccines, the production of antibodies plays a critical role. Antibodies neutralize pathogens and prevent diseases; therefore, the level of antibody production has been used as an indicator of protection.<sup><xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0099" ref-type="bibr">99</xref></sup> However, in the elderly, studies have shown lower levels of antibody production and shorter antibody retention following vaccination compared to young adults.<sup><xref rid="cit0100" ref-type="bibr">100</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></sup> This reduced antibody response in the elderly has been well-reported in seasonal influenza vaccines,<sup><xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></sup> pneumococcal polysaccharide vaccines,<sup><xref rid="cit0100" ref-type="bibr">100</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> and the zoster vaccine.<sup><xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0104" ref-type="bibr">104</xref></sup> Boosting vaccines are one way to enhance vaccine effectiveness; however, even the use of booster vaccines has shown decreased immune responses in the elderly when compared to young adults.<sup><xref rid="cit0105" ref-type="bibr">105</xref></sup> The reduced vaccine effectiveness in the elderly is closely associated with the immunosenescence of B cells.</p><p>Immunosenescence in B cells involves a decrease in the number of na&#239;ve B cells and a reduction in the B cell receptor (BCR) repertoire. As individuals age, there is a transition of HSCs in the bone marrow toward the myeloid cell lineage, resulting in a decrease in the production of na&#239;ve B cells.<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup> However, despite this transition, elderly individuals display similar frequencies of plasma cells and memory B cells in response to vaccination when compared to young adults.<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup> These findings are consistent with the previous study indicating that the frequencies of pro-B, pre-B, and immature B cells remain relatively stable between the ages of 24 and 88.<sup><xref rid="cit0107" ref-type="bibr">107</xref></sup> This highlights the need for a more comprehensive understanding of the mechanisms underlying the decline in na&#239;ve B cells with age. In addition, in the elderly population aged 89 and above, spectratype analysis has confirmed a reduction in the BCR repertoire. This reduction is considered a limiting factor in the immune response of B cells to antigens, similar to the impact of changes in T cell receptors.<sup><xref rid="cit0108" ref-type="bibr">108</xref></sup> The specific mechanisms for the diminishment observed in B cells are not yet fully understood.<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup></p><p>In comparison to young adults, the elderly cannot induce a sufficient antibody response to vaccination. B cells recognize antigens through BCRs and differentiate into plasma cells to produce antibodies (IgM and IgD). Subsequently, with interactions with follicular helper T cells, antibody class switching occurs, leading to the production of more potent antibodies such as IgG, IgE, and IgA.<sup><xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></sup> B cells isolated from the elderly display reduced expression of B lymphocyte-induced maturation protein (Blimp)-1, a master regulator of plasma cells, in response to antigen stimulation, indicating a decreased ability of B cells in the elderly to differentiate into plasma cells.<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup> Immunosenescent B cells also exhibit reduced responsiveness to BCRs, resulting in decreased B cell activation in response to antigens.<sup><xref rid="cit0109" ref-type="bibr">109</xref>,<xref rid="cit0110" ref-type="bibr">110</xref></sup> These immunosenescence phenomena of B cells are considered to be the culprit of the diminished antibody response to vaccination in the elderly, even though older people show a similar frequency of plasma cells and memory B cells compared to young adults when exposed to novel or previously encountered antigens<sup><xref rid="cit0106" ref-type="bibr">106</xref>,<xref rid="cit0109" ref-type="bibr">109</xref>,<xref rid="cit0110" ref-type="bibr">110</xref></sup></p><p>Unlike DCs, B cells are thought to maintain the function of TLR7 even with aging.<sup><xref rid="cit0109" ref-type="bibr">109&#8211;111</xref></sup> Both BCR and TLR7 signals, in conjunction with IFN-&#947;, induce the expression of T-bet in B cells.<sup><xref rid="cit0112" ref-type="bibr">112</xref></sup> T-bet expression is required for T-dependent class switching to IgG2.<sup><xref rid="cit0113" ref-type="bibr">113</xref>,<xref rid="cit0114" ref-type="bibr">114</xref></sup> In research where B cells isolated from the elderly were stimulated with a TLR7 agonist, these cells exhibited increased T-bet expression, similar to young adults.<sup><xref rid="cit0111" ref-type="bibr">111</xref></sup> Normal function of TLR9 in B cells is also observed in the elderly.<sup><xref rid="cit0109" ref-type="bibr">109&#8211;111</xref></sup> TLR9 signaling is necessary for class switching to IgG2 and plays a crucial role in the proliferation of na&#239;ve B cells and their antigen-presenting ability.<sup><xref rid="cit0115" ref-type="bibr">115</xref>,<xref rid="cit0116" ref-type="bibr">116</xref></sup> However, many of these roles in plasma cell differentiation and antibody class switching are interconnected with BCR signaling, suggesting that the antibody class switching ability of elderly individuals has decreased due to reduced BCR signals.<sup><xref rid="cit0109" ref-type="bibr">109</xref>,<xref rid="cit0110" ref-type="bibr">110</xref>,<xref rid="cit0113" ref-type="bibr">113</xref>,<xref rid="cit0114" ref-type="bibr">114</xref>,<xref rid="cit0117" ref-type="bibr">117</xref></sup></p><p>In the elderly, memory B cells are observed at levels similar to those in young adults. However, with aging, the frequencies and numbers of switched memory B cells, responsible for driving rapid secondary antibody responses upon re-exposure to the same antigen, decrease. This decrease is accompanied by an increase in the numbers of IgM memory and IgD<sup>&#8722;</sup> CD27<sup>&#8722;</sup> B cells.<sup><xref rid="cit0106" ref-type="bibr">106</xref>,<xref rid="cit0118" ref-type="bibr">118</xref></sup> These results once again signify a defect in the class-switching ability of B cells. Despite the reduced ability of B cells to undergo class-switching and differentiate into plasma cells, the responses of B cells in the elderly to new antigens tend to rely on preexisting immune cells. High-throughput parallel sequencing studies of influenza vaccine responses in the elderly revealed that they rely on responses driven by somatic mutations in the memory repertoire rather than new antibody sequences generated by naive B cells.<sup><xref rid="cit0119" ref-type="bibr">119</xref></sup> This immune response from the preexisting repertoire can also diminish vaccine effectiveness. In conclusion, the decrease in the number of naive B cells, reduction in BCR repertoire, decreased differentiation into plasma cells, and reduced class-switching ability collectively contribute to the reduced vaccine effectiveness in the elderly (<xref rid="f0001" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec disp-level="1" id="s0003"><title>Adjuvants addressing enhancement of vaccine effectiveness in the elderly</title><p>The innate immune system recognizes PAMPs, which are conserved molecules on pathogens, and DAMPs released from damaged cells in response to pathological conditions.<sup><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref></sup> The recognition of PAMPs and DAMPs by the innate immune system is mediated by PRRs.<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0121" ref-type="bibr">121</xref></sup> Activation of innate immunity through PRRs is essential, as it leads to antigen presentation and plays a significant role in the immune response to vaccines.<sup><xref rid="cit0122" ref-type="bibr">122</xref></sup> Adjuvants used to enhance vaccine effectiveness aim to activate PRRs on APCs within the innate immune system, thereby promoting effective adaptive immune responses to vaccination.<sup><xref rid="cit0122" ref-type="bibr">122</xref>,<xref rid="cit0123" ref-type="bibr">123</xref></sup> Therefore, when designing vaccines that exhibit high effectiveness in the elderly, it would be beneficial to use adjuvants that target PRRs on APCs whose function and expression have not diminished due to immunosenescence. Research on the decreased function of innate immunity due to immunosenescence has reported that some of TLRs and NLRP3 maintain their function and expression levels even with aging. Moreover, several recent studies on adjuvants are focusing on targeting TLRs and NLRP3 (<xref rid="t0001" ref-type="table">Table 1</xref>). In this section, we discuss major adjuvants targeting TLRs and NLRP3 that have been reported to retain their functionality in the elderly, based on their activation pathway.<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>The number of kinds of adjuvants used in vaccines currently under developments for major diseases affecting the elderly (Varicella-zoster virus, VZV; Influenza A; <italic toggle="yes">Streptococcus pneumoniae, S. pneumoniae</italic>) [<xref rid="cit0022" ref-type="bibr">22</xref>], emerging antibiotic resistance threats (<italic toggle="yes">Clostridioides difficile, C. difficile; Neisseria gonorrhoeae, N. gonorrhoeae; Klebsiella pneumoniae, K. pneumoniae; Shigella</italic> sp.) [<xref rid="cit0026" ref-type="bibr">26</xref>], and pathogens under active vaccine research (Respiratory Syncytial Virus; RSV, Hepatitis B virus, HBV, <italic toggle="yes">Mycobacterium tuberculosis</italic>, Mtb; SARS-CoV-2) [<xref rid="cit0029" ref-type="bibr">29</xref>, <xref rid="cit0047" ref-type="bibr">47</xref>, <xref rid="cit0281" ref-type="bibr">281</xref>] are classified based on their target PRRs. The numbers listed in the table represent the number of types of adjuvants classified based on the targeting Toll-like receptors and immune profiles. Please note that there was no information available on adjuvant developments associated with <italic toggle="yes">Acinetobacter baumannii, Candida auris</italic>, and <italic toggle="yes">Enterobacteriaceae</italic>, despite their listing as emerging antibiotic resistance threats by the Centers for Disease Control and Prevention. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vac.niaid.nih.gov/" ext-link-type="uri">https://vac.niaid.nih.gov/</ext-link>, last accessed on January 20, 2024).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;<hr/></th><th align="left" colspan="1" rowspan="1">&#160;<hr/></th><th colspan="12" align="center" rowspan="1">Target PRRs<hr/></th><th colspan="7" align="center" char="." rowspan="1">Immune profiles (Th responses)<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">3</th><th align="center" colspan="1" rowspan="1">4</th><th align="char" char="." colspan="1" rowspan="1">7</th><th align="left" colspan="1" rowspan="1">9</th><th align="left" colspan="1" rowspan="1">7/8</th><th align="char" char="." colspan="1" rowspan="1">2/4</th><th align="char" char="." colspan="1" rowspan="1">4/7</th><th align="char" char="." colspan="1" rowspan="1">4/7/8</th><th align="char" char="." colspan="1" rowspan="1">4/NLR</th><th align="char" char="." colspan="1" rowspan="1">NLR</th><th align="char" char="." colspan="1" rowspan="1">O</th><th align="char" char="." colspan="1" rowspan="1">U</th><th align="char" char="." colspan="1" rowspan="1">1</th><th align="char" char="." colspan="1" rowspan="1">2</th><th align="char" char="." colspan="1" rowspan="1">1/2</th><th align="char" char="." colspan="1" rowspan="1">17</th><th align="left" colspan="1" rowspan="1">1/17</th><th align="char" char="." colspan="1" rowspan="1">1/2/17</th><th align="char" char="." colspan="1" rowspan="1">U</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">VZV</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Influenza A</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">1</td><td align="center" colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">9</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">1</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. pneumoniae</italic></td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">RSV</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">1</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">HBV</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">1</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Mtb</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">9</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N. gonorrhoeae</italic></td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C. difficile</italic></td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. aureus</italic></td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">K. pneumoniae</italic></td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Shigella</italic> sp.</td><td align="left" colspan="1" rowspan="1">Pre</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="left" rowspan="1">Clinic</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr></tbody></table></table-wrap></p><sec disp-level="2" id="s0003-s2001"><title>Activation pathways for TLRs and NLRP3</title><p>TLRs that are expressed on APCs play a crucial role in recognizing conserved PAMPs, leading to the activation of APCs and subsequent induction of adaptive immunity through the activation of innate immunity.<sup><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0120" ref-type="bibr">120&#8211;122</xref></sup> Various adjuvants targeting TLRs have shown effective results in enhancing vaccine effectiveness.<sup><xref rid="cit0124" ref-type="bibr">124</xref>,<xref rid="cit0125" ref-type="bibr">125</xref></sup> TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed on the cell surface. They primarily recognize microbe-derived lipopeptides, peptidoglycan, lipopolysaccharides (LPS), and flagellin, leading to inflammatory responses.<sup><xref rid="cit0126" ref-type="bibr">126</xref></sup> On the other hand, TLR3, TLR7, TLR8, and TLR9 are expressed in intracellular vesicles. They recognize double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), and CpG DNA, inducing Type I IFN responses and inflammatory reactions.<sup><xref rid="cit0127" ref-type="bibr">127</xref></sup> Type I IFN promotes the differentiation of Th1 cells and facilitates antigen cross-presentation to CD8<sup>+</sup> T cells<sup><xref rid="cit0128" ref-type="bibr">128</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2</xref>).
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>TLR activation pathways. TLRs play a crucial role in the recognition of microbial components and the initiation of immune responses. TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed on the cell surface, where they primarily recognize microbe-derived lipopeptides, peptidoglycan, lipopolysaccharide (LPS), and flagellin, leading to inflammatory responses. TLR1 and TLR6 form heterodimers with TLR2 to execute their functions. TLR3, TLR7, TLR8, and TLR9 are located in intracellular vesicles, where they recognize dsRNA, ssRNA, and CpG DNA. MyD88 is a common signaling molecule utilized by all TLRs except TLR3. TLR3 uses TRIF as its signal transducer. TLR4 signaling molecule changes from MyD88 to TRIF once TLR4 relocates to endosomes. Upon binding to TLR ligands, MyD88 becomes activated, leading to the formation of the myddosome. Subsequently, the TAK1 complex and IKK complex are activated, which induces NF-&#954;B. Activation of MyD88 by TLR2 results in the activation of MAPKs, leading to the activation of ERK. This, in turn, results in the induction of cFos protein and the activation of the transcription factor AP1. Activation of MyD88 by TLR7, TLR8, and TLR9 ligand binding can directly induce IRF7. TLR3 and TLR4 activation through TRIF leads to the induction of TRAF6 and TRAF3. TRAF3 activates TBK1 and IKKi and induces the transcription factor IRF3. Additionally, TRAF6 can activate TAK1 and IKK. Activation of various TLRs results in the activation of specific transcription factors, which influence the immune profile. Transcription factor AP1 promotes Th2-biased immune responses by stimulating the production of anti-inflammatory cytokines. NF-&#954;B promotes the secretion of pro-inflammatory cytokines, inducing Th1-biased immune responses. Transcription factors IRF3 and IRF7 promote the secretion of type I IFN cytokines, along with the activation of CTL, contributing to Th1-biased immune responses. Abbreviations: TLR, toll-like receptor; ssRNA, double-stranded RNA; MyD88, myeloid differentiation factor 88; TRIF, TIR domain-containing adapter-inducing interferon-&#946;; TAK1, transforming growth factor-&#946;-activated kinase 1; IKK, I&#954;B kinase; NF-&#954;B, nuclear factor kappa-light-chain-enhancer of activated B cells; MAPKs, mitogen-activated protein kinases; ERK, extracellular signal-regulated kinase; AP1, dimeric transcription factor complex activator protein-1; IRF, induce interferon regulatory factor; TRAF, TNF receptor-associated factor; TBK, TANK-binding kinase; CTL, cytotoxic T lymphocytes.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_2317439_F0002_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_2317439_F0002_PB.jpg"/></alternatives></fig></p><p>TLR2 forms heterodimers with either TLR1 or TLR6 to recognize lipopeptides. TLR5, which is expressed on the cell surface, detects flagellin, and TLR4 senses LPS.<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0121" ref-type="bibr">121</xref></sup> Upon ligand binding, TLR2/1, TLR2/6, TLR4, and TLR5 activate myeloid differentiation factor 88 (MyD88), which subsequently assembles Myddosome composed of MyD88, IL-1 receptor-associated kinases (IRAK) 4, and IRAK1/2.<sup><xref rid="cit0126" ref-type="bibr">126</xref></sup> Myddosome activates the transforming growth factor-&#946;-activated kinase (TAK) 1 complex, which, in turn, activates the I&#954;B kinase (IKK) complex, leading to the activation of the transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B).<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0129" ref-type="bibr">129</xref>,<xref rid="cit0130" ref-type="bibr">130</xref></sup> NF-&#954;B promotes the secretion of pro-inflammatory cytokines and induces Th1 immune responses.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0131" ref-type="bibr">131</xref></sup> The activation of MyD88 by TLR2 ligand binding leads to the activation of mitogen-activated protein kinases (MAPKs). However, it is not clear whether the activation of MAPKs by TLR2 is connected to the pathways of TAK1 or IKK.<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0132" ref-type="bibr">132</xref>,<xref rid="cit0133" ref-type="bibr">133</xref></sup> Nonetheless, it is established that MyD88 activation by TLR2 ligand binding results in the activation of MAPKs, subsequently leading to the activation of ERK. This, in turn, triggers the production of cFos protein and induces the transcription factor activator protein 1 (AP1),<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0126" ref-type="bibr">126</xref>,<xref rid="cit0134" ref-type="bibr">134</xref></sup> leading to a decrease in IL-12 and the promotion of IL-10 expression.<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0133" ref-type="bibr">133</xref>,<xref rid="cit0134" ref-type="bibr">134</xref></sup></p><p>TLR7, TLR8, and TLR9, upon binding nucleic acid ligands, activate MyD88 and subsequently form Myddosome. They activate NF-&#954;B through a pathway similar to TLR2/1, TLR2/6, and TLR5.<sup><xref rid="cit0135" ref-type="bibr">135</xref></sup> Additionally, the Myddosome generated by TLR7, TLR8, and TLR9 signaling can directly interact with interferon regulatory factor (IRF) 7, leading to the activation of IRF7. IRF7 promotes the induction of Type I IFN.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0131" ref-type="bibr">131</xref></sup> Activation through TLR7, TLR8, and TLR9 results in the increased secretion of pro-inflammatory cytokines and Type I IFN, leading to Th1 immune responses and cytotoxic CD8<sup>+</sup> T cell immune responses.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0127" ref-type="bibr">127</xref>,<xref rid="cit0128" ref-type="bibr">128</xref>,<xref rid="cit0131" ref-type="bibr">131</xref></sup></p><p>MyD88 is a common signaling molecule used by all the TLRs except TLR3. TLR3 utilizes toll-interleukin-1 receptor domain-containing adapter-inducing interferon-&#946; (TRIF) as its signal transducer.<sup><xref rid="cit0120" ref-type="bibr">120</xref></sup> Furthermore, TLR4 signaling transitions from MyD88 to TRIF once TLR4 relocates to endosomes.<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> The engagement of TRIF through ligand binding of TLR3 and TLR4 recruits TNF receptor-associated factor (TRAF) 6 and TRAF3. TRAF6 activates the TAK1 complex and IKK complex, subsequently activating NF-&#954;B. Furthermore, TRAF6 derived from TLR3 signaling is known to activate induce IRF7.<sup><xref rid="cit0136" ref-type="bibr">136</xref>,<xref rid="cit0137" ref-type="bibr">137</xref></sup> TRAF3 activates TRAF-Associated NF-&#954;B Activator-binding kinase (TBK) 1 and IKKi, and these kinases, through phosphorylation, activate IRF3.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0133" ref-type="bibr">133</xref></sup> IRF3 promotes the production of Type I IFN, thereby inducing Th1 immune responses and cytotoxic CD8<sup>+</sup> T cell immune responses.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0127" ref-type="bibr">127</xref>,<xref rid="cit0128" ref-type="bibr">128</xref>,<xref rid="cit0131" ref-type="bibr">131</xref></sup></p><p>NOD-like receptors (NLRs) are cytosolic receptors that recognize PAMPs and DAMPs, thereby activating innate immunity.<sup><xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0054" ref-type="bibr">54</xref></sup> Three important NLRs are nucleotide-binding oligomerization domain (NOD) 1, NOD2, and NLRP3. Among these, NLRP3, upon binding to its ligand, assembles the NLRP3 inflammasome, which, in turn, activates caspase-1. The activated caspase-1 converts pro-inflammatory cytokines into biologically active cytokines, thereby promoting inflammatory immune responses.<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> Overall, NLRP3 activation also stimulates the expression of MHC II in APCs and induces the secretion of IL-1&#946; and IL-18, leading to Type 2 immune responses.<sup><xref rid="cit0138" ref-type="bibr">138</xref>,<xref rid="cit0139" ref-type="bibr">139</xref></sup></p></sec><sec disp-level="2" id="s0003-s2002"><title>Lipopolysaccharide</title><p>LPS are endotoxins found on the outer membrane of Gram-negative bacteria. They activate immune cells by binding to TLR4 and myeloid differentiation proteins 2. Immune cells stimulated by LPS secrete inflammatory cytokines, leading to innate and Th1-biased immune responses.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> LPS itself has inherent toxicity due to its endotoxic nature. To use it as an adjuvant, modifications are needed to maintain its immunostimulating effects while reducing its toxicity. Notable examples of modified LPS adjuvants include monophosphoryl lipid A (MPLA or MPL; MPL is a clinical-grade version of MPLA manufactured by GlaxoSmithKline) and glucopyranosyl lipid A (GLA).<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> Both MPLA and GLA stimulate TLR4, enhancing the effectiveness of vaccines. TLR4 expression is known to be similar in APCs from both the elderly and young adults, making them promising candidates for vaccine adjuvants in the elderly.<sup><xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></sup></p><p>MPLA is an agonist of TLR4, which activates APCs and promotes Th1 immune responses through NF-&#954;B by inducing the secretion of pro-inflammatory cytokines.<sup><xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0141" ref-type="bibr">141</xref></sup> While MPLA showed significantly less toxic than LPS in the mouse model, it still possesses low-level toxicity.<sup><xref rid="cit0142" ref-type="bibr">142</xref></sup> Interestingly, when MPLA is combined with liposomes and used as an adjuvant, it exhibits immunostimulating effects without toxicity.<sup><xref rid="cit0143" ref-type="bibr">143</xref></sup> MPLA is currently approved as a human vaccine adjuvant in the US and Europe. It is used in combination with aluminum in adjuvants for hepatitis B vaccines (Fendrix&#174;) and human papillomavirus vaccines (Cervarix&#174;), leading to enhanced antibody production and the activation of antigen-specific T cells.<sup><xref rid="cit0144" ref-type="bibr">144</xref></sup></p><p>GLA is an alternative to MPLA and serves as a synthetic LPS mimic. GLA primarily activates TLR4 in APCs, leading to the induction of Th1 immune responses.<sup><xref rid="cit0145" ref-type="bibr">145</xref>,<xref rid="cit0146" ref-type="bibr">146</xref></sup> GLA comes in various formulations, including GLA-aqueous nanosuspension (GLA-AF), GLA-stable emulsion (GLA-SE), GLA-liposome (GLA-LS), and GLA-aluminum hydroxide (GLA-alum).<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> Among these, GLA-SE, which is a form of squalene oil-in-water emulsion, has been extensively researched.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup> GLA-SE is known for inducing Th1 responses as well as a balanced IgG1/IgG2 response. It also promotes the expression of IFN-&#947; by NK cells and the formation of memory CD8<sup>+</sup> T cells in the mouse model.<sup><xref rid="cit0145" ref-type="bibr">145</xref>,<xref rid="cit0146" ref-type="bibr">146</xref></sup> GLA-SE induced Th1-type CD4<sup>+</sup> T cell responses and generated higher titers of Th1-type antibodies in H5N1 subunit vaccine experiments using mice and ferrets.<sup><xref rid="cit0147" ref-type="bibr">147</xref></sup> Coler et al. reported that GLA-SE induces the production of neutralizing antibodies against various influenza viruses in mice and non-human primates as a part of influenza vaccines.<sup><xref rid="cit0148" ref-type="bibr">148</xref></sup> Notably, GLA-SE promotes the expression of antigen-specific IFN-&#947;, leading to a significantly increased IFN-&#947;:IL-10 ratio (in mice).<sup><xref rid="cit0148" ref-type="bibr">148</xref></sup> Considering that GLA-SE activates APCs through TLR4 and induces IFN-&#947; production,<sup><xref rid="cit0149" ref-type="bibr">149</xref></sup> GLA-SE appears to have great potential as an adjuvant for elderly vaccines. Additionally, while GLA-SE did not yield significant prevention results in elderly individuals in respiratory syncytial virus vaccine experiments,<sup><xref rid="cit0150" ref-type="bibr">150</xref></sup> it has shown improved vaccine effectiveness along with enhanced APC function in the elderly, reaffirming its potential as an adjuvant for vaccines designed for the elderly.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup></p></sec><sec disp-level="2" id="s0003-s2003"><title>Aluminum</title><p>Aluminum was introduced as an adjuvant in human vaccines in the 1930s, particularly in diphtheria and tetanus vaccines, and has demonstrated an excellent safety profile.<sup><xref rid="cit0151" ref-type="bibr">151</xref>,<xref rid="cit0152" ref-type="bibr">152</xref></sup> The most widely used forms of aluminum in vaccines are aluminum hydroxide and aluminum phosphate.<sup><xref rid="cit0153" ref-type="bibr">153</xref></sup> Aluminum, as a mineral-based adjuvant, serves as a short-term antigen depot, allowing for the slow release of antigens into the immune system.<sup><xref rid="cit0154" ref-type="bibr">154</xref></sup> This enables sufficient antigen exposure for APCs, thereby enhancing vaccine effectiveness. Additionally, aluminum is known to act as an immunostimulant by activating NLRP3 in APCs, further augmenting the immune response to vaccines.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup></p><p>The mechanism by which aluminum activates NLRP3 is a subject of debate. However, through studies using mice, it can be believed that when cells at the injection site die, host DNA or uric acid is released, and these DAMPs are thought to activate NLRP3 in APCs.<sup><xref rid="cit0156" ref-type="bibr">156</xref>,<xref rid="cit0157" ref-type="bibr">157</xref></sup> NLRP3 activation results in the secretion of IL-1&#946;, IL-18, and IL-33, leading to the induction of Th2 immune responses.<sup><xref rid="cit0154" ref-type="bibr">154</xref>,<xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0158" ref-type="bibr">158</xref>,<xref rid="cit0159" ref-type="bibr">159</xref></sup> However, aluminum has a very low capacity to induce cell-mediated immunity (CMI) and is non-biodegradable, potentially causing nervous system disorders when administered to patients with renal failure.<sup><xref rid="cit0160" ref-type="bibr">160</xref>,<xref rid="cit0161" ref-type="bibr">161</xref></sup> Despite these concerns, aluminum remains widely used as an adjuvant in many vaccines, including those for hepatitis A, Influenza A, and meningococcal Group 3.<sup><xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0158" ref-type="bibr">158</xref></sup> Considering that aluminum might activate APCs via the NLRP3 pathway and that NLRP3 function is enhanced by immunosenescence,<sup><xref rid="cit0052" ref-type="bibr">52&#8211;54</xref></sup> aluminum has a high potential as a vaccine adjuvant for the elderly. However, the actual use of aluminum adjuvants alone does not seem to effectively induce immune responses in the elderly.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup> This underscores the need for further research on the mechanisms of action of aluminum, as well as the immunosenescence mechanisms in DCs.</p></sec><sec disp-level="2" id="s0003-s2004"><title>CpG ODN</title><p>CpG ODN, synthetic oligodeoxynucleotides (ODNs), is a single-stranded DNA molecule that includes unmethylated cyclic di-GMP (CpG) motifs, structurally resembling bacterial DNA.<sup><xref rid="cit0162" ref-type="bibr">162</xref>,<xref rid="cit0163" ref-type="bibr">163</xref></sup> CpG ODNs interact with TLR9 on immune cells, including DCs and B cells, thereby enhancing innate immune responses. TLR9 activation by CpG ODN leads to the secretion of Type I IFN and pro-inflammatory cytokines, ultimately resulting in the stimulation of humoral immunity, Th1-type cellular responses, and the production of cytotoxic T cells.<sup><xref rid="cit0163" ref-type="bibr">163</xref>,<xref rid="cit0164" ref-type="bibr">164</xref></sup> Additionally, CpG ODNs promote the expression of CD40 and CD80 on DCs and facilitate the secretion of IFN-&#947; by NK cells.<sup><xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0166" ref-type="bibr">166</xref></sup> Among CpG ODNs, only CpG ODN 1018 is approved by the FDA as an adjuvant for human vaccines. It has been evaluated as an adjuvant for SARS-CoV-2 vaccines, leading to the induction of Th1 immune responses and the generation of elevated levels of neutralizing antibodies in mice.<sup><xref rid="cit0167" ref-type="bibr">167</xref></sup> Furthermore, the Hepatitis B virus vaccine (Heplisav-B&#174;) that incorporates CpG ODN 1018 as an adjuvant has demonstrated diverse effects on the immune system, triggering B cell proliferation and the production of immunoglobulins. It also stimulates the secretion of various cytokines such as IL-6, IL-12, and IL-18, along with increased secretion of IFN-&#947; by NK cells. Notably, the inclusion of CpG ODN 1018 significantly enhances both the proportion and intensity of individuals achieving seroprotection. Enhanced immune responses, such as seroprotection rates, have also been confirmed even in the elderly, and it has been approved by the FDA for commercial use.<sup><xref rid="cit0168" ref-type="bibr">168</xref>,<xref rid="cit0169" ref-type="bibr">169</xref></sup></p><p>The alteration of TLR9 expression due to immunosenescence remains a subject of debate in humans.<sup><xref rid="cit0062" ref-type="bibr">62&#8211;64</xref>,<xref rid="cit0067" ref-type="bibr">67</xref></sup> Some studies have reported decreased TLR9 expression on DCs in the context of immunosenescence,<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> while others have suggested that TLR9 may decrease only slightly. Furthermore, it&#8217;s been proposed that TLR9 might not decrease in plasmacytoid DCs as a result of immune aging.<sup><xref rid="cit0062" ref-type="bibr">62&#8211;64</xref></sup> Therefore, there is a possibility that CpG ODN can activate APCs through TLR9 in aged DCs. Furthermore, CpG ODN promotes the expression of co-stimulators in DCs, while aged DCs exhibit reduced expression of co-stimulators.<sup><xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0069" ref-type="bibr">69</xref></sup> These characteristics of CpG ODN suggest a high potential for its use as an adjuvant in vaccines for the elderly. Another interesting point is that CpG ODN can activate TLR9 in B cells. It&#8217;s worth noting that TLR9 maintains its expression even in aging B cells.<sup><xref rid="cit0109" ref-type="bibr">109&#8211;111</xref></sup> TLR9 plays a crucial role in various aspects of B cell function, including B cell activation, plasma cell differentiation, antibody class switching, and antibody production.<sup><xref rid="cit0109" ref-type="bibr">109</xref>&#8211;<xref rid="cit0110" ref-type="bibr">110-112</xref>&#8211;<xref rid="cit0117" ref-type="bibr">117</xref></sup> Furthermore, it is assumed that inducing the expansion of CD27<sup>+</sup> IgM memory B cells via the TLR9 activation of B cells may partially alleviate the defect in class-switching attributed to CD27<sup>&#8722;</sup> B cells in immunosenescence.<sup><xref rid="cit0170" ref-type="bibr">170</xref></sup> Therefore, CpG ODN can activate TLR9 in both APCs including B cells, potentially enhancing vaccine effectiveness in the elderly population.</p><p>In addition, CpG can also enhance the efficacy of vaccines when used in conjugation with other adjuvants.<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0171" ref-type="bibr">171</xref></sup> Recently, the combination of aluminum and CpG 1018 as adjuvants for a recombinant protein vaccine against SARS-CoV-2 has received FDA approval for human use.<sup><xref rid="cit0167" ref-type="bibr">167</xref>,<xref rid="cit0171" ref-type="bibr">171</xref></sup> Interestingly, mice and hamsters vaccinated with the SARS-CoV-2 spiking protein using the combination adjuvant of aluminum and CpG 1018 induced Th1-dominant responses, resulting in high levels of neutralizing antibodies, broad-spectrum protection, and a high ratio of IFN-&#947;/IL-4, despite the presence of aluminum.<sup><xref rid="cit0167" ref-type="bibr">167</xref>,<xref rid="cit0172" ref-type="bibr">172</xref>,<xref rid="cit0173" ref-type="bibr">173</xref></sup></p></sec><sec disp-level="2" id="s0003-s2005"><title>Saponins</title><p>Saponins are natural substances containing glycosides of steroids, steroid alkaloids, and triterpene compounds. They act on cell membranes and enhance immune responses.<sup><xref rid="cit0174" ref-type="bibr">174</xref></sup> Extracts from <italic toggle="yes">Quillaja saponaria</italic>, such as Quil-A, and their derivatives, are highly regarded as adjuvants.<sup><xref rid="cit0175" ref-type="bibr">175</xref></sup> Among these, one fraction of Quil-A, QS-21, is actively researched as a vaccine adjuvant.<sup><xref rid="cit0175" ref-type="bibr">175</xref></sup> Despite numerous studies proposing the mechanism of QS-21 through mouse experiments, the exact mechanism has not been clearly established; however, it has been found that it does not act by binding to TLR2 and TLR4 of DCs.<sup><xref rid="cit0176" ref-type="bibr">176</xref></sup> Several studies using mice have suggested that the mechanism of action of QS-21 involves the activation of NLRP3 by the carbohydrate region of QS-21.<sup><xref rid="cit0177" ref-type="bibr">177</xref>,<xref rid="cit0178" ref-type="bibr">178</xref></sup> Activated NF-&#954;B by NLRP3 in APC leads to the secretion of pro-inflammatory cytokines such as IL-1&#946;, IL-6, IL-12, and IL-18, promoting Th1, Th17, and CTL responses.<sup><xref rid="cit0175" ref-type="bibr">175</xref>,<xref rid="cit0177" ref-type="bibr">177</xref>,<xref rid="cit0179" ref-type="bibr">179&#8211;181</xref></sup> The study using mice has also shown that QS-21 not only promotes Th1 immune responses but also Th2 immune responses, resulting in the production of IgG1 and an improved Th1/Th2 balance.<sup><xref rid="cit0182" ref-type="bibr">182</xref></sup> In addition to its immunostimulating effects, QS-21 has been found to enhance antigen uptake due to its high affinity for endosomal membrane cholesterol.<sup><xref rid="cit0177" ref-type="bibr">177</xref>,<xref rid="cit0178" ref-type="bibr">178</xref></sup> This high cholesterol affinity induced endosomal escape of antigens following uptake, thereby promoting cross-presentation and CTL responses.<sup><xref rid="cit0178" ref-type="bibr">178</xref>,<xref rid="cit0182" ref-type="bibr">182</xref></sup> Moreover, it was reported that QS-21 enters APC cells directly through cholesterol-dependent endocytosis, and its high affinity for endosomal membrane cholesterol destabilizes lysosomes within APCs, leading to inflammasome activation and an increased immune response to vaccines.<sup><xref rid="cit0183" ref-type="bibr">183</xref></sup> Research utilizing synthetic QS-21 has demonstrated its ability to promote antigen trafficking by APCs from the injection site to the draining lymph nodes in mice.<sup><xref rid="cit0176" ref-type="bibr">176</xref></sup> However, whether natural extract QS-21 has the same effect remains to be confirmed.<sup><xref rid="cit0182" ref-type="bibr">182</xref></sup> QS-21, with its various vaccine-enhancing effects, is often used in combination with other delivery systems because it does not have a direct antigen depot effect.<sup><xref rid="cit0184" ref-type="bibr">184</xref>,<xref rid="cit0185" ref-type="bibr">185</xref></sup> Notably, an adjuvant form frequently used in combination with QS-21 is AS01 (containing MPLA and QS-21 in liposomes). AS01 has been utilized in the development of vaccines for malaria (Mosquirix&#174;),<sup><xref rid="cit0186" ref-type="bibr">186</xref></sup> tuberculosis,<sup><xref rid="cit0187" ref-type="bibr">187</xref></sup> and zoster (Shingrix&#174;),<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> showing enhanced cellular immunity and high levels of antibody production. The immunostimulating abilities of saponin analogs like QS-21 suggest their high potential as vaccine adjuvants for the elderly, particularly since they appear to function through pathways other than TLRs, which are known to be diminished by immunosenescence.<sup><xref rid="cit0175" ref-type="bibr">175</xref>,<xref rid="cit0177" ref-type="bibr">177&#8211;179</xref>,<xref rid="cit0183" ref-type="bibr">183</xref></sup> Furthermore, the abilities of QS-21 to induce a combination of Th1, Th2, and Th17 immune responses and promote CTL activation through cross-presentation are significant advantages.<sup><xref rid="cit0175" ref-type="bibr">175</xref>,<xref rid="cit0177" ref-type="bibr">177&#8211;182</xref></sup> However, the mechanisms behind the immunostimulating effects of QS-21, including other saponin analogs, are not yet fully established.<sup><xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0180" ref-type="bibr">180</xref>,<xref rid="cit0182" ref-type="bibr">182</xref></sup></p><p>Matrix-M is an adjuvant composed of new saponin analogues extracted from <italic toggle="yes">Quillaja saponaria</italic>, forming nanoparticles of 40&#8201;nm with cholesterol and phospholipids.<sup><xref rid="cit0185" ref-type="bibr">185</xref></sup> Matrix-M has been reported to share a mechanism similar to other saponin analogues, eliciting Th1-dominant immune responses with a Th1/Th2 balance and enhancing immune cell trafficking. Matrix-M is known to activate innate immune cells through the inflammasome pathway and activate CD8<sup>+</sup> T cells through antigen cross-presentation.<sup><xref rid="cit0183" ref-type="bibr">183</xref>,<xref rid="cit0185" ref-type="bibr">185</xref>,<xref rid="cit0188" ref-type="bibr">188</xref></sup> The ability of Matrix-M to heighten immune responses allows the reduction in antigen amount without compromising vaccine efficacy.<sup><xref rid="cit0188" ref-type="bibr">188</xref></sup> It also exhibits high stability at 2&#8211;3&#176;C,<sup><xref rid="cit0184" ref-type="bibr">184</xref>,<xref rid="cit0185" ref-type="bibr">185</xref>,<xref rid="cit0189" ref-type="bibr">189</xref></sup> and mouse experiments have substantiated its capacity to augment CD86 expression in DCs.<sup><xref rid="cit0190" ref-type="bibr">190</xref></sup> Moreover, in mouse experiments employing Matrix-M-adjuvanted influenza HA recombinant protein vaccination, there was reported augmentation in the numbers of B cells and DCs in draining lymph nodes.<sup><xref rid="cit0184" ref-type="bibr">184</xref></sup> These findings suggest the potential of Matrix-M as an adjuvant that could enhance vaccine efficacy in the elderly by partially mitigating the reduced expression of co-stimulators in DCs and the decreased number of B cells caused by immunosenescence. This adjuvant has been used successfully in the Novavax Covid and influenza vaccines.<sup><xref rid="cit0191" ref-type="bibr">191</xref>,<xref rid="cit0192" ref-type="bibr">192</xref></sup></p></sec><sec disp-level="2" id="s0003-s2006"><title>MF59</title><p>MF59 is an oil-in-water emulsion adjuvant composed of squalene oil, Tween 80, and Span 85.<sup><xref rid="cit0193" ref-type="bibr">193</xref></sup> MF59 has been widely used as an adjuvant since its approval for use in influenza vaccines by the FDA in 1992.<sup><xref rid="cit0194" ref-type="bibr">194</xref></sup> MF59 functions as an antigen delivery system, allowing antigens to interact with APCs for an extended period, thereby increasing vaccine effectiveness.<sup><xref rid="cit0193" ref-type="bibr">193</xref>,<xref rid="cit0195" ref-type="bibr">195</xref></sup> Additionally, MF59 has been found to acts as an immunostimulant by activating PRRs, thus enhancing the immune response to antigens through the activation of innate immunity in mice.<sup><xref rid="cit0196" ref-type="bibr">196</xref></sup> Through these mechanisms, MF59 activates macrophages and DCs, promoting the secretion of chemokines such as C-C motif chemokine ligand (CCL) 2, CCL4, CCL5, and C-X-C motif chemokine ligand (CXCL) 8. The secretion of these chemokines leads to the migration of more immune cells to the vaccination site, increasing the exposure of antigens to more immunocytes.<sup><xref rid="cit0194" ref-type="bibr">194</xref>,<xref rid="cit0197" ref-type="bibr">197</xref></sup> The precise mechanism of action of MF59 is not yet fully understood; however, it is known to induce endogenous danger signals to PRRs and activate APCs through the NLRP3-independent apoptosis-associated speck-like protein containing a CARD (ASC) activation pathway and TLR-independent MyD88 activation pathway. Activated APCs promote the secretion of IL-1&#946; and IL-18, leading to the induction of a Th2-biased immune response and weak Th1 responses.<sup><xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0198" ref-type="bibr">198</xref>,<xref rid="cit0199" ref-type="bibr">199</xref></sup> This implies that MF59 may have the potential to activate APCs even when TLRs are functionally reduced due to immunosenescence.<sup><xref rid="cit0052" ref-type="bibr">52&#8211;54</xref></sup> Furthermore, MF59, by promoting the secretion of chemokines such as CCL2, CCL4, CCL5, and CXCL8, facilitates the migration of APCs to lymph nodes, mitigating the reduced migratory levels of APCs associated with immunosenescence.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0194" ref-type="bibr">194</xref>,<xref rid="cit0197" ref-type="bibr">197</xref></sup> Notably, the largest systematic review and meta-analysis have confirmed that MF59 can enhance antibody titers in individuals aged 60 and older when used as an adjuvant in influenza vaccines.<sup><xref rid="cit0200" ref-type="bibr">200</xref></sup> Additionally, it has been reported to augment vaccine effectiveness in preventing influenza-related medical encounters in individuals aged 65 and older.<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0200" ref-type="bibr">200</xref></sup></p></sec><sec disp-level="2" id="s0003-s2007"><title>Combination adjuvants</title><p>Each adjuvant functions through its unique mechanisms to enhance vaccine immunity. Therefore, researches aiming to combine these adjuvants to achieve a synergistic effect and further enhance vaccine effectiveness are actively underway. A prominent adjuvant combination system is the adjuvant systems (AS) developed by GlaxoSmithKline. AS combines delivery systems and multi-immunostimulants. To date, AS01, AS02, AS03, and AS04 have been developed. Among these, AS01, AS03, and AS04 are currently used in commercial vaccines.<sup><xref rid="cit0201" ref-type="bibr">201</xref></sup></p><p>AS01 is a saponin-liposome adjuvant system composed of MPLA, a TLR4 agonist, and QS-21.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup> Within AS01, the liposome serves as a delivery system, protecting antigens from degradation and extending their bioavailability. This enables APCs to recognize more antigens and keeps the antigen exposed to the immune system for a longer duration.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup> On the other hand, AS02 is a water-in-oil emulsion adjuvant that combines MPLA and QS-21.<sup><xref rid="cit0201" ref-type="bibr">201</xref></sup> MPLA stimulates APCs via TLR4, promoting the expression of cytokines and co-stimulatory molecules, as well as the secretion of IL-1&#946; and IL-18, leading to the induction of Th1 responses.<sup><xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0141" ref-type="bibr">141</xref></sup> Additionally, QS-21 induces antigen endosomal escape within APCs, promoting CTL responses and antigen-specific antibody responses.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup> Furthermore, studies in mice have reported a synergistic effect of MPLA and QS-21 in stimulating the secretion of IFN-&#947; by APCs.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup></p><p>The components of AS01 and AS02, MPLA and QS-21, are known to act through pathways that have not been reported to associated with immunosenescence.<sup><xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0177" ref-type="bibr">177</xref>,<xref rid="cit0178" ref-type="bibr">178</xref>,<xref rid="cit0180" ref-type="bibr">180</xref>,<xref rid="cit0181" ref-type="bibr">181</xref></sup> AS02 is a water-in-oil emulsion, which is also known to enhance both humoral and cellular immune responses.<sup><xref rid="cit0203" ref-type="bibr">203</xref></sup> AS01, in particular, has been approved by the FDA and has demonstrated its potential as an adjuvant for vaccines in the elderly in previous studies,<sup><xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0187" ref-type="bibr">187</xref></sup> Notably, the Shingles vaccine (Shingrix&#174;) for Herpes zoster, which can be problematic in the elderly, uses AS01 as an adjuvant and has been approved by the FDA.<sup><xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0204" ref-type="bibr">204</xref></sup></p><p>AS03 is a squalene-based oil-in-water emulsion adjuvant that contains DL-&#945;-tocopherol and Tween 80.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> The mechanism of vaccine effectiveness for AS03 is similar to that of MF59. AS03 is an emulsion that slowly releases antigens to APCs, allowing them to be exposed to immune system for an extended period.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Additionally, mouse experiments showed that squalene&#8217;s immunostimulating effects activate the NLRP3-independent ASC pathway and the TLR-independent MyD88 pathway, enhancing the immune response to the vaccine.<sup><xref rid="cit0153" ref-type="bibr">153</xref></sup> In addition to squalene, &#945;-tocopherol also possesses immunostimulating effects by promoting the secretion of CCL2, CCL3, IL-6, and CXCL1 in APCs, leading to the recruitment of more immune cells to the injection site. This, in turn, promotes the migration of APCs to the draining lymph nodes, countering the reduction in migratory levels due to immunosenescence in humans.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0205" ref-type="bibr">205</xref></sup> Through these effects, AS03 induces Th2-biased immune responses with weak Th1 responses.<sup><xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0206" ref-type="bibr">206</xref></sup> AS03 is currently used as an adjuvant in approved influenza vaccines in the United States and Europe and has been recently explored as an adjuvant for SARS-CoV-2 vaccines.<sup><xref rid="cit0207" ref-type="bibr">207</xref></sup></p><p>AS04 is an aluminum-based adjuvant that contains the TLR4 agonist MPLA.<sup><xref rid="cit0144" ref-type="bibr">144</xref>,<xref rid="cit0208" ref-type="bibr">208</xref></sup> Aluminum components promote the activation of NLRP3, leading to the secretion of IL-1&#946; and IL-18 and the induction of Th2-biased immune responses.<sup><xref rid="cit0154" ref-type="bibr">154</xref>,<xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0158" ref-type="bibr">158</xref>,<xref rid="cit0159" ref-type="bibr">159</xref></sup> Additionally, MPLA activates NF-&#954;B, inducing Th1 immune responses.<sup><xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0141" ref-type="bibr">141</xref>,<xref rid="cit0201" ref-type="bibr">201</xref></sup> The combined effects of aluminum and MPLA result in AS04 inducing balanced Th1/Th2 immune responses.<sup><xref rid="cit0201" ref-type="bibr">201</xref></sup> Therefore, AS04 appears to function effectively in immunosenescence conditions via TLR4 and NLRP3, making it a promising adjuvant for vaccines targeting the elderly. AS04 is currently used as an adjuvant in human papillomavirus vaccines (Cervarix&#174;) and hepatitis B virus vaccines (Fendrix&#174;).<sup><xref rid="cit0144" ref-type="bibr">144</xref></sup></p></sec><sec disp-level="2" id="s0003-s2008"><title>Delivery system as adjuvants</title><p>A vaccine delivery system includes carrier materials designed to protect vaccine antigens and facilitate their transport to target immune cells. The central objectives of a delivery system are to extend the bioavailability of the antigen, ensure prolonged exposure to APCs, and facilitate antigen uptake by APCs,<sup><xref rid="cit0171" ref-type="bibr">171</xref>,<xref rid="cit0209" ref-type="bibr">209</xref></sup> thus enhancing vaccine effectiveness and reducing the required antigen dose.<sup><xref rid="cit0171" ref-type="bibr">171</xref>,<xref rid="cit0209" ref-type="bibr">209</xref></sup> To ensure the optimal use of a delivery system for each vaccine, it&#8217;s crucial to consider aspects such as prolonging antigen bioavailability, enhancing APC uptake, facilitating lymph node trafficking, and promoting antigen presentation.<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> Notably, liposomes and virus-like particles (VLP), which are prominent among various delivery systems, are briefly described, along with adjuvants that can address immunosenescence.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0171" ref-type="bibr">171</xref>,<xref rid="cit0210" ref-type="bibr">210&#8211;212</xref></sup></p><p>Liposomes are spherical vesicles composed of a hollow phospholipid bilayer artificial membrane.<sup><xref rid="cit0210" ref-type="bibr">210</xref>,<xref rid="cit0213" ref-type="bibr">213</xref></sup> These phospholipids have a hydrophilic head and a hydrophobic tail, which make them ideal for encapsulating and delivering antigens, rendering them valuable as an adjuvant system.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup> Water-soluble antigens are encapsulated within the aqueous inner side of liposomes, while lipophilic antigens are situated in the lipid bilayer.<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> Liposomes serve to prevent antigen degradation and extend bioavailability, enabling APCs to recognize more antigens, consequently enhancing the vaccine&#8217;s effectiveness.<sup><xref rid="cit0202" ref-type="bibr">202</xref></sup> The adjuvant properties of liposomes depend on factors such as the type of encapsulated antigens and the lipid composition of the bilayer, leading to the investigation of various liposomal formulations as potential adjuvants.<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> As adjuvants, liposomes are known to induce robust humoral and cellular immune responses<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> and facilitate antigen cross-presentation<sup><xref rid="cit0215" ref-type="bibr">215</xref></sup> in animal models. Cationic adjuvant formulation, CFA01 (or CAF01), is a typical nano-scaled liposome containing N,N&#8217;-demethyl-N,N&#8217;-dioctadecylammonium (DDA) with the synthetic mycobacterial immunomodulator &#945;,&#945;&#8217;-trehalose 6,6&#8217;-dibehenate (TDB) inserted into the lipid bilayers.<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> Through mouse experiments, TDB is found to enhance vaccine effectiveness by interacting with the c-type lectin Mincle on APCs<sup><xref rid="cit0214" ref-type="bibr">214</xref></sup> and promoting Th1 and Th17 immune responses.<sup><xref rid="cit0216" ref-type="bibr">216</xref>,<xref rid="cit0217" ref-type="bibr">217</xref></sup> Additionally, mRNA vaccines delivered by lipid-based nanoparticles promote follicular T cell and germinal center formation.<sup><xref rid="cit0218" ref-type="bibr">218&#8211;220</xref></sup> The ability to induce the formation of germinal centers and stimulate immune memory is essential, especially in populations where immune responses might naturally decline with age. Recently, SARS-CoV-2 mRNA-1273 using this lipid-based nanoparticle has proven immunogenicity and safety in elderly people.<sup><xref rid="cit0221" ref-type="bibr">221</xref></sup> Although the formation of follicular T cell and germinal center formation have been not described directly, the SARS-CoV-2 mRNA-1273 vaccine induced high levels of binding and neutralizing antibodies in older adults, with time- and dose-dependent trends<sup><xref rid="cit0221" ref-type="bibr">221</xref></sup> and responses similar to those in younger adults.<sup><xref rid="cit0222" ref-type="bibr">222</xref></sup></p><p>VLPs are a delivery system of virus-derived structures, which have a size of 20&#8211;100&#8201;nm and the form of native virus particles.<sup><xref rid="cit0212" ref-type="bibr">212</xref>,<xref rid="cit0223" ref-type="bibr">223</xref></sup> The nano-size of VLPs is optimal for facilitating the movement of antigens to lymphatic vessels and lymph nodes, and their resemblance to native virus structures makes them readily taken up by APCs.<sup><xref rid="cit0224" ref-type="bibr">224</xref></sup> VLPs can be manufactured through various expression systems, including mammal cell lines, plants, bacteria, yeast, and insect cell lines. However, achieving human-optimized post-translational modifications for optimal immunogenicity and preventing contamination, such as by LPS, can be challenging.<sup><xref rid="cit0225" ref-type="bibr">225</xref></sup> Nevertheless, VLPs have been confirmed to enhance the effectiveness of vaccines as adjuvants in animal experiments. VLPs, with their self-assembled structural capsid proteins closely resembling native viruses and efficient display of vaccine antigens on their outer surface, effectively enhance uptake by APCs, thereby improving vaccine effectiveness.<sup><xref rid="cit0212" ref-type="bibr">212</xref>,<xref rid="cit0225" ref-type="bibr">225</xref></sup> Furthermore, VLPs can express multivalent antigenic epitopes on their surface, allowing for the effective activation of B cells through extensive cross-linking of BCRs.<sup><xref rid="cit0226" ref-type="bibr">226</xref></sup> Currently, VLPs are utilized as adjuvants in vaccines such as Cervarix&#174; and Gardasil&#174; for human papillomavirus and Sci-B-Vac<sup>TM</sup> for hepatitis viruses, which are available on the market.<sup><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0171" ref-type="bibr">171</xref>,<xref rid="cit0211" ref-type="bibr">211</xref>,<xref rid="cit0212" ref-type="bibr">212</xref>,<xref rid="cit0227" ref-type="bibr">227</xref></sup></p></sec><sec disp-level="2" id="s0003-s2009"><title>Safety and reactogenicity</title><p>The adjuvants described in this review are reported to act through the activation of PRRs. Such adjuvants, by activating the innate immune system, can induce not only adjuvant-associated local reactogenicity but also life-threatening systemic reactogenicity.<sup><xref rid="cit0228" ref-type="bibr">228</xref></sup> Aluminum can induce IL-1 and Th2 responses, leading to increased IgE production, which may trigger allergy and anaphylaxis (in animal models).<sup><xref rid="cit0229" ref-type="bibr">229&#8211;232</xref></sup> Additionally, an increase in aluminum concentration can impact the brain and bone tissue, leading to neurological syndrome and dialysis-associated dementia in humans.<sup><xref rid="cit0233" ref-type="bibr">233</xref>,<xref rid="cit0234" ref-type="bibr">234</xref></sup> Squalene-based adjuvants such as MF59, AS01, and AS02 are known to have high levels of reactogenicity.<sup><xref rid="cit0228" ref-type="bibr">228</xref></sup> Generally, autoimmune responses are a major concern for adverse reactions caused by these oil emulsion adjuvants, both in humans and animals.<sup><xref rid="cit0235" ref-type="bibr">235&#8211;237</xref></sup> In the elderly population, the utilization of MF59 as an adjuvant for influenza recombinant protein vaccine resulted in a higher incidence of local adverse effects (redness, swelling, and pain) and systemic adverse effects (headache and malaise) in comparison to virosomal vaccines.<sup><xref rid="cit0238" ref-type="bibr">238</xref></sup> AS04 also exhibited local and systemic reactogenicity in healthy individuals aged 14&#8211;40.<sup><xref rid="cit0239" ref-type="bibr">239</xref></sup> QS-21 demonstrates reactogenicity, leading to hemolysis in vitro,<sup><xref rid="cit0240" ref-type="bibr">240</xref></sup> and is recognized for inducing pain at the injection site when employed as an adjuvant.<sup><xref rid="cit0241" ref-type="bibr">241</xref></sup> Nevertheless, this reactogenicity has been documented to diminish when QS-21 is utilized in combination with a delivery system of cholesterol or liposomes.<sup><xref rid="cit0202" ref-type="bibr">202</xref>,<xref rid="cit0242" ref-type="bibr">242</xref></sup> LPS has inherent reactogenicity and can disrupt the immune tolerance balance by inducing potent IL-17.<sup><xref rid="cit0243" ref-type="bibr">243</xref></sup> Therefore, MPLA and GLA have been developed to reduce such reactogenicity.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup></p><p>The clinical symptoms due to the reactogenicity of these adjuvants are mild in most cases. Local toxicity such as pain, redness, inflammation, swelling, abscesses, and nodules at the vaccination site typically resolve within a few days.<sup><xref rid="cit0228" ref-type="bibr">228</xref></sup> Additionally, adjusting the dosage of adjuvants can reduce the likelihood of reactogenicity.<sup><xref rid="cit0244" ref-type="bibr">244</xref>,<xref rid="cit0245" ref-type="bibr">245</xref></sup> Nonetheless, it is crucial to meticulously weigh the reactogenicity of adjuvants against the impact of bolstering vaccine effectiveness.<sup><xref rid="cit0246" ref-type="bibr">246</xref></sup> Notably, understanding of adjuvant reactogenicity and safety in the elderly is still poor. Given the potential variability in adjuvant reactogenicity based on health status and age,<sup><xref rid="cit0228" ref-type="bibr">228</xref>,<xref rid="cit0247" ref-type="bibr">247</xref></sup> with a tendency for heightened concerns in the elderly population,<sup><xref rid="cit0248" ref-type="bibr">248</xref></sup> further research is needed on adjuvant-associated reactogenicity in the elderly.</p></sec><sec disp-level="2" id="s0003-s2010"><title>Adjuvants that required further studies</title><p>TLR2 forms heterodimers with TLR1 and TLR6, serving as PRRs that specifically recognize bacterial lipopeptides. Upon ligand binding, MyD88 is activated, leading to the activation of NF-&#954;B and subsequent promotion of the secretion of pro-inflammatory cytokines.<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0134" ref-type="bibr">134</xref></sup> In addition, activation of the IKK complex and MAPKs results in the inhibition of IL-12 expression and the promotion of IL-10 expression, mediated through the transcription factor AP1<sup><xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0134" ref-type="bibr">134</xref></sup> (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Through these mechanisms, TLR2 agonists have the potential to induce both Th1 and Th2 responses, making them valuable candidates for adjuvants. PAM2CSK4, PAM3CSK4, and macrophage-activating lipopeptide 2 (MALP2) are the most extensively studied TLR2 agonists.<sup><xref rid="cit0249" ref-type="bibr">249</xref></sup> MALP2, in particular, possesses the unique ability to directly activate B cells and has gained significant attention as a novel immunostimulant for vaccine adjuvants.<sup><xref rid="cit0250" ref-type="bibr">250</xref></sup> PorB has been reported to induce cross-presentation to APCs,<sup><xref rid="cit0251" ref-type="bibr">251</xref></sup> and when used as an adjuvant, to present antigens via MyD88 signaling, to induce germinal center formation and antibody production, and to strengthen the follicular DCs network in mouse model.<sup><xref rid="cit0252" ref-type="bibr">252</xref>,<xref rid="cit0253" ref-type="bibr">253</xref></sup> The expression of TLR2 in aged DCs is similar to that in young adults&#8217; DCs.<sup><xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></sup> Therefore, TLR2 agonists show promise as adjuvants for vaccines in the elderly. However, most studies on TLR2 agonists have focused on anticancer.<sup><xref rid="cit0249" ref-type="bibr">249</xref>,<xref rid="cit0254" ref-type="bibr">254</xref></sup> To fully harness TLR2 agonists as adjuvants for vaccines against infectious diseases in the elderly, further research is warranted.</p><p>TLR5 is a cell surface-expressed PRR responsible for recognizing bacterial flagellin. TLR5 activates NF-&#954;B through the MyD88 pathway, promoting the secretion of pro-inflammatory cytokines and inducing Th1 immune responses.<sup><xref rid="cit0162" ref-type="bibr">162</xref>,<xref rid="cit0255" ref-type="bibr">255</xref></sup> The phenomenon of immunosenescence affecting TLR5 on APCs remains unclear. Previous studies have presented conflicting findings, with some reporting an increase in TLR5 signaling in the elderly, leading to an increase in the secretion of IL-8.<sup><xref rid="cit0131" ref-type="bibr">131</xref></sup> while others have indicated a decrease in TLR5 expression levels and a reduction in cytokine secretion related to TLR5.<sup><xref rid="cit0064" ref-type="bibr">64</xref></sup> Nevertheless, experiments involving intranasal vaccination of mice with flagellin as an adjuvant have demonstrated the production of IgG and IgA, along with IFN-&#947; and CD8<sup>+</sup> cell immune responses.<sup><xref rid="cit0256" ref-type="bibr">256</xref></sup> Furthermore, administering an influenza vaccine with a flagellin adjuvant to individuals aged 65 and above resulted in high antibody levels and seroprotection.<sup><xref rid="cit0257" ref-type="bibr">257</xref></sup> However, caution must be taken with the high reactivity of flagellin.<sup><xref rid="cit0258" ref-type="bibr">258</xref>,<xref rid="cit0259" ref-type="bibr">259</xref></sup> In the phase 1 clinical study of &#8216;VaxInnate&#8217;s Universal Flu Vaccine,&#8217; it was established that doses of 0.3 and 1.0&#8201;&#956;g exhibited safety and provoked an immune response. Conversely, the administration of higher doses, specifically 3 and 10&#8201;&#956;g, was correlated with the onset of flu-like symptoms. A separate investigation by Treanor et al. in human subjects aligned with these findings, indicating that doses exceeding 3&#8201;&#956;g led to the emergence of moderately severe systemic symptoms, coupled with significant elevations in serum C-reactive protein levels.<sup><xref rid="cit0260" ref-type="bibr">260</xref></sup> Considering the history of influenza vaccine causing Bell&#8217;s palsy with intranasal vaccination, administration of flagellin via intranasal route indicates the need for caution. In addition to flagellin, other TLR5 agonists like Mobilan and Entolimod are under investigation, although their primary applications are in anticancer vaccines.<sup><xref rid="cit0162" ref-type="bibr">162</xref></sup> Therefore, further research is necessary to explore the potential use of TLR5 agonists as adjuvants for vaccines in the elderly.</p><p>Montanides are water-in-oil adjuvants composed of squalene, with Montanides ISA51 as a representative example.<sup><xref rid="cit0261" ref-type="bibr">261</xref></sup> Although the mechanism of action of Montanides remains largely unknown, it has been reported to enhance antigen uptake by influencing cell membranes.<sup><xref rid="cit0171" ref-type="bibr">171</xref></sup> Furthermore, there is speculation that Montanides ISA51 activates immune cells through the signaling of DAMPs at the injection sites,<sup><xref rid="cit0122" ref-type="bibr">122</xref>,<xref rid="cit0262" ref-type="bibr">262</xref></sup> suggesting its potential as an adjuvant for vaccines in the elderly. While systemic adverse effects such as headache and nausea, as well as local adverse effects such as swelling and injection site pain,<sup><xref rid="cit0263" ref-type="bibr">263</xref></sup> have been reported, Montanides ISA51 has been found to have the ability to effectively induce humoral and cellular immune responses through Th1/Th2 cytokines.<sup><xref rid="cit0122" ref-type="bibr">122</xref>,<xref rid="cit0262" ref-type="bibr">262&#8211;264</xref></sup> This highlights its potential for utilization as a vaccine adjuvant in the future.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup></p></sec></sec><sec disp-level="1" id="s0004"><title>Conclusions and perspectives</title><p>Enhancing vaccine effectiveness in the elderly can not only reduce the burden on the public health system but also prevent the development and transmission of antibiotic resistance through preventing diseases and minimizing the use of antibiotics.<sup><xref rid="cit0009" ref-type="bibr">9&#8211;11</xref></sup> Strategies to improve vaccine effectiveness in the elderly include antigen discovery, improvements in vaccine programs (such as adjusting antigen dosage, modifying administration routes, and optimizing booster schedules), and the incorporation of adjuvants.<sup><xref rid="cit0265" ref-type="bibr">265</xref></sup> However, antigen discovery has its limitations, and even with booster vaccines in the elderly, effectiveness might not reach the levels seen in young adults. Therefore, the use of adjuvants could be the most dramatic means to increase vaccine effectiveness.<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup></p><p>When selecting and developing adjuvants to enhance vaccine effectiveness in the elderly, it is crucial to consider both immunosenescence and the mechanisms of adjuvants. However, it&#8217;s important to note that research results have provided varying findings, highlighting the need for further investigation. For instance, there is an ongoing debate about whether the expression and functionality of TLR5 and TLR9 are diminished as a result of immunosenescence.<sup><xref rid="cit0062" ref-type="bibr">62&#8211;64</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0131" ref-type="bibr">131</xref></sup> Nevertheless, research utilizing adjuvants targeting TLR5 and TLR9 has demonstrated excellent effectiveness even in the elderly population.<sup><xref rid="cit0167" ref-type="bibr">167</xref>,<xref rid="cit0257" ref-type="bibr">257</xref></sup></p><p>The safety of adjuvants is also a crucial consideration in the selection of adjuvants to enhance vaccine efficacy in the elderly.<sup><xref rid="cit0246" ref-type="bibr">246</xref></sup> Various adjuvants have distinct reactogenicity, and this can lead to different adverse effects based on health status and age.<sup><xref rid="cit0228" ref-type="bibr">228</xref>,<xref rid="cit0247" ref-type="bibr">247</xref></sup> Especially, as the elderly are known to be more vulnerable to such reactogenicity compared to other age groups, safety should be the foremost consideration when designing adjuvants for vaccines in the elderly.<sup><xref rid="cit0238" ref-type="bibr">238</xref>,<xref rid="cit0246" ref-type="bibr">246</xref>,<xref rid="cit0248" ref-type="bibr">248</xref></sup> Generally, even for previously approved adjuvants, a new evaluation of vaccine safety is required when used with different types of antigens. A new safety assessment is also necessary when combining previously approved adjuvants.<sup><xref rid="cit0266" ref-type="bibr">266</xref></sup> Notably, the safety assessment of an adjuvanted vaccine ultimately based on the final vaccine formulation, as adjuvants are not deemed active ingredients for approval.<sup><xref rid="cit0267" ref-type="bibr">267</xref></sup> The evaluation of vaccine safety entails comprehensive research on the impact of incorporating adjuvants into vaccines, encompassing the assessment of harmful effects in vaccine recipients based on the mechanisms of action of adjuvants and antigens.<sup><xref rid="cit0267" ref-type="bibr">267</xref></sup> There has been significant effort to establish standard methodologies for evaluating the safety of vaccines and adjuvants.<sup><xref rid="cit0268" ref-type="bibr">268</xref></sup> The WHO, the Food and Drug Administration of the USA, and the European Medicines Agency Evaluation of Medicines for Human Use provide guidelines regarding the safety of adjuvants and vaccines.<sup><xref rid="cit0266" ref-type="bibr">266</xref>,<xref rid="cit0268" ref-type="bibr">268&#8211;272</xref></sup> However, the criteria for toxicity assessment are not yet clear, and research on the reactogenicity of adjuvants in the elderly is still limited.<sup><xref rid="cit0267" ref-type="bibr">267</xref>,<xref rid="cit0268" ref-type="bibr">268</xref></sup> Hence, it is imperative to acknowledge that regulatory toxicity requirements are evolving and may be revised in the future, based on scientific advancements.</p><p>It is also necessary to conduct studies that directly compare the effectiveness of different adjuvants in humans.<sup><xref rid="cit0238" ref-type="bibr">238</xref></sup> There may be limitations in applying animal experimental results related to immunosenescence to humans.<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup> Because, there are fundamental immunological differences between mice and humans, such as expression/diversity and response of PRRs, distinct differentiation signals for CD4<sup>+</sup> Th-subtypes, and a large number of variances in cell surface marker and/or receptor&#8211;ligand specificity that dictate migration, homing and function of lymphocytes and other immune cells.<sup><xref rid="cit0273" ref-type="bibr">273</xref></sup> Furthermore, humans have a much longer life expectancy than mice, which means the memory T cell pool must be maintained for a substantially greater time. The longevity of human memory T cell populations may face limitations that might not be present in murine experiments.<sup><xref rid="cit0274" ref-type="bibr">274</xref>,<xref rid="cit0275" ref-type="bibr">275</xref></sup> The human studies cited in this review showed the results of effectiveness by comparing them to the non-adjuvant group. Therefore, it was challenging to directly compare the effects of various vaccine adjuvants for the same antigen. However, due to economic constraints, conducting direct comparisons of adjuvant effects at the clinical stage using the same antigen in vaccines with different adjuvants is practically close to impossible. An alternative, more feasible approach would be actively verifying adjuvant effects through various meta-analyses.<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0248" ref-type="bibr">248</xref>,<xref rid="cit0276" ref-type="bibr">276</xref>,<xref rid="cit0277" ref-type="bibr">277</xref></sup></p><p>Despite these challenges, research on adjuvants is actively ongoing (<xref rid="t0001" ref-type="table">Table 1</xref>). Numerous studies have demonstrated that adjuvants can indeed enhance vaccine effectiveness in the elderly. In particular, the induction of innate immunity through various combinations of adjuvants has shown promising results in further increasing vaccine effectiveness. In future research, the development of new adjuvants and studies focused on enhancing immune responses by combining existing adjuvants should continue. However, it&#8217;s important to note that an excessive combination of adjuvants may lead to excessive immune responses, potentially reducing vaccine effectiveness and raising the cost of vaccine production. To develop the optimal adjuvant formulation, it is necessary to identify the ideal adjuvant targets for each vaccination, adjust adjuvant dosages, modify emulsion formulations, and implement new delivery systems.</p><p>The augmentation of vaccine effectiveness in the elderly, achieved by the mitigation of immunosenescence through adjuvants, can be realized through diverse pathways. For example, the reduction in the number of naive B and T cells, a representative phenomenon of immunosenescence, might be indirectly mitigated by the elevation of immune cell migration to draining lymph nodes and the augmentation of immune cell trafficking to the vaccination site, facilitated by adjuvants.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0185" ref-type="bibr">185</xref>,<xref rid="cit0188" ref-type="bibr">188</xref>,<xref rid="cit0194" ref-type="bibr">194</xref></sup> Moreover, the activation of APCs and alterations in the cytokine milieu resulting from adjuvant action can impact the interplay between APCs and B and T cells. This, in turn, influences the proliferation and differentiation of B and T cells, the generation of B and T memory cells, and the formation and function of Tregs.<sup><xref rid="cit0170" ref-type="bibr">170</xref>,<xref rid="cit0278" ref-type="bibr">278&#8211;280</xref></sup> Consequently, comprehending the mechanisms for surmounting immunosenescence and enhancing vaccine effectiveness in the elderly through adjuvants necessitates a multifaceted approach. In addition, research on adjuvants targeting not only APCs but also T cells and non-conventional T cell lineages beyond CD4<sup>+</sup> and CD8<sup>+</sup> T cells, such as MAITs, CD1, and &#947;/&#948; T cells, could contribute to enhancing vaccine effectiveness in the elderly.<sup><xref rid="cit0281" ref-type="bibr">281</xref></sup></p><p>In this review, our primary focus has been on adjuvants targeting some PRRs, which have been reported to conserve their functionality even in aged APCs. Many adjuvants indeed target PRRs, and in most cases, they have demonstrated the induction of Th1 or Th2 immune responses (<xref rid="t0002" ref-type="table">Table 2</xref>). In the future, there is a need for research on adjuvants that can not only induce Th1 and Th2 responses but also promote Th17 responses, which can strongly stimulate mucosal immunity.<sup><xref rid="cit0282" ref-type="bibr">282</xref>,<xref rid="cit0283" ref-type="bibr">283</xref></sup> For example, although not addressed in this review paper, the double mutant labile toxin (dmLT) adjuvant holds promise as a vaccine adjuvant for the elderly, capable of eliciting both mucosal and systemic immunity, along with Th17 responses.<sup><xref rid="cit0284" ref-type="bibr">284&#8211;287</xref></sup> In addition, the substantial germinal center responses induced by mRNA vaccines present a potential strategy to alleviate the decline in naive B cells and the dysfunction of memory B cells in the elderly.<sup><xref rid="cit0219" ref-type="bibr">219</xref>,<xref rid="cit0220" ref-type="bibr">220</xref>,<xref rid="cit0288" ref-type="bibr">288</xref></sup> Certainly, thoughtful consideration from diverse perspectives is imperative in the development or selection of adjuvants for vaccines targeting the elderly in the future.<table-wrap position="float" id="t0002" orientation="landscape"><label>Table 2.</label><caption><p>The characteristics of adjuvants and their application in clinical development against infectious diseases.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><tbody><tr><td rowspan="2" align="left" colspan="1">Adjuvants<hr/></td><td rowspan="2" align="center" colspan="1">Characteristics<hr/></td><td colspan="3" align="center" rowspan="1">Clinical trial developments<hr/></td></tr><tr><td align="center" colspan="1" rowspan="1">Diseases<hr/></td><td align="center" colspan="1" rowspan="1">NCT No.<hr/></td><td align="center" char="." colspan="1" rowspan="1">Phase<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">MPLA</td><td rowspan="6" align="left" colspan="1"><list list-type="bullet"><list-item><p>Activating TLR4 to induce Th1 responses.</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines and to express co-stimulatory molecules</p></list-item><list-item><p>Approved in the USA and Europe</p></list-item></list></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05005559">NCT05005559</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05370040">NCT05370040</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Influenza A virus/Season flu</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03945825">NCT03945825</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Influenza A virus/pandemic flu</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03038776">NCT03038776</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Hepatitis B virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01951677">NCT01951677</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Campylobacter jejuni</italic></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05500417">NCT05500417</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">GLA-SE</td><td rowspan="8" align="left" colspan="1"><list list-type="bullet"><list-item><p>Alternative to MPLA, synthetic LPS mimic</p></list-item><list-item><p>Form of squalene oil-in-water emulsion</p></list-item><list-item><p>Activating TLR4 to induce Th1 responses</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines</p></list-item><list-item><p>Promoting NK-cells to secret IFN-&#947;</p></list-item><list-item><p>Increasing IFN-&#947;:IL-10 ratio</p></list-item><list-item><p>Effectiveness and safety</p></list-item><list-item><p>Balanced IgG1/IgG2</p></list-item><list-item><p>Inducing memory CD8<sup>+</sup> T cells</p></list-item></list></td><td align="left" colspan="1" rowspan="1">Influenza A virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01991561">NCT01991561</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Respiratory syncytial virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02508194">NCT02508194</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03806686">NCT03806686</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01599897">NCT01599897</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Mycobacterium leprae</italic></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03302897">NCT03302897</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">ETEC</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03729219">NCT03729219</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Schistosoma</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01154049">NCT01154049</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="char" char="." colspan="1" rowspan="1">&#12288;</td></tr><tr><td align="left" colspan="1" rowspan="1">Aluminun</td><td rowspan="4" align="left" colspan="1"><list list-type="bullet"><list-item><p>Mineral-based emulsion</p></list-item><list-item><p>Activating NLRP3 to induce Th2 responses</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines</p></list-item><list-item><p>Excellent safety profiles</p></list-item><list-item><p>Low capacity to induce CMI</p></list-item></list></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05197712">NCT05197712</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Respiratory syncytial virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02247726">NCT02247726</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Human immunodeficiency virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04915768">NCT04915768</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Human immunodeficiency virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00006327">NCT00006327</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">CpG ODN</td><td rowspan="4" align="left" colspan="1"><list list-type="bullet"><list-item><p>Single-stranded DNA molecule resembling bacterial DNA</p></list-item><list-item><p>Activating TLR9 to induce Th1 responses</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines and type I IFN and to express co-stimulatory molecules</p></list-item><list-item><p>Promoting NK-cells to secret IFN-&#947;</p></list-item><list-item><p>Inducing CTL</p></list-item><list-item><p>Activating B cells via binding to TLR9 on B cells</p></list-item><list-item><p>Hepatitis B virus (Heplisave-B&#174;)</p></list-item></list></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04944368">NCT04944368</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05175625">NCT05175625</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Influenza A virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03038776">NCT03038776</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Hepatitis B virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01951677">NCT01951677</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">QS-21</td><td rowspan="2" align="left" colspan="1"><list list-type="bullet"><list-item><p>Fraction of saponin</p></list-item><list-item><p>Activating NLRP3 to induce Th1/Th2 and Th17 responses</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines</p></list-item><list-item><p>Promoting endosomal escape of antigens, thereby inducing cross-presentation and CTL responses</p></list-item><list-item><p>Promoting APC to uptake antigens and to migrate to draining lymph nodes</p></list-item></list></td><td align="left" colspan="1" rowspan="1">Influenza A virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01897701">NCT01897701</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="char" char="." colspan="1" rowspan="1">&#12288;</td></tr><tr><td align="left" colspan="1" rowspan="1">Matrix -M</td><td rowspan="6" align="left" colspan="1"><list list-type="bullet"><list-item><p>Saponin analogues forming nanoparticles with cholesterol and phospholipids</p></list-item><list-item><p>Inducing the rapid recruitment and activation of APCs and leukocytes</p></list-item><list-item><p>Activating of innate immune cells by the inflammasome pathway</p></list-item><list-item><p>Inducing a strong Th1-dominant immune response with Th1/Th2 balanced (multifunctional CD4<sup>+</sup> T cells producing IFN-&#947;, IL-2, or TNF-&#945;)</p></list-item><list-item><p>Inducing CD8<sup>+</sup> T cell responses through antigen cross-presentation</p></list-item></list></td><td align="left" colspan="1" rowspan="1">Malaria</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05252845">NCT05252845</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Respiratory Syncytial Viruses</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03026348">NCT03026348</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Influenza A virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04120194">NCT04120194</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05112848">NCT05112848</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05112848">NCT05112848</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link></td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">MF59</td><td rowspan="3" align="left" colspan="1"><list list-type="bullet"><list-item><p>Oil-in-water emulation composed of squalene, Tween 80, and Span 80</p></list-item><list-item><p>Activating NLRP3 to induce Th1/Th2 responses</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret CCL2, CCL4, CCL5, CLXCL8, and pro-inflammatory cytokine</p></list-item><list-item><p>Promoting APC to migrate to draining lymph nodes</p></list-item><list-item><p>Promoting more immune cells to migrate to the vaccine injection site</p></list-item><list-item><p>Good at safety and effectiveness</p></list-item><list-item><p>Influenza (Focetria&#174; and Celtura&#174;)</p></list-item></list></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04495933">NCT04495933</ext-link></td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Seasonal influenza</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04576702">NCT04576702</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="char" char="." colspan="1" rowspan="1">&#12288;</td></tr><tr><td align="left" colspan="1" rowspan="1">AS01</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet"><list-item><p>Liposomal adjuvant containing MPLA and QS-21 (oil-in-water)</p></list-item><list-item><p>Activating TLR4 and NLRP3 to induce Th1/Th2 and Th17 responses</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines</p></list-item><list-item><p>Promoting APCs to present antigen</p></list-item><list-item><p>IFN-&#947; secretion of APC by synergic effects of QS-21 and MPLA</p></list-item><list-item><p>Promoting endosomal escape of antigens, thereby inducing cross presentation and CTL responses</p></list-item><list-item><p>Promoting NK cells to secret IFN-&#947;</p></list-item><list-item><p>Potential as an adjuvant for vaccines in the elderly</p></list-item><list-item><p>Malaria (Mosqirix&#174;), Herpes zoster (Shingrix&#174;)</p></list-item></list></td><td align="left" colspan="1" rowspan="1">Malaria</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00866619">NCT00866619</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">AS03</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet"><list-item><p>Squalene-based emulsion comprised DL-&#945;-tocopherol and Tween 80 (oil-in-water)</p></list-item><list-item><p>Activating NLRP3 to induce Th2 with weak Th1</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret CCL2, CCL3, and CXCL1</p></list-item><list-item><p>Inducing IL-6 secretion in the immune system</p></list-item><list-item><p>Promoting APC to migrate to draining lymph nodes</p></list-item></list></td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04742738">NCT04742738</ext-link></td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">AS04</td><td rowspan="3" align="left" colspan="1"><list list-type="bullet"><list-item><p>Aluminum-based emulsion containing MPLA</p></list-item><list-item><p>Activating NLRP3 and TLR4 to induce Th1/Th2 responses</p></list-item><list-item><p>Prolongating the interaction between antigens and APCs</p></list-item><list-item><p>Promoting APCs to secret pro-inflammatory cytokines</p></list-item><list-item><p>Strong antibody production</p></list-item><list-item><p>HBV (Fendix&#174;) and Human papillomavirus (Cervarix&#174;)</p></list-item></list></td><td align="left" colspan="1" rowspan="1">Influenza A virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00616928">NCT00616928</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Human papilloma virus</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00128661">NCT00128661</ext-link></td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="left" colspan="1" rowspan="1">&#12288;</td><td align="char" char="." colspan="1" rowspan="1">&#12288;</td></tr></tbody></table></table-wrap></p><p>Determining the optimal adjuvants for enhancing vaccine efficacy in the elderly poses challenges. The effects of adjuvants and vaccine effectiveness synergize with an efficient antigen system, eliciting an immune response capable of defending against the target disease.<sup><xref rid="cit0267" ref-type="bibr">267</xref>,<xref rid="cit0268" ref-type="bibr">268</xref></sup> The efficacy of a particular adjuvant may vary based on the types of antigens employed. According to the development of various vaccine platforms, the significance of adjuvants has gained prominence. Notably, antigens of recombinant proteins, peptides, plasmid DNA, mRNA, and miRNA alone may fall short in inducing vaccine immunogenicity, underscoring the heightened importance of adjuvants in eliciting robust vaccine responses.<sup><xref rid="cit0289" ref-type="bibr">289</xref></sup> Developing new adjuvants and optimizing existing ones through combinations and dosages holds the potential to enhance vaccine effectiveness in the elderly population. These efforts can contribute to disease prevention and a reduction in antibiotic resistance, ultimately benefiting public health.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work supported by a grant (22202MFDS173) from Ministry of Food and Drug Safety in 2022, and the Korean Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HV22C0079 and HV23C0090), and the Gyeongsang National University Fund for Professors on Sabbatical Leave, 2023. The funders had no role in decision to publish, or preparation of the manuscript. MID (Medical Illustration &amp; Design), a part of the Medical Research Support Services of Yonsei University College of Medicine, for providing excellent support with medical illustration.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="s0006"><title>Abbreviations</title><p>
<def-list><def-item><term>AP1</term><def><p>Activator Protein 1</p></def></def-item><def-item><term>APCs</term><def><p>antigen-presenting cells</p></def></def-item><def-item><term>AS</term><def><p>adjuvant systems</p></def></def-item><def-item><term>ASC</term><def><p>apoptosis-associated speck-like protein containing a CARD</p></def></def-item><def-item><term>BCR</term><def><p>B cell receptor</p></def></def-item><def-item><term>Blimp</term><def><p>B lymphocyte-induced maturation protein</p></def></def-item><def-item><term>CCL</term><def><p>C-C motif chemokine ligand</p></def></def-item><def-item><term>CMI</term><def><p>cell-mediated immunity</p></def></def-item><def-item><term>CTLs</term><def><p>cytotoxic T lymphocytes</p></def></def-item><def-item><term>CXCL</term><def><p>C-X-C motif chemokine ligand</p></def></def-item><def-item><term>DAMPs</term><def><p>danger-associated molecular patterns</p></def></def-item><def-item><term>DCs</term><def><p>dendritic cell</p></def></def-item><def-item><term>DDA</term><def><p>N, N&#8217;-demethyl-N, N&#8217;-dioctadecylammonium</p></def></def-item><def-item><term>dsRNA</term><def><p>double-stranded RNA</p></def></def-item><def-item><term>DUSP</term><def><p>dual-specific phosphatase</p></def></def-item><def-item><term>ERKs</term><def><p>extracellular signal-regulated kinases</p></def></def-item><def-item><term>GLA</term><def><p>glucopyranosyl lipid A</p></def></def-item><def-item><term>HSCs</term><def><p>hematopoietic stem cells</p></def></def-item><def-item><term>IFN</term><def><p>interferons</p></def></def-item><def-item><term>IKK</term><def><p>I&#954;B kinase</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>IRAK</term><def><p>IL-1 receptor-associated kinases</p></def></def-item><def-item><term>IRF</term><def><p>induce interferon regulatory factor</p></def></def-item><def-item><term>JNK</term><def><p>c-Jun N-terminal kinase</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharides</p></def></def-item><def-item><term>MALP2</term><def><p>macrophage-activating lipopeptide 2</p></def></def-item><def-item><term>MAPKs</term><def><p>mitogen-activated protein kinases</p></def></def-item><def-item><term>MPLA</term><def><p>monophosphoryl lipid A</p></def></def-item><def-item><term>Mtb</term><def><p>Mycobacterium tuberculosis</p></def></def-item><def-item><term>MyD88</term><def><p>myeloid differentiation factor 88</p></def></def-item><def-item><term>NF-&#954;B</term><def><p>nuclear factor kappa-light-chain-enhancer of activated B cells</p></def></def-item><def-item><term>NK</term><def><p>natural killer</p></def></def-item><def-item><term>NLRP3</term><def><p>nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 3</p></def></def-item><def-item><term>NOD</term><def><p>nucleotide-binding Oligomerization Domain</p></def></def-item><def-item><term>ODNs</term><def><p>oligodeoxynucleotides</p></def></def-item><def-item><term>PAMPs</term><def><p>pathogen-associated molecular patterns</p></def></def-item><def-item><term>PRRs</term><def><p>pattern recognition receptors</p></def></def-item><def-item><term>ssRNA</term><def><p>single-stranded RNA</p></def></def-item><def-item><term>TAK1</term><def><p>transforming growth factor-&#946;-activated kinase</p></def></def-item><def-item><term>TBK</term><def><p>TRAF-Associated NF-&#954;B Activator-binding kinase</p></def></def-item><def-item><term>TCRs</term><def><p>T cell receptors</p></def></def-item><def-item><term>TDB</term><def><p>&#945;, &#945;&#8217;-trehalose 6, 6&#8217;-dibehenate</p></def></def-item><def-item><term>TNF</term><def><p>tumor necrosis factor</p></def></def-item><def-item><term>TRAF</term><def><p>TNF receptor-associated factor</p></def></def-item><def-item><term>Tregs</term><def><p>regulatory T cells</p></def></def-item><def-item><term>TRIF</term><def><p>toll-interleukin-1 receptor domain-containing adapter-inducing interferon-&#946;</p></def></def-item><def-item><term>VLP</term><def><p>virus-like particles</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Centers for Disease Control and Prevention</surname></string-name></person-group>. <article-title>Antibiotic resistance threats in the United States, 2019</article-title>. <publisher-loc>Atlanta (GA)</publisher-loc>: <publisher-name>U.S. Department of Health and Human Services, CDC</publisher-name>; <year>2019</year>.</mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;neill</surname><given-names>J.</given-names></string-name></person-group><part-title>Antimicrobial resistance: tackling a crisis for the health and wealth of nations</part-title>. In: <person-group person-group-type="author"><collab>eEllcomeTrust</collab></person-group>, editor. <source>The review on antimicrobial resistance</source>. <publisher-name>HM Goverment</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Breijyeh</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jubeh</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Karaman</surname><given-names>R</given-names></string-name></person-group>. <article-title>Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it</article-title>. <source>Molecules</source>. <year>2020</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1340</fpage>. doi:<pub-id pub-id-type="doi">10.3390/molecules25061340</pub-id>.<pub-id pub-id-type="pmid">32187986</pub-id><pub-id pub-id-type="pmcid">PMC7144564</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Angulo</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Collignon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wegener</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Braam</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>CD</given-names></string-name></person-group>. <article-title>The routine use of antibiotics to promote animal growth does little to benefit protein undernutrition in the developing world</article-title>. <source>Clin Infect Dis</source>. <year>2005</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1007</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1086/433191</pub-id>.<pub-id pub-id-type="pmid">16142667</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mezali</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hamdi</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Prevalence and antimicrobial resistance of salmonella isolated from meat and meat products in Algiers (Algeria)</article-title>. <source>Foodborne Pathog Dis</source>. <year>2012</year>;<volume>9</volume>(<issue>6</issue>):<fpage>522</fpage>&#8211;<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.1089/fpd.2011.1032</pub-id>.<pub-id pub-id-type="pmid">22571639</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Costanzo</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Roviello</surname><given-names>GN</given-names></string-name></person-group>. <article-title>The potential role of vaccines in preventing antimicrobial resistance (AMR): an update and future perspectives</article-title>. <source>Vaccines</source>. <year>2023</year>;<volume>11</volume>(<issue>2</issue>):<fpage>333</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines11020333</pub-id>.<pub-id pub-id-type="pmid">36851210</pub-id><pub-id pub-id-type="pmcid">PMC9962013</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Micoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Serruto</surname><given-names>D</given-names></string-name></person-group>. <article-title>The role of vaccines in combatting antimicrobial resistance</article-title>. <source>Nat Rev Microbiol</source>. <year>2021</year>;<volume>19</volume>(<issue>5</issue>):<fpage>287</fpage>&#8211;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-020-00506-3</pub-id>.<pub-id pub-id-type="pmid">33542518</pub-id><pub-id pub-id-type="pmcid">PMC7861009</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Atkins</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Lafferty</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Deeny</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Robotham</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Jit</surname><given-names>M</given-names></string-name></person-group>. <article-title>Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance</article-title>. <source>Lancet Infect Dis</source>. <year>2018</year>;<volume>18</volume>(<issue>6</issue>):<fpage>204</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(17)30478-4</pub-id>.<pub-id pub-id-type="pmid">29146178</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Payne</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Reaction: alternative modalities to address antibiotic-resistant pathogens</article-title>. <source>Chem</source>. <year>2017</year>;<volume>3</volume>(<issue>3</issue>):<fpage>369372</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chempr.2017.08.017</pub-id>.</mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Andreano</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Oro</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Finco</surname><given-names>O</given-names></string-name></person-group>. <article-title>Vaccine evolution and its application to fight modern threats</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1722</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.01722</pub-id>.<pub-id pub-id-type="pmid">31404139</pub-id><pub-id pub-id-type="pmcid">PMC6669413</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Holm</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frost</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hasso-Agopsowicz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>K</given-names></string-name></person-group>. <article-title>Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study</article-title>. <source>Int J Infect Dis</source>. <year>2023</year>;<volume>130</volume>(<issue>8</issue>):<fpage>e011341</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2023.04.026</pub-id>.<pub-id pub-id-type="pmcid">PMC10335446</pub-id><pub-id pub-id-type="pmid">37414432</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Gellin</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Beigi</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Despres</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lynfield</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Maldonado</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mouton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rawlins</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rothholz</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>N</given-names></string-name></person-group>. et al. <article-title>A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: recommendations from the national vaccine advisory committee</article-title>. <source>Public Health Rep</source>. <year>2016</year>;<volume>131</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1177/003335491613100105</pub-id>.<pub-id pub-id-type="pmcid">PMC4716466</pub-id><pub-id pub-id-type="pmid">26843664</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kennedy</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Read</surname><given-names>AF</given-names></string-name></person-group>. <article-title>Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance</article-title>. <source>Proc Natl Acad Sci</source>. <year>2018</year>;<volume>115</volume>(<issue>51</issue>):<fpage>12878</fpage>&#8211;<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1717159115</pub-id>.<pub-id pub-id-type="pmid">30559199</pub-id><pub-id pub-id-type="pmcid">PMC6304978</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heymann</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Kieny</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></string-name></person-group>. <article-title>Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics</article-title>. <source>Lancet Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1108</fpage>&#8211;<lpage>1109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00374-7</pub-id>.<pub-id pub-id-type="pmid">35753317</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>WHO</surname></string-name></person-group>. <article-title>Vaccines for antimicrobial resistance (AMR)</article-title>. WHO; <year>2023</year>. [accessed 2023 Oct 16]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research/anti-microbial-resistance" ext-link-type="uri">https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research/anti-microbial-resistance</ext-link>.</mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hasso-Agopsowicz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hausdorff</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Fiore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tayler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Klemm</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Srikantiah</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Friede</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World Health Organization action framework</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>4</issue>):<fpage>1011</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab062</pub-id>.<pub-id pub-id-type="pmcid">PMC8366823</pub-id><pub-id pub-id-type="pmid">33493317</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>WHO</surname></string-name></person-group>. <article-title>Ageing and health</article-title>. <publisher-name>WHO</publisher-name>; <year>2022</year><month>Oct</month><day>1</day> [accessed 2023 Sept 16]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/ageing-and-health" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/ageing-and-health</ext-link>.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cobelens</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Suri</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Helinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Makanga</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weinberg</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Schaffmeister</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deege</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></string-name></person-group>. <article-title>Accelerating research and development of new vaccines against tuberculosis: a global roadmap</article-title>. <source>Lancet Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>4</issue>):<fpage>108</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00810-0</pub-id>.<pub-id pub-id-type="pmcid">PMC8884775</pub-id><pub-id pub-id-type="pmid">35240041</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franco</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Peri</surname><given-names>F</given-names></string-name></person-group>. <article-title>Developing new anti-tuberculosis vaccines: focus on adjuvants</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>78</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cells10010078</pub-id>.<pub-id pub-id-type="pmid">33466444</pub-id><pub-id pub-id-type="pmcid">PMC7824815</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wagner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weinberger</surname><given-names>B</given-names></string-name></person-group>. <article-title>Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>717</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.00717</pub-id>.<pub-id pub-id-type="pmid">32391017</pub-id><pub-id pub-id-type="pmcid">PMC7190794</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crooke</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Ovsyannikova</surname><given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Poland</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>RB</given-names></string-name></person-group>. <article-title>Immunosenescence and human vaccine immune responses</article-title>. <source>Immun Ageing</source>. <year>2019</year>;<volume>16</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12979-019-0164-9</pub-id>.<pub-id pub-id-type="pmid">31528180</pub-id><pub-id pub-id-type="pmcid">PMC6743147</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ciabattini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nardini</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Santoro</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Garagnani</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Franceschi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Medaglini</surname><given-names>D</given-names></string-name></person-group>. <article-title>Vaccination in the elderly: the challenge of immune changes with aging</article-title>. <source>Semin Immunol</source>. <year>2018</year>;<volume>40</volume>:<fpage>83</fpage>&#8211;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2018.10.010</pub-id>.<pub-id pub-id-type="pmid">30501873</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nandi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pecetta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bloom</surname><given-names>DE</given-names></string-name></person-group>. <source>EClinMed</source><volume>57</volume>. ; <year>2023</year><article-title>Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020&#8211;2022</article-title>. p. <fpage>101848</fpage> doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101848</pub-id>.<pub-id pub-id-type="pmcid">PMC9900305</pub-id><pub-id pub-id-type="pmid">36776504</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Punjabi</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Madaline</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gendlina</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nori</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pirofski</surname><given-names>L-A</given-names></string-name></person-group>. <article-title>Prevalence of methicillin-resistant staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2021</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1156</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1017/ice.2020.440</pub-id>.<pub-id pub-id-type="pmid">32843125</pub-id><pub-id pub-id-type="pmcid">PMC7588710</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coppola</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ottenhoff</surname><given-names>TH</given-names></string-name></person-group>. <article-title>Genome wide approaches discover novel mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination</article-title>. <source>Semin Immunol</source>. <year>2018</year>;<volume>39</volume>:<fpage>88</fpage>&#8211;<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2018.07.001</pub-id>.<pub-id pub-id-type="pmid">30327124</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flynn</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Guarner</surname><given-names>J</given-names></string-name></person-group>. <article-title>Emerging Antimicrobial Resistance</article-title>. <source>Mod Pathol</source>. <year>2023</year>;<volume>36</volume>(<issue>9</issue>):<fpage>100249</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.modpat.2023.100249</pub-id>.<pub-id pub-id-type="pmid">37353202</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Orme</surname><given-names>IM</given-names></string-name></person-group>. <article-title>The Achilles heel of BCG</article-title>. <source>Tuberculosis</source>. <year>2010</year>;<volume>90</volume>(<issue>6</issue>):<fpage>329</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tube.2010.06.002</pub-id>.<pub-id pub-id-type="pmid">20659816</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rangaka</surname><given-names>MX</given-names></string-name>, <string-name name-style="western"><surname>Frick</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Churchyard</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Basteiro</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hanekom</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Hamada</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Quaife</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></string-name></person-group>. et al. <article-title>Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment</article-title>. <source>Lancet Respir Med</source>. <year>2023</year>;<volume>11</volume>(<issue>4</issue>):<fpage>380</fpage>&#8211;<lpage>390</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(23)00084-X</pub-id>.<pub-id pub-id-type="pmid">36966794</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>da Costa</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Onyebujoh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Thiry</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zumla</surname><given-names>A</given-names></string-name></person-group>. <article-title>Advances in development of new tuberculosis vaccines</article-title>. <source>Curr Opin Pulm Med</source>. <year>2023</year>;<volume>29</volume>(<issue>3</issue>):<fpage>143</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCP.0000000000000950</pub-id>.<pub-id pub-id-type="pmid">36866744</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Allen</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Toapanta</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Tennant</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Understanding immunosenescence and its impact on vaccination of older adults</article-title>. <source>Vaccine</source>. <year>2020</year>;<volume>38</volume>(<issue>52</issue>):<fpage>8264</fpage>&#8211;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.11.002</pub-id>.<pub-id pub-id-type="pmid">33229108</pub-id><pub-id pub-id-type="pmcid">PMC7719605</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Accardi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Caruso</surname><given-names>C</given-names></string-name></person-group>. <article-title>Immune-inflammatory responses in the elderly: an update</article-title>. <source>Immun Ageing</source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1186/s12979-018-0117-8</pub-id>.<pub-id pub-id-type="pmcid">PMC5833087</pub-id><pub-id pub-id-type="pmid">29507595</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weinberger</surname><given-names>B</given-names></string-name></person-group>. <article-title>Adjuvant strategies to improve vaccination of the elderly population</article-title>. <source>Curr Opin Pharmacol</source>. <year>2018</year>;<volume>41</volume>:<fpage>34</fpage>&#8211;<lpage>41</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coph.2018.03.014</pub-id>.<pub-id pub-id-type="pmid">29677646</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osterholm</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Sommer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Belongia</surname><given-names>EA</given-names></string-name></person-group>. <article-title>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>36</fpage>&#8211;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(11)70295-X</pub-id>.<pub-id pub-id-type="pmid">22032844</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weeraratna</surname><given-names>AT</given-names></string-name></person-group>. <article-title>How the ageing microenvironment influences tumour progression</article-title>. <source>Nat Rev Cancer</source>. <year>2020</year>;<volume>20</volume>(<issue>2</issue>):<fpage>89</fpage>&#8211;<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41568-019-0222-9</pub-id>.<pub-id pub-id-type="pmid">31836838</pub-id><pub-id pub-id-type="pmcid">PMC7377404</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name></person-group>. et al. <article-title>Immunosenescence: molecular mechanisms and diseases</article-title>. <source>Signal Transduct Target Ther</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>200</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-023-01451-2</pub-id>.<pub-id pub-id-type="pmid">37179335</pub-id><pub-id pub-id-type="pmcid">PMC10182360</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nikolich-&#381;ugich</surname><given-names>J</given-names></string-name></person-group>. <article-title>Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections</article-title>. <source>Nat Rev Immunol</source>. <year>2008</year>;<volume>8</volume>(<issue>7</issue>):<fpage>512</fpage>&#8211;<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2318</pub-id>.<pub-id pub-id-type="pmid">18469829</pub-id><pub-id pub-id-type="pmcid">PMC5573867</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cristofalo</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Lorenzini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tresini</surname><given-names>M</given-names></string-name></person-group>. <article-title>Replicative senescence: a critical review</article-title>. <source>Mech Ageing Dev</source>. <year>2004</year>;<volume>125</volume>(<issue>10&#8211;11</issue>):<fpage>827</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mad.2004.07.010</pub-id>.<pub-id pub-id-type="pmid">15541776</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ping</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name></person-group>. et al. <article-title>Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion</article-title>. <source>Cancer Lett</source>. <year>2019</year>;<volume>452</volume>:<fpage>244</fpage>&#8211;<lpage>253</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2019.03.040</pub-id>.<pub-id pub-id-type="pmid">30928379</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname><given-names>E</given-names></string-name></person-group>. <article-title>Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty</article-title>. <source>Nat Rev Cardiol</source>. <year>2018</year>;<volume>15</volume>(<issue>9</issue>):<fpage>505</fpage>&#8211;<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41569-018-0064-2</pub-id>.<pub-id pub-id-type="pmid">30065258</pub-id><pub-id pub-id-type="pmcid">PMC6146930</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franceschi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bonaf&#232;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valensin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olivieri</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>De Luca</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ottaviani</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>De Benedictis</surname><given-names>G</given-names></string-name></person-group>. <article-title>Inflamm&#8208;aging: an evolutionary perspective on immunosenescence</article-title>. <source>Ann NY Acad Sci</source>. <year>2000</year>;<volume>908</volume>(<issue>1</issue>):<fpage>244</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06651.x</pub-id>.<pub-id pub-id-type="pmid">10911963</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hsueh</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Hoft</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>G</given-names></string-name></person-group>. <article-title>Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>249</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-017-02689-5</pub-id>.<pub-id pub-id-type="pmid">29339767</pub-id><pub-id pub-id-type="pmcid">PMC5770447</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hsueh</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Varvares</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Hoft</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>G</given-names></string-name></person-group>. <article-title>Human regulatory T cells induce T-lymphocyte senescence</article-title>. <source>Blood</source>. <year>2012</year>;<volume>120</volume>(<issue>10</issue>):<fpage>2021</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2012-03-416040</pub-id>.<pub-id pub-id-type="pmid">22723548</pub-id><pub-id pub-id-type="pmcid">PMC3437594</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chou</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Effros</surname><given-names>RB</given-names></string-name></person-group>. <article-title>T cell replicative senescence in human aging</article-title>. <source>Curr Pharm Des</source>. <year>2013</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1680</fpage>&#8211;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.2174/138161213805219711</pub-id>.<pub-id pub-id-type="pmid">23061726</pub-id><pub-id pub-id-type="pmcid">PMC3749774</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Henson</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?</article-title><source>Nat Rev Immunol</source>. <year>2011</year>;<volume>11</volume>(<issue>4</issue>):<fpage>289</fpage>&#8211;<lpage>295</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2959</pub-id>.<pub-id pub-id-type="pmid">21436838</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wherry</surname><given-names>EJ</given-names></string-name></person-group>. <article-title>T cell exhaustion</article-title>. <source>Nat Immunol</source>. <year>2011</year>;<volume>12</volume>(<issue>6</issue>):<fpage>492</fpage>&#8211;<lpage>499</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.2035</pub-id>.<pub-id pub-id-type="pmid">21739672</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name></person-group>. <article-title>Vaccine adjuvants: mechanisms and platforms</article-title>. <source>Signal Transduct Target Ther</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>283</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-023-01557-7</pub-id>.<pub-id pub-id-type="pmid">37468460</pub-id><pub-id pub-id-type="pmcid">PMC10356842</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nanishi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Angelidou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rotman</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ozonoff</surname><given-names>A</given-names></string-name></person-group>. <article-title>Precision vaccine adjuvants for older adults: a scoping review</article-title>. <source>Clin Infect Dis</source>. <year>2022</year>;<volume>75</volume>(<issue>Supplement_1</issue>):<fpage>72</fpage>&#8211;<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac302</pub-id>.<pub-id pub-id-type="pmcid">PMC9376277</pub-id><pub-id pub-id-type="pmid">35439286</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbas</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Lichtman</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Pillai</surname><given-names>S</given-names></string-name></person-group>. <source>Basic immunology: functions and disorders of the immune system</source>. <publisher-loc>Philadelphia (PA)</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frasca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Blomberg</surname><given-names>BB</given-names></string-name></person-group>. <article-title>B cell immunosenescence</article-title>. <source>Annu Rev Cell Dev Biol</source>. <year>2020</year>;<volume>36</volume>(<issue>1</issue>):<fpage>551</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-cellbio-011620-034148</pub-id>.<pub-id pub-id-type="pmid">33021823</pub-id><pub-id pub-id-type="pmcid">PMC8060858</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Metcalf</surname><given-names>TU</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Cameron</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Ghneim</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wertheimer</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hiscott</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Nikolich-Zugich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Haddad</surname><given-names>EK</given-names></string-name></person-group>. <article-title>Human monocyte subsets are transcriptionally and functionally altered in aging in response to pattern recognition receptor agonists</article-title>. <source>J Immunol</source>. <year>2017</year>;<volume>199</volume>(<issue>4</issue>):<fpage>1405</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1700148</pub-id>.<pub-id pub-id-type="pmid">28696254</pub-id><pub-id pub-id-type="pmcid">PMC5548610</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henson</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lanna</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Riddell</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Franzese</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Macaulay</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Griffiths</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Puleston</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Tooze</surname><given-names>SA</given-names></string-name></person-group>. et al. <article-title>p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>(<issue>9</issue>):<fpage>4004</fpage>&#8211;<lpage>4016</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI75051</pub-id>.<pub-id pub-id-type="pmid">25083993</pub-id><pub-id pub-id-type="pmcid">PMC4151208</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Latz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Duewell</surname><given-names>P</given-names></string-name></person-group>. <article-title>NLRP3 inflammasome activation in inflammaging</article-title>. <source>Semin Immunol</source>. <year>2018</year>;<volume>40</volume>:<fpage>61</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2018.09.001</pub-id>.<pub-id pub-id-type="pmid">30268598</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franchi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Amer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Body-Malapel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kanneganti</surname><given-names>T-D</given-names></string-name>, <string-name name-style="western"><surname>&#214;z&#246;ren</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jagirdar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Inohara</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vandenabeele</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bertin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Coyle</surname><given-names>A</given-names></string-name></person-group>. et al. <article-title>Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1&#946; in salmonella-infected macrophages</article-title>. <source>Nat Immunol</source>. <year>2006</year>;<volume>7</volume>(<issue>6</issue>):<fpage>576</fpage>&#8211;<lpage>582</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni1346</pub-id>.<pub-id pub-id-type="pmid">16648852</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miao</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Alpuche-Aranda</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Dors</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Bader</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Aderem</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1&#946; via Ipaf</article-title>. <source>Nat Immunol</source>. <year>2006</year>;<volume>7</volume>(<issue>6</issue>):<fpage>569</fpage>&#8211;<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni1344</pub-id>.<pub-id pub-id-type="pmid">16648853</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lartigue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bolen</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Haddad</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gaudilliere</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ganio</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Fragiadakis</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Spitzer</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Douchet</surname><given-names>I</given-names></string-name></person-group>. et al. <article-title>Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states</article-title>. <source>Nat Med</source>. <year>2017</year>;<volume>23</volume>(<issue>2</issue>):<fpage>174</fpage>&#8211;<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.4267</pub-id>.<pub-id pub-id-type="pmid">28092664</pub-id><pub-id pub-id-type="pmcid">PMC5320935</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thevaranjan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Puchta</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Naidoo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Szamosi</surname>, <given-names>J.C.</given-names></string-name>, <string-name name-style="western"><surname>Verschoor</surname>, <given-names>C P.</given-names></string-name>, <string-name name-style="western"><surname>Loukov</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Schenck</surname>, <given-names>L P.</given-names></string-name>, <string-name name-style="western"><surname>Jury</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Foley</surname>, <given-names>K P.</given-names></string-name>, <string-name name-style="western"><surname>Schertzer</surname>, <given-names>J D.</given-names></string-name></person-group> et al. <article-title>Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction</article-title>. <source>Cell Host &amp; Microbe</source>. <year>2017</year>;<volume>21</volume>(<issue>4</issue>):<fpage>455</fpage>&#8211;<lpage>466.e4</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2017.03.002</pub-id>.<pub-id pub-id-type="pmid">28407483</pub-id><pub-id pub-id-type="pmcid">PMC5392495</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schirmer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smeekens</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Vlamakis</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jaeger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Oosting</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Franzosa</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Ter Horst</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bonder</surname><given-names>MJ</given-names></string-name></person-group>. et al. <article-title>Linking the human gut microbiome to inflammatory cytokine production capacity</article-title>. <source>Cell</source>. <year>2016</year>;<volume>167</volume>(<issue>4</issue>):<fpage>1125</fpage>&#8211;<lpage>36.e8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2016.10.020</pub-id>.<pub-id pub-id-type="pmid">27814509</pub-id><pub-id pub-id-type="pmcid">PMC5131922</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Puchta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Naidoo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Verschoor</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Loukov</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Thevaranjan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mandur</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>P-S</given-names></string-name>, <string-name name-style="western"><surname>Jordana</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Loeb</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>Z</given-names></string-name></person-group>. et al. <article-title>TNF drives monocyte dysfunction with age and results in impaired anti-pneumococcal immunity</article-title>. <source>PloS Pathog</source>. <year>2016</year>;<volume>12</volume>(<issue>1</issue>):<fpage>e1005368</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1005368</pub-id>.<pub-id pub-id-type="pmid">26766566</pub-id><pub-id pub-id-type="pmcid">PMC4713203</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parish</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Effros</surname><given-names>RB</given-names></string-name></person-group>. <article-title>Modulation of T lymphocyte replicative senescence via TNF-&#945; inhibition: role of caspase-3</article-title>. <source>J Immunol</source>. <year>2009</year>;<volume>182</volume>(<issue>7</issue>):<fpage>4237</fpage>&#8211;<lpage>4243</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.0803449</pub-id>.<pub-id pub-id-type="pmid">19299722</pub-id><pub-id pub-id-type="pmcid">PMC3773494</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frasca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Landin</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Blomberg</surname><given-names>BB</given-names></string-name></person-group>. <article-title>High TNF-&#945; levels in resting B cells negatively correlate with their response</article-title>. <source>Exp Gerontol</source>. <year>2014</year>;<volume>54</volume>:<fpage>116</fpage>&#8211;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2014.01.004</pub-id>.<pub-id pub-id-type="pmid">24440385</pub-id><pub-id pub-id-type="pmcid">PMC3989457</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aiello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ligotti</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Garnica</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Accardi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Calabr&#242;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pojero</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Arasanz</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bocanegra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blanco</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chocarro</surname><given-names>L</given-names></string-name></person-group>. et al. <article-title>How can we improve vaccination response in old people? Part I: targeting immunosenescence of innate immunity cells</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>17</issue>):<fpage>9880</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms23179880</pub-id>.<pub-id pub-id-type="pmid">36077278</pub-id><pub-id pub-id-type="pmcid">PMC9456428</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>S</given-names></string-name></person-group>. <article-title>Impact of aging on dendritic cell functions in humans</article-title>. <source>Ageing Res Rev</source>. <year>2011</year>;<volume>10</volume>(<issue>3</issue>):<fpage>336</fpage>&#8211;<lpage>345</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arr.2010.06.004</pub-id>.<pub-id pub-id-type="pmid">20619360</pub-id><pub-id pub-id-type="pmcid">PMC3030666</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>S</given-names></string-name></person-group>. <article-title>Role of dendritic cells in inflammation and loss of tolerance in the elderly</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>896</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2017.00896</pub-id>.<pub-id pub-id-type="pmid">28798751</pub-id><pub-id pub-id-type="pmcid">PMC5526855</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Panda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mohanty</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Duin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Newman</surname><given-names>FK</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Towle</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Belshe</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Fikrig</surname><given-names>E</given-names></string-name></person-group>. et al. <article-title>Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response</article-title>. <source>J Immunol</source>. <year>2010</year>;<volume>184</volume>(<issue>5</issue>):<fpage>2518</fpage>&#8211;<lpage>2527</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.0901022</pub-id>.<pub-id pub-id-type="pmid">20100933</pub-id><pub-id pub-id-type="pmcid">PMC3867271</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garbe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bratke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Virchow</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Lommatzsch</surname><given-names>M</given-names></string-name></person-group>. <article-title>Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age</article-title>. <source>Hum Immunol</source>. <year>2012</year>;<volume>73</volume>(<issue>5</issue>):<fpage>493</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.humimm.2012.02.007</pub-id>.<pub-id pub-id-type="pmid">22386694</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Della Bella</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bierti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Presicce</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Arienti</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Valenti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saresella</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vergani</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Villa</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Peripheral blood dendritic cells and monocytes are differently regulated in the elderly</article-title>. <source>Clin Immunol</source>. <year>2007</year>;<volume>122</volume>(<issue>2</issue>):<fpage>220</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clim.2006.09.012</pub-id>.<pub-id pub-id-type="pmid">17101294</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jing</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shaheen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Drake</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gravenstein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood</article-title>. <source>Hum Immunol</source>. <year>2009</year>;<volume>70</volume>(<issue>10</issue>):<fpage>777</fpage>&#8211;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.humimm.2009.07.005</pub-id>.<pub-id pub-id-type="pmid">19596035</pub-id><pub-id pub-id-type="pmcid">PMC5718338</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wille-Reece</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Flynn</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Lor&#233;</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Koup</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Saul</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kedl</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Mattapallil</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Roederer</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates</article-title>. <source>J Exp Med</source>. <year>2006</year>;<volume>203</volume>(<issue>5</issue>):<fpage>1249</fpage>&#8211;<lpage>1258</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20052433</pub-id>.<pub-id pub-id-type="pmid">16636134</pub-id><pub-id pub-id-type="pmcid">PMC2121207</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Smithey</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Rudd</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Nikolich&#8208;&#381;ugich</surname><given-names>J</given-names></string-name></person-group>. <article-title>Age&#8208;associated alterations in CD8&#945;+ dendritic cells impair CD8 T&#8208;cell expansion in response to an intracellular bacterium</article-title>. <source>Aging Cell</source>. <year>2012</year>;<volume>11</volume>(<issue>6</issue>):<fpage>968</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1474-9726.2012.00867.x</pub-id>.<pub-id pub-id-type="pmid">22862959</pub-id><pub-id pub-id-type="pmcid">PMC3533767</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crooke</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Ovsyannikova</surname><given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Poland</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>RB</given-names></string-name></person-group>. <article-title>Immunosenescence: a systems-level overview of immune cell biology and strategies for improving vaccine responses</article-title>. <source>Exp Gerontol</source>. <year>2019</year>;<volume>124</volume>:<fpage>110632</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2019.110632</pub-id>.<pub-id pub-id-type="pmid">31201918</pub-id><pub-id pub-id-type="pmcid">PMC6849399</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brice&#241;o</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lissina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wanke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Afonso</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ragon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miquel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gostick</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Papagno</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Stiasny</surname><given-names>K</given-names></string-name></person-group>. et al. <article-title>Reduced na&#239;ve CD 8 + T -cell priming efficacy in elderly adults</article-title>. <source>Aging Cell</source>. <year>2016</year>;<volume>15</volume>(<issue>1</issue>):<fpage>14</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acel.12384</pub-id>.<pub-id pub-id-type="pmid">26472076</pub-id><pub-id pub-id-type="pmcid">PMC4717282</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sridharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Esposo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kaushal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tay</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Osann</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity</article-title>. <source>Age</source>. <year>2011</year>;<volume>33</volume>(<issue>3</issue>):<fpage>363</fpage>&#8211;<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11357-010-9191-3</pub-id>.<pub-id pub-id-type="pmid">20953722</pub-id><pub-id pub-id-type="pmcid">PMC3168606</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tosi</surname><given-names>MF</given-names></string-name></person-group>. <article-title>Innate immune responses to infection</article-title>. <source>J Allergy Clin Immunol</source>. <year>2005</year>;<volume>116</volume>(<issue>2</issue>):<fpage>241</fpage>&#8211;<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2005.05.036</pub-id>.<pub-id pub-id-type="pmid">16083775</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></string-name></person-group>. <article-title>Innate immunity: impact on the adaptive immune response</article-title>. <year>1997</year>;<volume>9</volume>(<issue>1</issue>):<fpage>4</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0952-7915(97)80152-5</pub-id>.<pub-id pub-id-type="pmid">9039775</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Understanding immunosenescence to improve responses to vaccines</article-title>. <source>Nat Immunol</source>. <year>2013</year>;<volume>14</volume>(<issue>5</issue>):<fpage>428</fpage>&#8211;<lpage>436</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.2588</pub-id>.<pub-id pub-id-type="pmid">23598398</pub-id><pub-id pub-id-type="pmcid">PMC4183346</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vallejo</surname><given-names>AN</given-names></string-name></person-group>. <article-title>CD28 extinction in human T cells: altered functions and the program of T&#8208;cell senescence</article-title>. <source>Immunol Rev</source>. <year>2005</year>;<volume>205</volume>(<issue>1</issue>):<fpage>158</fpage>&#8211;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00256.x</pub-id>.<pub-id pub-id-type="pmid">15882352</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weng</surname><given-names>N-P</given-names></string-name>, <string-name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>J</given-names></string-name></person-group>. <article-title>CD28&#8722; T cells: their role in the age-associated decline of immune function</article-title>. <source>Trends Immunol</source>. <year>2009</year>;<volume>30</volume>(<issue>7</issue>):<fpage>306</fpage>&#8211;<lpage>312</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.it.2009.03.013</pub-id>.<pub-id pub-id-type="pmid">19540809</pub-id><pub-id pub-id-type="pmcid">PMC2801888</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Appay</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nixon</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Donahoe</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gillespie</surname><given-names>GMA</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ogg</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Spiegel</surname><given-names>HML</given-names></string-name>, <string-name name-style="western"><surname>Conlon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Spina</surname><given-names>CA</given-names></string-name></person-group>. et al. <article-title>HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function</article-title>. <source>J Exp Med</source>. <year>2000</year>;<volume>192</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.192.1.63</pub-id>.<pub-id pub-id-type="pmid">10880527</pub-id><pub-id pub-id-type="pmcid">PMC1887711</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W-W</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Signal inhibition by the dual-specific phosphatase 4 impairs T cell-dependent B-cell responses with age</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2012</year>;<volume>109</volume>(<issue>15</issue>):<fpage>879</fpage>&#8211;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1109797109</pub-id>.<pub-id pub-id-type="pmcid">PMC3326453</pub-id><pub-id pub-id-type="pmid">22434910</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>S</given-names></string-name></person-group>. <article-title>Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection</article-title>. <source>Front Microbiol</source>. <year>2016</year>;<volume>7</volume>:<fpage>2111</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2016.02111</pub-id>.<pub-id pub-id-type="pmid">28082969</pub-id><pub-id pub-id-type="pmcid">PMC5186782</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mandal</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>DNA-damage-induced differentiation in hematopoietic stem cells</article-title>. <source>Cell</source>. <year>2012</year>;<volume>148</volume>(<issue>5</issue>):<fpage>847</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2012.02.011</pub-id>.<pub-id pub-id-type="pmid">22385954</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Steinmann</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Klaus</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller&#8208;Hermelink</surname><given-names>HK</given-names></string-name></person-group>. <article-title>The involution of the ageing human thymic epithelium is independent of puberty: a morphometric study</article-title>. <source>Scand J Immunol</source>. <year>1985</year>;<volume>22</volume>(<issue>5</issue>):<fpage>563</fpage>&#8211;<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-3083.1985.tb01916.x</pub-id>.<pub-id pub-id-type="pmid">4081647</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Czesnikiewicz-Guzik</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W-W</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hiruma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lamar</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z-Z</given-names></string-name>, <string-name name-style="western"><surname>Ouslander</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>T cell subset-specific susceptibility to aging</article-title>. <source>Clin Immunol</source>. <year>2008</year>;<volume>127</volume>(<issue>1</issue>):<fpage>107</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clim.2007.12.002</pub-id>.<pub-id pub-id-type="pmid">18222733</pub-id><pub-id pub-id-type="pmcid">PMC2435295</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qi</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Mechanisms shaping the na&#239;ve T cell repertoire in the elderly&#8212;thymic involution or peripheral homeostatic proliferation?</article-title><source>Exp Gerontol</source>. <year>2014</year>;<volume>54</volume>:<fpage>71</fpage>&#8211;<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2014.01.005</pub-id>.<pub-id pub-id-type="pmid">24440389</pub-id><pub-id pub-id-type="pmcid">PMC4096164</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hale</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Boursalian</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Turk</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Fink</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Thymic output in aged mice</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2006</year>;<volume>103</volume>(<issue>22</issue>):<fpage>8447</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0601040103</pub-id>.<pub-id pub-id-type="pmid">16717190</pub-id><pub-id pub-id-type="pmcid">PMC1482512</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naylor</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vallejo</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W-W</given-names></string-name>, <string-name name-style="western"><surname>Koetz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bryl</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Witkowski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fulbright</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name></person-group>. et al. <article-title>The influence of age on T cell generation and TCR diversity</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>174</volume>(<issue>11</issue>):<fpage>7446</fpage>&#8211;<lpage>7452</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.174.11.7446</pub-id>.<pub-id pub-id-type="pmid">15905594</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haynes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lefebvre</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Age-related deficiencies in antigen-specific CD4 T cell responses: lessons from mouse models</article-title>. <source>Aging Dis</source>. <year>2011</year>;<volume>2</volume>:<fpage>374</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">22396889</pub-id><pub-id pub-id-type="pmcid">PMC3295078</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kohler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Pierer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kimmig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Oppmann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>M&#246;wes</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>J&#252;lke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Romagnani</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thiel</surname><given-names>A</given-names></string-name></person-group>. <article-title>Post&#8208;thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults</article-title>. <source>Eur J Immunol</source>. <year>2005</year>;<volume>35</volume>(<issue>6</issue>):<fpage>1987</fpage>&#8211;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.200526181</pub-id>.<pub-id pub-id-type="pmid">15909312</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Valkenburg</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Venturi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>THY</given-names></string-name>, <string-name name-style="western"><surname>Bird</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Doherty</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Davenport</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Kedzierska</surname><given-names>K</given-names></string-name></person-group>. <article-title>Early priming minimizes the age-related immune compromise of CD8+ T cell diversity and function</article-title>. <source>PloS Pathog</source>. <year>2012</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e1002544</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1002544</pub-id>.<pub-id pub-id-type="pmid">22383879</pub-id><pub-id pub-id-type="pmcid">PMC3285595</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W-W</given-names></string-name>, <string-name name-style="western"><surname>Tsang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Krishnan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity</article-title>. <source>Nat Med</source>. <year>2012</year>;<volume>18</volume>(<issue>10</issue>):<fpage>1518</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2963</pub-id>.<pub-id pub-id-type="pmid">23023500</pub-id><pub-id pub-id-type="pmcid">PMC3466346</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pereira</surname><given-names>BI</given-names></string-name>, <string-name name-style="western"><surname>De Maeyer</surname><given-names>RPH</given-names></string-name>, <string-name name-style="western"><surname>Covre</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Nehar-Belaid</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lanna</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Marches</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname><given-names>DCO</given-names></string-name>, <string-name name-style="western"><surname>Riddell</surname><given-names>NE</given-names></string-name></person-group>. et al. <article-title>Sestrins induce natural killer function in senescent-like CD8+ T cells</article-title>. <source>Nat Immunol</source>. <year>2020</year>;<volume>21</volume>(<issue>6</issue>):<fpage>684</fpage>&#8211;<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-020-0643-3</pub-id>.<pub-id pub-id-type="pmid">32231301</pub-id><pub-id pub-id-type="pmcid">PMC10249464</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suarez&#8208;&#193;lvarez</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Schlangen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Raneros</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>M&#225;rquez-Kisinousky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az-Corte</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aransay</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Larrea</surname><given-names>C</given-names></string-name></person-group>. <article-title>Phenotypic characteristics of aged CD4 + CD28 null T lymphocytes are determined by changes in the whole-genome DNA methylation pattern</article-title>. <source>Aging Cell</source>. <year>2017</year>;<volume>16</volume>(<issue>2</issue>):<fpage>293</fpage>&#8211;<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acel.12552</pub-id>.<pub-id pub-id-type="pmid">28026094</pub-id><pub-id pub-id-type="pmcid">PMC5334526</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>I</given-names></string-name></person-group>. <article-title>Aging and human CD4+ regulatory T cells</article-title>. <source>Mech Ageing Dev</source>. <year>2009</year>;<volume>130</volume>(<issue>8</issue>):<fpage>509</fpage>&#8211;<lpage>517</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mad.2009.06.003</pub-id>.<pub-id pub-id-type="pmid">19540259</pub-id><pub-id pub-id-type="pmcid">PMC2753872</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lages</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Suffia</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><given-names>Velilla</given-names><surname>PA</surname></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Warshaw</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><given-names>Hildeman</given-names><surname>DA</surname></string-name>, <string-name name-style="western"><surname>Belkaid</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chougnet</surname><given-names>C.</given-names></string-name></person-group><article-title>Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>(<issue>3</issue>):<fpage>1835</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.181.3.1835</pub-id>.<pub-id pub-id-type="pmid">18641321</pub-id><pub-id pub-id-type="pmcid">PMC2587319</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosenkranz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weyer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tolosa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gaenslen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Leyhe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gasser</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stoltze</surname><given-names>L</given-names></string-name></person-group>. <article-title>Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration</article-title>. <source>J Neuroimmunol</source>. <year>2007</year>;<volume>188</volume>(<issue>1&#8211;2</issue>):<fpage>117</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.05.011</pub-id>.<pub-id pub-id-type="pmid">17582512</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shariff</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cobbold</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bruton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ainsworth</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Sinclair</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Nayak</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>PAH</given-names></string-name></person-group>. <article-title>Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals</article-title>. <source>J Immunol</source>. <year>2002</year>;<volume>169</volume>(<issue>4</issue>):<fpage>1984</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.169.4.1984</pub-id>.<pub-id pub-id-type="pmid">12165524</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Henson</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lanna</surname><given-names>A</given-names></string-name></person-group>. <article-title>Senescence of T lymphocytes: implications for enhancing human immunity</article-title>. <source>Trends Immunol</source>. <year>2016</year>;<volume>37</volume>(<issue>12</issue>):<fpage>866</fpage>&#8211;<lpage>876</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.it.2016.09.002</pub-id>.<pub-id pub-id-type="pmid">27720177</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>Pantaleo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></string-name></person-group>. <article-title>Immune correlates of vaccine protection against HIV-1 acquisition</article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>(<issue>310</issue>):<fpage>310rv7</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aac7732</pub-id>.<pub-id pub-id-type="pmcid">PMC4751141</pub-id><pub-id pub-id-type="pmid">26491081</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>WHO</surname></string-name></person-group>. <article-title>Correlates of vaccine-induced protection: methods and implications</article-title>. <publisher-loc>Geneva (Switzerland)</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siegrist</surname><given-names>C-A</given-names></string-name>, <string-name name-style="western"><surname>Aspinall</surname><given-names>R</given-names></string-name></person-group>. <article-title>B-cell responses to vaccination at the extremes of age</article-title>. <source>Nat Rev Immunol</source>. <year>2009</year>;<volume>9</volume>(<issue>3</issue>):<fpage>185</fpage>&#8211;<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2508</pub-id>.<pub-id pub-id-type="pmid">19240757</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jefferson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rivetti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rivetti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rudin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Di Pietrantonj</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Demicheli</surname><given-names>V</given-names></string-name></person-group>. <article-title>Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>(<issue>9492</issue>):<fpage>1165</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(05)67339-4</pub-id>.<pub-id pub-id-type="pmid">16198765</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schenkein</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></string-name></person-group>. <article-title>Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>(<issue>43</issue>):<fpage>5521</fpage>&#8211;<lpage>5526</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.071</pub-id>.<pub-id pub-id-type="pmid">18706464</pub-id><pub-id pub-id-type="pmcid">PMC2574975</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cunningham</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Lal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kovac</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chlibek</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>S-J</given-names></string-name>, <string-name name-style="western"><surname>D&#237;ez-Domingo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Godeaux</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McElhaney</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Puig-Barber&#224;</surname><given-names>J</given-names></string-name></person-group>. et al. <article-title>Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>11</issue>):<fpage>1019</fpage>&#8211;<lpage>1032</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1603800</pub-id>.<pub-id pub-id-type="pmid">27626517</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Triglav</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Poljak</surname><given-names>M</given-names></string-name></person-group>. <article-title>Vaccination indications and limits in the elderly</article-title>. <source>Acta Dermatovenerol Alp Pannonica Adriat</source>. <year>2013</year>;<volume>22</volume>:<fpage>65</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">24089135</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaml</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weiskirchner</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Luft</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hoster</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hasford</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bartlett</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Neuner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>K-H</given-names></string-name></person-group>. et al. <article-title>Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers</article-title>. <source>Vaccine</source>. <year>2006</year>;<volume>24</volume>(<issue>47&#8211;48</issue>):<fpage>6808</fpage>&#8211;<lpage>6811</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.037</pub-id>.<pub-id pub-id-type="pmid">16872725</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frasca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blomberg</surname><given-names>BB</given-names></string-name></person-group>. <article-title>The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>25</issue>):<fpage>2834</fpage>&#8211;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.023</pub-id>.<pub-id pub-id-type="pmid">27108193</pub-id><pub-id pub-id-type="pmcid">PMC4876633</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rossi</surname><given-names>MID</given-names></string-name>, <string-name name-style="western"><surname>Yokota</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Medina</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Garrett</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Comp</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Schipul</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Kincade</surname><given-names>PW</given-names></string-name></person-group>. <article-title>B lymphopoiesis is active throughout human life, but there are developmental age-related changes</article-title>. <source>Blood</source>. <year>2003</year>;<volume>101</volume>(<issue>2</issue>):<fpage>576</fpage>&#8211;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2002-03-0896</pub-id>.<pub-id pub-id-type="pmid">12393702</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y-C</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duggan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Vaughan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kondeatis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nilsson</surname><given-names>B-O</given-names></string-name>, <string-name name-style="western"><surname>Wikby</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kipling</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dunn&#8208;Walters</surname><given-names>DK</given-names></string-name></person-group>. et al. <article-title>B&#8208;cell diversity decreases in old age and is correlated with poor health status</article-title>. <source>Aging Cell</source>. <year>2009</year>;<volume>8</volume>(<issue>1</issue>):<fpage>18</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1474-9726.2008.00443.x</pub-id>.<pub-id pub-id-type="pmid">18986373</pub-id><pub-id pub-id-type="pmcid">PMC2667647</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>Y</given-names></string-name></person-group>. <article-title>B cell dysfunction associated with aging and autoimmune diseases</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>318</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.00318</pub-id>.<pub-id pub-id-type="pmid">30873171</pub-id><pub-id pub-id-type="pmcid">PMC6400972</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mouat</surname><given-names>IC</given-names></string-name>, <string-name name-style="western"><surname>Goldberg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Horwitz</surname><given-names>MS</given-names></string-name></person-group>. <article-title>Age-associated B cells in autoimmune diseases</article-title>. <source>Cell Mol Life Sci</source>. <year>2022</year>;<volume>79</volume>(<issue>8</issue>):<fpage>402</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-022-04433-9</pub-id>.<pub-id pub-id-type="pmid">35798993</pub-id><pub-id pub-id-type="pmcid">PMC9263041</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frasca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Eramo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Blomberg</surname><given-names>BB</given-names></string-name></person-group>. <article-title>Aging effects on T-bet expression in human B cell subsets</article-title>. <source>Cell Immunol</source>. <year>2017</year>;<volume>321</volume>:<fpage>68</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cellimm.2017.04.007</pub-id>.<pub-id pub-id-type="pmid">28457482</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rubtsova</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rubtsov</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>van Dyk</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Marrack</surname><given-names>P</given-names></string-name></person-group>. <article-title>T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2013</year>;<volume>110</volume>(<issue>34</issue>):<fpage>3216</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1312348110</pub-id>.<pub-id pub-id-type="pmid">23922396</pub-id><pub-id pub-id-type="pmcid">PMC3752276</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Karnell</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Naiman</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zerrouki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Morehouse</surname><given-names>C</given-names></string-name></person-group>. et al. <article-title>IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1758</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-018-03750-7</pub-id>.<pub-id pub-id-type="pmid">29717110</pub-id><pub-id pub-id-type="pmcid">PMC5931508</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jenks</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Cashman</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Zumaquero</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Marigorta</surname><given-names>UM</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tomar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Woodruff</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bugrovsky</surname><given-names>R</given-names></string-name></person-group>. et al. <article-title>Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus</article-title>. <source>Immunity</source>. <year>2018</year>;<volume>49</volume>(<issue>4</issue>):<fpage>725</fpage>&#8211;<lpage>39.e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2018.08.015</pub-id>.<pub-id pub-id-type="pmid">30314758</pub-id><pub-id pub-id-type="pmcid">PMC6217820</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jegerlehner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maurer</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bessa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hinton</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Kopf</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></string-name></person-group>. <article-title>TLR9 signaling in B cells determines class switch recombination to IgG2a</article-title>. <source>J Immunol</source>. <year>2007</year>;<volume>178</volume>(<issue>4</issue>):<fpage>2415</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2415</pub-id>.<pub-id pub-id-type="pmid">17277148</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lederman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Harding</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mohner</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sieg</surname><given-names>S</given-names></string-name></person-group>. <article-title>TLR9 stimulation drives na&#239;ve B cells to proliferate and to attain enhanced antigen presenting function</article-title>. <source>Eur J Immunol</source>. <year>2007</year>;<volume>37</volume>(<issue>8</issue>):<fpage>2205</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.200636984</pub-id>.<pub-id pub-id-type="pmid">17621369</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suthers</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Sarantopoulos</surname><given-names>S</given-names></string-name></person-group>. <article-title>TLR7/TLR9-and B cell receptor-signaling crosstalk: promotion of potentially dangerous B cells</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>775</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2017.00775</pub-id>.<pub-id pub-id-type="pmid">28751890</pub-id><pub-id pub-id-type="pmcid">PMC5507964</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Okubo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Uehara</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sugane</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Agematsu</surname><given-names>K</given-names></string-name></person-group>. <article-title>Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>175</volume>(<issue>5</issue>):<fpage>3262</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.175.5.3262</pub-id>.<pub-id pub-id-type="pmid">16116217</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weinstein</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Penland</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sasaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X-S</given-names></string-name>, <string-name name-style="western"><surname>Dekker</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>N-Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Lineage structure of the human antibody repertoire in response to influenza vaccination</article-title>. <source>Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>(<issue>171</issue>):<fpage>171ra19</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3004794</pub-id>.<pub-id pub-id-type="pmcid">PMC3699344</pub-id><pub-id pub-id-type="pmid">23390249</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R-F</given-names></string-name></person-group>. <article-title>Toll-like receptor signaling and its role in cell-mediated immunity</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>812774</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.812774</pub-id>.<pub-id pub-id-type="pmid">35309296</pub-id><pub-id pub-id-type="pmcid">PMC8927970</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name></person-group>. <article-title>Infection and atherosclerosis: TLR-dependent pathways</article-title>. <source>Cell Mol Life Sci</source>. <year>2020</year>;<volume>77</volume>(<issue>14</issue>):<fpage>2751</fpage>&#8211;<lpage>2769</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-020-03453-7</pub-id>.<pub-id pub-id-type="pmid">32002588</pub-id><pub-id pub-id-type="pmcid">PMC7223178</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seder</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Vaccine adjuvants: putting innate immunity to work</article-title>. <source>Immunity</source>. <year>2010</year>;<volume>33</volume>(<issue>4</issue>):<fpage>492</fpage>&#8211;<lpage>503</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id>.<pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></string-name></person-group>. <article-title>A guide to vaccinology: from basic principles to new developments</article-title>. <source>Nat Rev Immunol</source>. <year>2021</year>;<volume>21</volume>(<issue>2</issue>):<fpage>83</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id>.<pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hutchinson</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <article-title>Small-molecule modulators of toll-like receptors</article-title>. <source>Acc Chem Res</source>. <year>2020</year>;<volume>53</volume>(<issue>5</issue>):<fpage>1046</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.accounts.9b00631</pub-id>.<pub-id pub-id-type="pmid">32233400</pub-id></mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ong</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>BSX</given-names></string-name>, <string-name name-style="western"><surname>Kawasaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kawai</surname><given-names>T</given-names></string-name></person-group>. <article-title>Exploration of pattern recognition receptor agonists as candidate adjuvants</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2021</year>;<volume>11</volume>:<fpage>968</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2021.745016</pub-id>.<pub-id pub-id-type="pmcid">PMC8526852</pub-id><pub-id pub-id-type="pmid">34692565</pub-id></mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kawai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Akira</surname><given-names>S</given-names></string-name></person-group>. <article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat Immunol</source>. <year>2010</year>;<volume>11</volume>(<issue>5</issue>):<fpage>373</fpage>&#8211;<lpage>384</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.1863</pub-id>.<pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blasius</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Beutler</surname><given-names>B</given-names></string-name></person-group>. <article-title>Intracellular toll-like receptors</article-title>. <source>Immunity</source>. <year>2010</year>;<volume>32</volume>(<issue>3</issue>):<fpage>305</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2010.03.012</pub-id>.<pub-id pub-id-type="pmid">20346772</pub-id></mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desmet</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></string-name></person-group>. <article-title>Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination</article-title>. <source>Nat Rev Immunol</source>. <year>2012</year>;<volume>12</volume>(<issue>7</issue>):<fpage>479</fpage>&#8211;<lpage>491</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri3247</pub-id>.<pub-id pub-id-type="pmid">22728526</pub-id></mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nanda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>P</given-names></string-name></person-group>. <article-title>Molecular control of the NEMO family of ubiquitin-binding proteins</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>673</fpage>&#8211;<lpage>685</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrm3644</pub-id>.<pub-id pub-id-type="pmid">23989959</pub-id></mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>K-S</given-names></string-name>, <string-name name-style="western"><surname>Dutta</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vayttaden</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ebert</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>De Nardo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bagirzadeh</surname><given-names>R</given-names></string-name></person-group>. et al. <article-title>Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use</article-title>. <source>Sci Signal</source>. <year>2016</year>;<volume>9</volume>(<issue>409</issue>):<fpage>3</fpage>&#8211;<lpage>3</lpage>. doi:<pub-id pub-id-type="doi">10.1126/scisignal.aab2191</pub-id>.<pub-id pub-id-type="pmcid">PMC5381726</pub-id><pub-id pub-id-type="pmid">26732763</pub-id></mixed-citation></ref><ref id="cit0131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Piecychna</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Allore</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bockenstedt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Malawista</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bucala</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>AC</given-names></string-name></person-group>. et al. <article-title>Age&#8208;associated elevation in TLR5 leads to increased inflammatory responses in the elderly</article-title>. <source>Aging Cell</source>. <year>2012</year>;<volume>11</volume>(<issue>1</issue>):<fpage>104</fpage>&#8211;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00759.x</pub-id>.<pub-id pub-id-type="pmid">22023165</pub-id><pub-id pub-id-type="pmcid">PMC3257374</pub-id></mixed-citation></ref><ref id="cit0132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Kagan</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Toll-like receptors and the control of immunity</article-title>. <source>Cell</source>. <year>2020</year>;<volume>180</volume>(<issue>6</issue>):<fpage>1044</fpage>&#8211;<lpage>1066</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id>.<pub-id pub-id-type="pmid">32164908</pub-id><pub-id pub-id-type="pmcid">PMC9358771</pub-id></mixed-citation></ref><ref id="cit0133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kawasaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kawai</surname><given-names>T</given-names></string-name></person-group>. <article-title>Toll-like receptor signaling pathways</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>461</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id>.<pub-id pub-id-type="pmid">25309543</pub-id><pub-id pub-id-type="pmcid">PMC4174766</pub-id></mixed-citation></ref><ref id="cit0134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></string-name></person-group>. <article-title>Modulating vaccine responses with dendritic cells and Toll&#8208;like receptors</article-title>. <source>Immunol Rev</source>. <year>2004</year>;<volume>199</volume>(<issue>1</issue>):<fpage>227</fpage>&#8211;<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00144.x</pub-id>.<pub-id pub-id-type="pmid">15233738</pub-id></mixed-citation></ref><ref id="cit0135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McWhirter</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Rosains</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rowe</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Golenbock</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Maniatis</surname><given-names>T</given-names></string-name></person-group>. <article-title>IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>101</volume>(<issue>1</issue>):<fpage>233</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2237236100</pub-id>.<pub-id pub-id-type="pmid">14679297</pub-id><pub-id pub-id-type="pmcid">PMC314168</pub-id></mixed-citation></ref><ref id="cit0136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ning</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pagano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>G</given-names></string-name></person-group>. <article-title>IRF7: activation, regulation, modification and function</article-title>. <source>Genes Immun</source>. <year>2011</year>;<volume>12</volume>(<issue>6</issue>):<fpage>399</fpage>&#8211;<lpage>414</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gene.2011.21</pub-id>.<pub-id pub-id-type="pmid">21490621</pub-id><pub-id pub-id-type="pmcid">PMC4437765</pub-id></mixed-citation></ref><ref id="cit0137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Philbin</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Gallington</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Cort&#233;s</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Suter</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Shuckett</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stoler-Barak</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tomai</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1&#8211;dependent pathways</article-title>. <source>J Allergy Clin Immunol</source>. <year>2012</year>;<volume>130</volume>(<issue>1</issue>):<fpage>195</fpage>&#8211;<lpage>204. e9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2012.02.042</pub-id>.<pub-id pub-id-type="pmid">22521247</pub-id><pub-id pub-id-type="pmcid">PMC3387351</pub-id></mixed-citation></ref><ref id="cit0138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maisonneuve</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Philpott</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></string-name></person-group>. <article-title>Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>(<issue>34</issue>):<fpage>12294</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1400478111</pub-id>.<pub-id pub-id-type="pmid">25136133</pub-id><pub-id pub-id-type="pmcid">PMC4151741</pub-id></mixed-citation></ref><ref id="cit0139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooney</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brain</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Danis</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pichulik</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Allan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname><given-names>DJP</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Jewell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>A</given-names></string-name></person-group>. et al. <article-title>NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation</article-title>. <source>Nat Med</source>. <year>2010</year>;<volume>16</volume>(<issue>1</issue>):<fpage>90</fpage>&#8211;<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2069</pub-id>.<pub-id pub-id-type="pmid">19966812</pub-id></mixed-citation></ref><ref id="cit0140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reed</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Casper</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Duthie</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>CB</given-names></string-name></person-group>. <article-title>Correlates of GLA family adjuvants&#8217; activities</article-title>. <source>Semin Immunol</source>. <year>2018</year>;<volume>39</volume>:<fpage>22</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2018.10.004</pub-id>.<pub-id pub-id-type="pmid">30366662</pub-id><pub-id pub-id-type="pmcid">PMC6289613</pub-id></mixed-citation></ref><ref id="cit0141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alving</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>SG</given-names></string-name></person-group>. <article-title>Adjuvants for human vaccines</article-title>. <source>Curr Opin Immunol</source>. <year>2012</year>;<volume>24</volume>(<issue>3</issue>):<fpage>310</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coi.2012.03.008</pub-id>.<pub-id pub-id-type="pmid">22521140</pub-id><pub-id pub-id-type="pmcid">PMC3383374</pub-id></mixed-citation></ref><ref id="cit0142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamdy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Molavi</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Haddadi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alshamsan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gobti</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Elhasi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Samuel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lavasanifar</surname><given-names>A</given-names></string-name></person-group>. <article-title>Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>(<issue>39</issue>):<fpage>5046</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.035</pub-id>.<pub-id pub-id-type="pmid">18680779</pub-id></mixed-citation></ref><ref id="cit0143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fries</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Egan</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Hollingdale</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Silverman</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alving</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1992</year>;<volume>89</volume>(<issue>1</issue>):<fpage>358</fpage>&#8211;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.89.1.358</pub-id>.<pub-id pub-id-type="pmid">1729706</pub-id><pub-id pub-id-type="pmcid">PMC48236</pub-id></mixed-citation></ref><ref id="cit0144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Morel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lockman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Giannini</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Bisteau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Carlsen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kielland</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vosters</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Vanderheyde</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schiavetti</surname><given-names>F</given-names></string-name></person-group>. et al. <article-title>AS04, an Aluminum Salt- and TLR4 Agonist-Based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity</article-title>. <source>J Immunol</source>. <year>2009</year>;<volume>183</volume>(<issue>10</issue>):<fpage>6186</fpage>&#8211;<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id>.<pub-id pub-id-type="pmid">19864596</pub-id></mixed-citation></ref><ref id="cit0145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cauwelaert</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Desbien</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Pine</surname><given-names>SO</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Coler</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Orr</surname><given-names>MT</given-names></string-name></person-group>. <article-title>The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction</article-title>. <source>PloS One</source>. <year>2016</year>;<volume>11</volume>(<issue>1</issue>):<fpage>e0146372</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0146372</pub-id>.<pub-id pub-id-type="pmid">26731269</pub-id><pub-id pub-id-type="pmcid">PMC4701231</pub-id></mixed-citation></ref><ref id="cit0146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pantel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cheong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dandamudi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brane</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ruane</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bozzacco</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></string-name></person-group>. et al. <article-title>A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T&#8208;cell immunity in vivo</article-title>. <source>Eur J Immunol</source>. <year>2012</year>;<volume>42</volume>(<issue>1</issue>):<fpage>101</fpage>&#8211;<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.201141855</pub-id>.<pub-id pub-id-type="pmid">22002164</pub-id><pub-id pub-id-type="pmcid">PMC3517108</pub-id></mixed-citation></ref><ref id="cit0147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clegg</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Roque</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Van Hoeven</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Rininger</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bowen</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>SG</given-names></string-name></person-group>. <article-title>Adjuvant solution for pandemic influenza vaccine production</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2012</year>;<volume>109</volume>(<issue>43</issue>):<fpage>17585</fpage>&#8211;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1207308109</pub-id>.<pub-id pub-id-type="pmid">23045649</pub-id><pub-id pub-id-type="pmcid">PMC3491477</pub-id></mixed-citation></ref><ref id="cit0148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coler</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Shaverdian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Raman</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>DeVos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hancock</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>JM</given-names></string-name></person-group>. et al. <article-title>A synthetic adjuvant to enhance and expand immune responses to influenza vaccines</article-title>. <source>PloS One</source>. <year>2010</year>;<volume>5</volume>(<issue>10</issue>):<fpage>e13677</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0013677</pub-id>.<pub-id pub-id-type="pmid">21060869</pub-id><pub-id pub-id-type="pmcid">PMC2965144</pub-id></mixed-citation></ref><ref id="cit0149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ashour</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rebs</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arampatzi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>A-E</given-names></string-name>, <string-name name-style="western"><surname>Dudek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hofmann</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Frantz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cochain</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Streckfu&#223;-B&#246;meke</surname><given-names>K</given-names></string-name></person-group>. et al. <article-title>An interferon gamma response signature links myocardial aging and immunosenescence</article-title>. <source>Cardiovasc Res</source>. <year>2023</year>;<volume>119</volume>(<issue>14</issue>):<fpage>2458</fpage>&#8211;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cvr/cvad068</pub-id>.<pub-id pub-id-type="pmid">37141306</pub-id><pub-id pub-id-type="pmcid">PMC10651211</pub-id></mixed-citation></ref><ref id="cit0150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Falloon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Esser</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Villafana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Takas</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></string-name></person-group>. <article-title>An adjuvanted, postfusion F protein&#8211;based vaccine did not prevent respiratory syncytial virus illness in older adults</article-title>. <source>J Infect Dis</source>. <year>2017</year>;<volume>216</volume>(<issue>11</issue>):<fpage>1362</fpage>&#8211;<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jix503</pub-id>.<pub-id pub-id-type="pmid">29029260</pub-id><pub-id pub-id-type="pmcid">PMC5853767</pub-id></mixed-citation></ref><ref id="cit0151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>HogenEsch</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>CB</given-names></string-name></person-group>. <article-title>Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want</article-title>. <source>NPJ Vaccin</source>. <year>2018</year>;<volume>3</volume>(<issue>1</issue>):<fpage>51</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id>.<pub-id pub-id-type="pmcid">PMC6180056</pub-id><pub-id pub-id-type="pmid">30323958</pub-id></mixed-citation></ref><ref id="cit0152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Powell</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Andrianov</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Fusco</surname><given-names>PC</given-names></string-name></person-group>. <article-title>Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes</article-title>. <source>Clin Exp Vaccine Res</source>. <year>2015</year>;<volume>4</volume>(<issue>1</issue>):<fpage>23</fpage>&#8211;<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.7774/cevr.2015.4.1.23</pub-id>.<pub-id pub-id-type="pmid">25648619</pub-id><pub-id pub-id-type="pmcid">PMC4313107</pub-id></mixed-citation></ref><ref id="cit0153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></string-name></person-group>. <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat Rev Drug Discov</source>. <year>2021</year>;<volume>20</volume>(<issue>6</issue>):<fpage>454</fpage>&#8211;<lpage>475</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id>.<pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></mixed-citation></ref><ref id="cit0154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Awate</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Babiuk</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></string-name></person-group>. <article-title>Mechanisms of action of adjuvants</article-title>. <source>Front Immunol</source>. <year>2013</year>;<volume>4</volume>:<fpage>114</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2013.00114</pub-id>.<pub-id pub-id-type="pmid">23720661</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id></mixed-citation></ref><ref id="cit0155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>B</given-names></string-name></person-group>. <article-title>Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>24</issue>):<fpage>3167</fpage>&#8211;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id>.<pub-id pub-id-type="pmid">31047671</pub-id></mixed-citation></ref><ref id="cit0156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stephen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Scales</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Benson</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Erben</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Garside</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Brewer</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity</article-title>. <source>NPJ Vaccin</source>. <year>2017</year>;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-016-0001-5</pub-id>.<pub-id pub-id-type="pmcid">PMC5604741</pub-id><pub-id pub-id-type="pmid">29263862</pub-id></mixed-citation></ref><ref id="cit0157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marichal</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ohata</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bedoret</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mesnil</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sabatel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lekeux</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Coban</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Akira</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></string-name></person-group>. et al. <article-title>DNA released from dying host cells mediates aluminum adjuvant activity</article-title>. <source>Nat Med</source>. <year>2011</year>;<volume>17</volume>(<issue>8</issue>):<fpage>996</fpage>&#8211;<lpage>1002</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2403</pub-id>.<pub-id pub-id-type="pmid">21765404</pub-id></mixed-citation></ref><ref id="cit0158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fox</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Barnes V</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dowling</surname><given-names>QM</given-names></string-name>, <string-name name-style="western"><surname>Vedvick</surname><given-names>TS</given-names></string-name></person-group>. <article-title>Working together: interactions between vaccine antigens and adjuvants</article-title>. <source>Ther Adv Vaccines</source>. <year>2013</year>;<volume>1</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2051013613480144</pub-id>.<pub-id pub-id-type="pmid">24757512</pub-id><pub-id pub-id-type="pmcid">PMC3967670</pub-id></mixed-citation></ref><ref id="cit0159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>T</given-names></string-name></person-group>. <article-title>Nanomaterial-based vaccine adjuvants</article-title>. <source>J Mater Chem B</source>. <year>2016</year>;<volume>4</volume>(<issue>33</issue>):<fpage>5496</fpage>&#8211;<lpage>5509</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C6TB01131D</pub-id>.<pub-id pub-id-type="pmid">30774955</pub-id><pub-id pub-id-type="pmcid">PMC6377210</pub-id></mixed-citation></ref><ref id="cit0160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X-D</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>G</given-names></string-name></person-group>. <article-title>Particulate alum via Pickering emulsion for an enhanced COVID&#8208;19 vaccine adjuvant</article-title>. <source>Adv Mater</source>. <year>2020</year>;<volume>32</volume>(<issue>40</issue>):<fpage>2004210</fpage>. doi:<pub-id pub-id-type="doi">10.1002/adma.202004210</pub-id>.<pub-id pub-id-type="pmid">32864794</pub-id></mixed-citation></ref><ref id="cit0161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moyer</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>JYH</given-names></string-name>, <string-name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Menis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abbott</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Bhiman</surname><given-names>JN</given-names></string-name></person-group>. et al. <article-title>Engineered immunogen binding to alum adjuvant enhances humoral immunity</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>3</issue>):<fpage>430</fpage>&#8211;<lpage>440</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-020-0753-3</pub-id>.<pub-id pub-id-type="pmid">32066977</pub-id><pub-id pub-id-type="pmcid">PMC7069805</pub-id></mixed-citation></ref><ref id="cit0162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luchner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reinke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Milicic</surname><given-names>A</given-names></string-name></person-group>. <article-title>TLR agonists as vaccine adjuvants targeting cancer and infectious diseases</article-title>. <source>Pharmaceutics</source>. <year>2021</year>;<volume>13</volume>(<issue>2</issue>):<fpage>142</fpage>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics13020142</pub-id>.<pub-id pub-id-type="pmid">33499143</pub-id><pub-id pub-id-type="pmcid">PMC7911620</pub-id></mixed-citation></ref><ref id="cit0163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bode</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Steinhagen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kinjo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Klinman</surname><given-names>DM</given-names></string-name></person-group>. <article-title>CpG DNA as a vaccine adjuvant</article-title>. <source>Expert Rev Vaccines</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>499</fpage>&#8211;<lpage>511</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erv.10.174</pub-id>.<pub-id pub-id-type="pmid">21506647</pub-id><pub-id pub-id-type="pmcid">PMC3108434</pub-id></mixed-citation></ref><ref id="cit0164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vollmer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Krieg</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists</article-title>. <source><italic toggle="yes">Adv Drug Deliv Rev</italic></source>. <year>2009</year>;<volume>61</volume>(<issue>3</issue>):<fpage>195</fpage>&#8211;<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addr.2008.12.008</pub-id>.<pub-id pub-id-type="pmid">19211030</pub-id></mixed-citation></ref><ref id="cit0165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krug</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rothenfusser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hornung</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jahrsd&#246;rfer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Blackwell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ballas</surname><given-names>ZK</given-names></string-name>, <string-name name-style="western"><surname>Endres</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Krieg</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hartmann</surname><given-names>G</given-names></string-name></person-group>. <article-title>Identification of CpG oligonucleotide sequences with high induction of IFN&#8208;&#945;/&#946; in plasmacytoid dendritic cells</article-title>. <source>Eur J Immunol</source>. <year>2001</year>;<volume>31</volume>(<issue>7</issue>):<fpage>2154</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-4141(200107)31:7&amp;#x0003c;2154:AID-IMMU2154&amp;#x0003e;3.0.CO;2-U</pub-id>.<pub-id pub-id-type="pmid">11449369</pub-id></mixed-citation></ref><ref id="cit0166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kranzer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lipford</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Heeg</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>R</given-names></string-name></person-group>. <article-title>CpG&#8208;oligodeoxynucleotides enhance T&#8208;cell receptor&#8208;triggered interferon&#8208;&#947; production and up&#8208;regulation of CD69 via induction of antigen&#8208;presenting cell&#8208;derived interferon type I and interleukin&#8208;12</article-title>. <source>Immunology</source>. <year>2000</year>;<volume>99</volume>(<issue>2</issue>):<fpage>170</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2567.2000.00964.x</pub-id>.<pub-id pub-id-type="pmid">10692033</pub-id><pub-id pub-id-type="pmcid">PMC2327140</pub-id></mixed-citation></ref><ref id="cit0167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuo</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>M-Y</given-names></string-name>, <string-name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Traquina</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y-J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>LTC</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y-C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C-C</given-names></string-name></person-group>. et al. <article-title>Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>20085</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-77077-z</pub-id>.<pub-id pub-id-type="pmid">33208827</pub-id><pub-id pub-id-type="pmcid">PMC7676267</pub-id></mixed-citation></ref><ref id="cit0168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lentino</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ellison</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shockey</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Akella</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Erby</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Heyward</surname><given-names>WL</given-names></string-name></person-group>. et al. <article-title>Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>5</issue>):<fpage>668</fpage>&#8211;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.12.038</pub-id>.<pub-id pub-id-type="pmid">29289383</pub-id></mixed-citation></ref><ref id="cit0169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooper</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mackie</surname><given-names>D</given-names></string-name></person-group>. <article-title>Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV&#8482; safety and efficacy</article-title>. <source>Expert Rev Vaccines</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>417</fpage>&#8211;<lpage>427</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erv.10.162</pub-id>.<pub-id pub-id-type="pmid">21506639</pub-id></mixed-citation></ref><ref id="cit0170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McMillan</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Donnell</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Sanyal</surname><given-names>M</given-names></string-name></person-group>. <article-title>Pattern recognition receptor ligand-induced differentiation of human transitional B cells</article-title>. <source>PloS One</source>. <year>2022</year>;<volume>17</volume>(<issue>8</issue>):<fpage>e0273810</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0273810</pub-id>.<pub-id pub-id-type="pmid">36040923</pub-id><pub-id pub-id-type="pmcid">PMC9426890</pub-id></mixed-citation></ref><ref id="cit0171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gilmartin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Toth</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hussein</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stephenson</surname><given-names>R</given-names></string-name></person-group>. <article-title>Advances in infectious disease vaccine adjuvants</article-title>. <source>Vaccines</source>. <year>2022</year>;<volume>10</volume>(<issue>7</issue>):<fpage>1120</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines10071120</pub-id>.<pub-id pub-id-type="pmid">35891284</pub-id><pub-id pub-id-type="pmcid">PMC9316175</pub-id></mixed-citation></ref><ref id="cit0172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lien</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>T-Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y-J</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>W-C</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>M-Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>LTC</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>Y-C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name></person-group>. <article-title>Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern</article-title>. <source>Clin Infect Dis</source>. <year>2022</year>;<volume>74</volume>(<issue>11</issue>):<fpage>1899</fpage>&#8211;<lpage>905</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab711</pub-id>.<pub-id pub-id-type="pmid">34739037</pub-id><pub-id pub-id-type="pmcid">PMC9187310</pub-id></mixed-citation></ref><ref id="cit0173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lien</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y-J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>W-C</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>T-Y</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Traquina</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>M-Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>LTC</given-names></string-name>, <string-name name-style="western"><surname>Chuang</surname><given-names>Y-S</given-names></string-name></person-group>. et al. <article-title>CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>8761</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-88283-8</pub-id>.<pub-id pub-id-type="pmid">33888840</pub-id><pub-id pub-id-type="pmcid">PMC8062487</pub-id></mixed-citation></ref><ref id="cit0174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moses</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Papadopoulou</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Osbourn</surname><given-names>A</given-names></string-name></person-group>. <article-title>Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives</article-title>. <source><italic toggle="yes">Crit Rev Biochem Mol Biol</italic></source>. <year>2014</year>;<volume>49</volume>(<issue>6</issue>):<fpage>439</fpage>&#8211;<lpage>462</lpage>. doi:<pub-id pub-id-type="doi">10.3109/10409238.2014.953628</pub-id>.<pub-id pub-id-type="pmid">25286183</pub-id><pub-id pub-id-type="pmcid">PMC4266039</pub-id></mixed-citation></ref><ref id="cit0175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajput</surname><given-names>ZI</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>S-H</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>C-W</given-names></string-name>, <string-name name-style="western"><surname>Arijo</surname><given-names>AG</given-names></string-name></person-group>. <article-title>Adjuvant effects of saponins on animal immune responses</article-title>. <source>J Zhejiang Univ Sci B</source>. <year>2007</year>;<volume>8</volume>(<issue>3</issue>):<fpage>153</fpage>&#8211;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1631/jzus.2007.B0153</pub-id>.<pub-id pub-id-type="pmid">17323426</pub-id><pub-id pub-id-type="pmcid">PMC1810383</pub-id></mixed-citation></ref><ref id="cit0176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chea</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pillarsetty</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Livingston</surname><given-names>PO</given-names></string-name>, <string-name name-style="western"><surname>Ragupathi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Gin</surname><given-names>DY</given-names></string-name></person-group>. et al. <article-title>Development of a minimal saponin vaccine adjuvant based on QS-21</article-title>. <source>Nat Chem</source>. <year>2014</year>;<volume>6</volume>(<issue>7</issue>):<fpage>635</fpage>&#8211;<lpage>643</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nchem.1963</pub-id>.<pub-id pub-id-type="pmid">24950335</pub-id><pub-id pub-id-type="pmcid">PMC4215704</pub-id></mixed-citation></ref><ref id="cit0177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M-A</given-names></string-name></person-group>. <article-title>Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review</article-title>. <source>Phytomedicine</source>. <year>2019</year>;<volume>60</volume>:<fpage>152905</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phymed.2019.152905</pub-id>.<pub-id pub-id-type="pmid">31182297</pub-id><pub-id pub-id-type="pmcid">PMC7127804</pub-id></mixed-citation></ref><ref id="cit0178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marciani</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Elucidating the mechanisms of action of saponin-derived adjuvants</article-title>. <source>Trends Pharmacol Sci</source>. <year>2018</year>;<volume>39</volume>(<issue>6</issue>):<fpage>573</fpage>&#8211;<lpage>585</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tips.2018.03.005</pub-id>.<pub-id pub-id-type="pmid">29655658</pub-id></mixed-citation></ref><ref id="cit0179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>GD</given-names></string-name></person-group>. <article-title>Dectin-1: a signalling non-TLR pattern-recognition receptor</article-title>. <source>Nat Rev Immunol</source>. <year>2006</year>;<volume>6</volume>(<issue>1</issue>):<fpage>33</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri1745</pub-id>.<pub-id pub-id-type="pmid">16341139</pub-id></mixed-citation></ref><ref id="cit0180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pifferi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fuentes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A</given-names></string-name></person-group>. <article-title>Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action</article-title>. <source>Nat Rev Chem</source>. <year>2021</year>;<volume>5</volume>(<issue>3</issue>):<fpage>197</fpage>&#8211;<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41570-020-00244-3</pub-id>.<pub-id pub-id-type="pmid">33521324</pub-id><pub-id pub-id-type="pmcid">PMC7829660</pub-id></mixed-citation></ref><ref id="cit0181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tuo</surname><given-names>W</given-names></string-name></person-group>. <article-title>QS-21: a potent vaccine adjuvant</article-title>. <source>Nat Prod Chem Res</source>. <year>2016</year>;<volume>3</volume>(<issue>4</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4172/2329-6836.1000e113</pub-id><pub-id pub-id-type="pmcid">PMC4874334</pub-id><pub-id pub-id-type="pmid">27213168</pub-id></mixed-citation></ref><ref id="cit0182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name></person-group>. <article-title>Natural and synthetic saponins as vaccine adjuvants</article-title>. <source>Vaccines</source>. <year>2021</year>;<volume>9</volume>(<issue>222</issue>):<fpage>9030222</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines9030222</pub-id>.<pub-id pub-id-type="pmcid">PMC8001307</pub-id><pub-id pub-id-type="pmid">33807582</pub-id></mixed-citation></ref><ref id="cit0183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Welsby</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Detienne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>N&#8217;Kuli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wouters</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bechtold</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>De Wit</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gineste</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reinheckel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Elouahabi</surname><given-names>A</given-names></string-name></person-group>. et al. <article-title>Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>7</volume>:<fpage>663</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2016.00663</pub-id>.<pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></mixed-citation></ref><ref id="cit0184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>L&#246;vgren Bengtsson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Morein</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></string-name></person-group>. <article-title>ISCOM technology-based matrix M&#8482; adjuvant: success in future vaccines relies on formulation</article-title>. <source>Expert Rev Vaccines</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>401</fpage>&#8211;<lpage>403</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id>.<pub-id pub-id-type="pmid">21506635</pub-id></mixed-citation></ref><ref id="cit0185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Altenburg</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Bosman</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>de Vries</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Rimmelzwaan</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Stertman</surname><given-names>L</given-names></string-name></person-group>. <article-title>Matrix-M&#8482; adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice</article-title>. <source>Immunol Res</source>. <year>2018</year>;<volume>66</volume>(<issue>2</issue>):<fpage>224</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12026-018-8991-x</pub-id>.<pub-id pub-id-type="pmid">29594879</pub-id><pub-id pub-id-type="pmcid">PMC5899102</pub-id></mixed-citation></ref><ref id="cit0186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>RTS</surname><given-names>SCTP</given-names></string-name></person-group>. <article-title>First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>1863</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22007715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1102287</pub-id></mixed-citation></ref><ref id="cit0187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Der Meeren</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nduba</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Muyoyeta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Van Brakel</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ayles</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Henostroza</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Thienemann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></string-name></person-group>. et al. <article-title>Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>17</issue>):<fpage>1621</fpage>&#8211;<lpage>1634</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1803484</pub-id>.<pub-id pub-id-type="pmid">30280651</pub-id><pub-id pub-id-type="pmcid">PMC6151253</pub-id></mixed-citation></ref><ref id="cit0188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stertman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Palm</surname><given-names>AKE</given-names></string-name>, <string-name name-style="western"><surname>Zarnegar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Carow</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lunderius Andersson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Carnrot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>G</given-names></string-name></person-group>. et al. <article-title>The matrix-M&#8482; adjuvant: a critical component of vaccines for the 21st century</article-title>. <source>Hum Vaccin Immunother</source>. <year>2023</year>;<volume>19</volume>(<issue>1</issue>):<fpage>2189885</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2023.2189885</pub-id>.<pub-id pub-id-type="pmid">37113023</pub-id><pub-id pub-id-type="pmcid">PMC10158541</pub-id></mixed-citation></ref><ref id="cit0189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Stertman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Flyer</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Massare</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>R-H</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kwilas</surname><given-names>SA</given-names></string-name></person-group>. et al. <article-title>Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>16</issue>):<fpage>1927</fpage>&#8211;<lpage>1935</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.033</pub-id>.<pub-id pub-id-type="pmid">26921779</pub-id></mixed-citation></ref><ref id="cit0190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Reimer</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Lilja</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Stertman</surname><given-names>L</given-names></string-name></person-group>. <article-title>Immune enhancing properties of the novel Matrix-M&#8482; adjuvant leads to potentiated immune responses to an influenza vaccine in mice</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>13</issue>):<fpage>1725</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.01.039</pub-id>.<pub-id pub-id-type="pmid">23384754</pub-id></mixed-citation></ref><ref id="cit0191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Plested</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fiske</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pham</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cloney-Clark</surname><given-names>S</given-names></string-name></person-group>. et al. <article-title>Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial</article-title>. <source>Lancet Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00192-4</pub-id>.<pub-id pub-id-type="pmid">34563277</pub-id></mixed-citation></ref><ref id="cit0192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toback</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galiza</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cosgrove</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Galloway</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Swift</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Rajaram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graves-Jones</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>F</given-names></string-name></person-group>. et al. <article-title>Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Respir Med</source>. <year>2022</year>;<volume>10</volume>(<issue>2</issue>):<fpage>167</fpage>&#8211;<lpage>179</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(21)00409-4</pub-id>.<pub-id pub-id-type="pmid">34800364</pub-id><pub-id pub-id-type="pmcid">PMC8598212</pub-id></mixed-citation></ref><ref id="cit0193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;hagan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ott</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Seubert</surname><given-names>A</given-names></string-name></person-group>. <article-title>The mechanism of action of MF59&#8211;an innately attractive adjuvant formulation</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>29</issue>):<fpage>4341</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.061</pub-id>.<pub-id pub-id-type="pmid">22682289</pub-id></mixed-citation></ref><ref id="cit0194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Ott</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Nest</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Giudice</surname><given-names>GD</given-names></string-name></person-group>. <article-title>The history of MF59&#174; adjuvant: a phoenix that arose from the ashes</article-title>. <source>Expert Rev Vaccines</source>. <year>2013</year>;<volume>12</volume>(<issue>1</issue>):<fpage>13</fpage>&#8211;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erv.12.140</pub-id>.<pub-id pub-id-type="pmid">23256736</pub-id></mixed-citation></ref><ref id="cit0195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cantisani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pezzicoli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cioncada</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Malzone</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Oro</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Piccioli</surname><given-names>D</given-names></string-name></person-group>. <article-title>Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>194</volume>(<issue>4</issue>):<fpage>1717</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1400623</pub-id>.<pub-id pub-id-type="pmid">25589069</pub-id></mixed-citation></ref><ref id="cit0196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vono</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taccone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caccin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gallotta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Donvito</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Falzoni</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Palmieri</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pallaoro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Di Virgilio</surname><given-names>F</given-names></string-name></person-group>. et al. <article-title>The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2013</year>;<volume>110</volume>(<issue>52</issue>):<fpage>21095</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1319784110</pub-id>.<pub-id pub-id-type="pmid">24324152</pub-id><pub-id pub-id-type="pmcid">PMC3876261</pub-id></mixed-citation></ref><ref id="cit0197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calabro</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tortoli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baudner</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Pacitto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cortese</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Seubert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wack</surname><given-names>A</given-names></string-name></person-group>. <article-title>Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1812</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.090</pub-id>.<pub-id pub-id-type="pmid">21215831</pub-id></mixed-citation></ref><ref id="cit0198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ko</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Immunology and efficacy of MF59-adjuvanted vaccines</article-title>. <source>Hum Vaccin Immunother</source>. <year>2018</year>;<volume>14</volume>(<issue>12</issue>):<fpage>3041</fpage>&#8211;<lpage>3045</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2018.1495301</pub-id>.<pub-id pub-id-type="pmid">30015572</pub-id><pub-id pub-id-type="pmcid">PMC6343625</pub-id></mixed-citation></ref><ref id="cit0199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chappell</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Mordant</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wijesundara</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Ellenberg</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lackenby</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Cheung</surname><given-names>STM</given-names></string-name>, <string-name name-style="western"><surname>Modhiran</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Avumegah</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>CL</given-names></string-name></person-group>. et al. <article-title>Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial</article-title>. <source>Lancet Infect Dis</source>. <year>2021</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1383</fpage>&#8211;<lpage>1394</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00200-0</pub-id>.<pub-id pub-id-type="pmid">33887208</pub-id><pub-id pub-id-type="pmcid">PMC8055208</pub-id></mixed-citation></ref><ref id="cit0200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>HZ</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>MG</given-names></string-name></person-group>. <article-title>Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis</article-title>. <source>J Infect Dis</source>. <year>2019</year>;<volume>219</volume>(<issue>10</issue>):<fpage>1525</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiy720</pub-id>.<pub-id pub-id-type="pmid">30551178</pub-id><pub-id pub-id-type="pmcid">PMC6775043</pub-id></mixed-citation></ref><ref id="cit0201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levast</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Awate</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Babiuk</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gerdts</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>van Drunen Littel-van den Hurk</surname><given-names>S</given-names></string-name></person-group>. <article-title>Vaccine potentiation by combination adjuvants</article-title>. <source>Vaccines</source>. <year>2014</year>;<volume>2</volume>(<issue>2</issue>):<fpage>297</fpage>&#8211;<lpage>322</lpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines2020297</pub-id>.<pub-id pub-id-type="pmid">26344621</pub-id><pub-id pub-id-type="pmcid">PMC4494260</pub-id></mixed-citation></ref><ref id="cit0202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Laup&#232;ze</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hergli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Collignon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></string-name></person-group>. <article-title>Adjuvant system AS01: helping to overcome the challenges of modern vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id>.<pub-id pub-id-type="pmid">27448771</pub-id></mixed-citation></ref><ref id="cit0203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chomez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></string-name></person-group>. <article-title>GlaxoSmithkline Adjuvant Systems in vaccines: concepts, achievements and perspectives</article-title>. <source>Expert Rev Vaccines</source>. <year>2007</year>;<volume>6</volume>(<issue>5</issue>):<fpage>723</fpage>&#8211;<lpage>739</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14760584.6.5.723</pub-id>.<pub-id pub-id-type="pmid">17931153</pub-id></mixed-citation></ref><ref id="cit0204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cunningham</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Godeaux</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Chlibek</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Diez-Domingo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>S-J</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McElhaney</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Poder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Puig-Barber&#224;</surname><given-names>J</given-names></string-name></person-group>. et al. <article-title>Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>22</issue>):<fpage>2087</fpage>&#8211;<lpage>2096</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1501184</pub-id>.<pub-id pub-id-type="pmid">25916341</pub-id></mixed-citation></ref><ref id="cit0205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bourguignon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baras</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jacob</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Planty</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Elouahabi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Harvengt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Carlsen</surname><given-names>H</given-names></string-name></person-group>. et al. <article-title>Adjuvant system AS03 containing &#945;-tocopherol modulates innate immune response and leads to improved adaptive immunity</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>13</issue>):<fpage>2461</fpage>&#8211;<lpage>2473</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.011</pub-id>.<pub-id pub-id-type="pmid">21256188</pub-id></mixed-citation></ref><ref id="cit0206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>van der Most</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lodaya</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Coccia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lofano</surname><given-names>G</given-names></string-name></person-group>. <article-title>&#8220;World in motion&#8221;&#8211;emulsion adjuvants rising to meet the pandemic challenges</article-title>. <source>NPJ Vaccin</source>. <year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>158</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-021-00418-0</pub-id>.<pub-id pub-id-type="pmcid">PMC8692316</pub-id><pub-id pub-id-type="pmid">34934069</pub-id></mixed-citation></ref><ref id="cit0207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sobolev</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Binda</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Farrell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lorenc</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pradines</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duffner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cason</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zambon</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events</article-title>. <source>Nat Immunol</source>. <year>2016</year>;<volume>17</volume>(<issue>2</issue>):<fpage>204</fpage>&#8211;<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.3328</pub-id>.<pub-id pub-id-type="pmid">26726811</pub-id><pub-id pub-id-type="pmcid">PMC6485475</pub-id></mixed-citation></ref><ref id="cit0208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Del Giudice</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Correlates of adjuvanticity: a review on adjuvants in licensed vaccines</article-title>. <source>Semin Immunol</source>. <year>2018</year>;<volume>39</volume>:<fpage>14</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id>.<pub-id pub-id-type="pmid">29801750</pub-id></mixed-citation></ref><ref id="cit0209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaurav</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Madan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sudheesh</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Pandey</surname><given-names>RS</given-names></string-name></person-group>. <article-title>Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage</article-title>. <source>Artif Cells, Nanomed Biotechnol</source>. <year>2018</year>;<volume>46</volume>(<issue>sup3</issue>):<fpage>818</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21691401.2018.1513941</pub-id>.<pub-id pub-id-type="pmid">30307332</pub-id></mixed-citation></ref><ref id="cit0210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daraee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Etemadi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kouhi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alimirzalu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name></person-group>. <article-title>Application of liposomes in medicine and drug delivery</article-title>. <source>Artif Cells, Nanomed Biotechnol</source>. <year>2016</year>;<volume>44</volume>(<issue>1</issue>):<fpage>381</fpage>&#8211;<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.3109/21691401.2014.953633</pub-id>.<pub-id pub-id-type="pmid">25222036</pub-id></mixed-citation></ref><ref id="cit0211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name></person-group>. et al. <article-title>Recent progress on the versatility of virus-like particles</article-title>. <source>Vaccines</source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>139</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines8010139</pub-id>.<pub-id pub-id-type="pmid">32244935</pub-id><pub-id pub-id-type="pmcid">PMC7157238</pub-id></mixed-citation></ref><ref id="cit0212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nooraei</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bahrulolum</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hoseini</surname><given-names>ZS</given-names></string-name>, <string-name name-style="western"><surname>Katalani</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hajizade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ahmadian</surname><given-names>G</given-names></string-name></person-group>. <article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title>. <source>J Nanobiotechnology</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id>.<pub-id pub-id-type="pmid">33632278</pub-id><pub-id pub-id-type="pmcid">PMC7905985</pub-id></mixed-citation></ref><ref id="cit0213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mishra</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chauhan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Teotia</surname><given-names>D</given-names></string-name></person-group>. <article-title>A comprehensive review on Liposomes: a novel drug delivery system</article-title>. <source>J Drug Delivery Ther</source>. <year>2018</year>;<volume>8</volume>(<issue>6</issue>):<fpage>400</fpage>&#8211;<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.22270/jddt.v8i6.2071</pub-id>.</mixed-citation></ref><ref id="cit0214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schwendener</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Liposomes as vaccine delivery systems: a review of the recent advances</article-title>. <source>Ther Adv Vaccines</source>. <year>2014</year>;<volume>2</volume>(<issue>6</issue>):<fpage>159</fpage>&#8211;<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2051013614541440</pub-id>.<pub-id pub-id-type="pmid">25364509</pub-id><pub-id pub-id-type="pmcid">PMC4212474</pub-id></mixed-citation></ref><ref id="cit0215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name></person-group>. et al. <article-title>Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy</article-title>. <source>Biomaterials</source>. <year>2019</year>;<volume>207</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.03.037</pub-id>.<pub-id pub-id-type="pmid">30947117</pub-id></mixed-citation></ref><ref id="cit0216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Werninghaus</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ritter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jozefowski</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wenzel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Russkamp</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schleicher</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wirtz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kirschning</surname><given-names>C</given-names></string-name></person-group>. et al. <article-title>The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling</article-title>. <source>PloS One</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e53531</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0053531</pub-id>.<pub-id pub-id-type="pmid">23308247</pub-id><pub-id pub-id-type="pmcid">PMC3538599</pub-id></mixed-citation></ref><ref id="cit0217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schweneker</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gorka</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Schweneker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Poeck</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tschopp</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peschel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ruland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gro&#223;</surname><given-names>O</given-names></string-name></person-group>. <article-title>The mycobacterial cord factor adjuvant analogue trehalose-6, 6&#8242;-dibehenate (TDB) activates the Nlrp3 inflammasome</article-title>. <source>Immunobiology</source>. <year>2013</year>;<volume>218</volume>(<issue>4</issue>):<fpage>664</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.imbio.2012.07.029</pub-id>.<pub-id pub-id-type="pmid">22921586</pub-id></mixed-citation></ref><ref id="cit0218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alameh</surname><given-names>M-G</given-names></string-name>, <string-name name-style="western"><surname>Tomb&#225;cz</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bettini</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lederer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ndeupen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sittplangkoon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wilmore</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Gaudette</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Soliman</surname><given-names>OY</given-names></string-name>, <string-name name-style="western"><surname>Pine</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>(<issue>12</issue>):<fpage>2877</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2021.11.001</pub-id>.<pub-id pub-id-type="pmid">34852217</pub-id><pub-id pub-id-type="pmcid">PMC8566475</pub-id></mixed-citation></ref><ref id="cit0219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lederer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bettini</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Parvathaneni</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Painter</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lundgreen</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Weirick</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Muralidharan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Casta&#241;o</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>RR</given-names></string-name></person-group>. et al. <article-title>Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>6</issue>):<fpage>1008</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2022.01.027</pub-id>.<pub-id pub-id-type="pmid">35202565</pub-id><pub-id pub-id-type="pmcid">PMC8808747</pub-id></mixed-citation></ref><ref id="cit0220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Naradikian</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Parkhouse</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cain</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Moody</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Verkerke</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Myles</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname><given-names>E</given-names></string-name></person-group>. et al. <article-title>Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses</article-title>. <source>J Exp Med</source>. <year>2018</year>;<volume>215</volume>(<issue>6</issue>):<fpage>1571</fpage>&#8211;<lpage>1588</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20171450</pub-id>.<pub-id pub-id-type="pmid">29739835</pub-id><pub-id pub-id-type="pmcid">PMC5987916</pub-id></mixed-citation></ref><ref id="cit0221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Widge</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Makhene</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Pruijssers</surname><given-names>AJ</given-names></string-name></person-group>. et al. <article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>25</issue>):<fpage>2427</fpage>&#8211;<lpage>2438</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2028436</pub-id>.<pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></mixed-citation></ref><ref id="cit0222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Makhene</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Coler</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>McCullough</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>LJ</given-names></string-name></person-group>. et al. <article-title>An mRNA vaccine against SARS-CoV-2&#8212;preliminary report</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>20</issue>):<fpage>1920</fpage>&#8211;<lpage>1931</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id>.<pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></mixed-citation></ref><ref id="cit0223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jennings</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></string-name></person-group>. <article-title>The coming of age of virus-like particle vaccines</article-title>. <source>J Biol Chem</source>. <year>2008</year>;<volume>389</volume>(<issue>5</issue>):<fpage>521</fpage>&#8211;<lpage>536</lpage>. doi:<pub-id pub-id-type="doi">10.1515/BC.2008.064</pub-id>.<pub-id pub-id-type="pmid">18953718</pub-id></mixed-citation></ref><ref id="cit0224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walsh</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>KH</given-names></string-name></person-group>. <article-title>Dendritic cells and other innate determinants of T helper cell polarisation</article-title>. <source>Trends Immunol</source>. <year>2013</year>;<volume>34</volume>(<issue>11</issue>):<fpage>521</fpage>&#8211;<lpage>530</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.it.2013.07.006</pub-id>.<pub-id pub-id-type="pmid">23973621</pub-id></mixed-citation></ref><ref id="cit0225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wijewardhana</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>JF</given-names></string-name></person-group>. <article-title>Virus-like particle, liposome, and polymeric particle-based vaccines against HIV-1</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>345</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.00345</pub-id>.<pub-id pub-id-type="pmid">29541072</pub-id><pub-id pub-id-type="pmcid">PMC5835502</pub-id></mixed-citation></ref><ref id="cit0226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></string-name>, <string-name name-style="western"><surname>Zha</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cabral-Miranda</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></string-name></person-group>. <article-title>Major findings and recent advances in virus&#8211;like particle (VLP)-based vaccines</article-title>. <source>Semin Immunol</source>. <year>2017</year>;<volume>34</volume>:<fpage>123</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2017.08.014</pub-id>.<pub-id pub-id-type="pmid">28887001</pub-id></mixed-citation></ref><ref id="cit0227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adepoju</surname><given-names>P</given-names></string-name></person-group>. <article-title>RTS, S malaria vaccine pilots in three African countries</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>393</volume>(<issue>10182</issue>):<fpage>1685</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)30937-7</pub-id>.<pub-id pub-id-type="pmid">31034365</pub-id></mixed-citation></ref><ref id="cit0228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></string-name></person-group>. <article-title>Comparative safety of vaccine adjuvants: a summary of current evidence and future needs</article-title>. <source>Drug Saf</source>. <year>2015</year>;<volume>38</volume>(<issue>11</issue>):<fpage>1059</fpage>&#8211;<lpage>1074</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40264-015-0350-4</pub-id>.<pub-id pub-id-type="pmid">26446142</pub-id><pub-id pub-id-type="pmcid">PMC4615573</pub-id></mixed-citation></ref><ref id="cit0229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Swart</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Kuiken</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Timmerman</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Amerongen</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>van den Hoogen</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Vos</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Neijens</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Andeweg</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Osterhaus</surname><given-names>ADME</given-names></string-name></person-group>. <article-title>Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection</article-title>. <source>J Virol</source>. <year>2002</year>;<volume>76</volume>(<issue>22</issue>):<fpage>11561</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.76.22.11561-11569.2002</pub-id>.<pub-id pub-id-type="pmid">12388717</pub-id><pub-id pub-id-type="pmcid">PMC136757</pub-id></mixed-citation></ref><ref id="cit0230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Barnard</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ong</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>B-H</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>CTK</given-names></string-name>, <string-name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></string-name></person-group>. <article-title>Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>(<issue>6</issue>):<fpage>2995</fpage>&#8211;<lpage>3007</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.02980-14</pub-id>.<pub-id pub-id-type="pmid">25520500</pub-id><pub-id pub-id-type="pmcid">PMC4337527</pub-id></mixed-citation></ref><ref id="cit0231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Audibert</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Lise</surname><given-names>LD</given-names></string-name></person-group>. <article-title>Adjuvants: current status, clinical perspectives and future prospects</article-title>. <source>Trends Pharmacol Sci</source>. <year>1993</year>;<volume>14</volume>(<issue>5</issue>):<fpage>174</fpage>&#8211;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0165-6147(93)90204-W</pub-id>.<pub-id pub-id-type="pmid">8212313</pub-id></mixed-citation></ref><ref id="cit0232"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goto</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Maeyama</surname><given-names>J-I</given-names></string-name>, <string-name name-style="western"><surname>Eto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yoshihara</surname><given-names>S</given-names></string-name></person-group>. <article-title>Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines</article-title>. <source>Vaccine</source>. <year>1993</year>;<volume>11</volume>(<issue>9</issue>):<fpage>914</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0264-410X(93)90377-A</pub-id>.<pub-id pub-id-type="pmid">8212836</pub-id></mixed-citation></ref><ref id="cit0233"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reusche</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Seydel</surname><given-names>U</given-names></string-name></person-group>. <article-title>Dialysis-associated encephalopathy: light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis</article-title>. <source>Acta Neuropathol (Berl)</source>. <year>1993</year>;<volume>86</volume>(<issue>3</issue>):<fpage>249</fpage>&#8211;<lpage>258</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00304139</pub-id>.<pub-id pub-id-type="pmid">8213083</pub-id></mixed-citation></ref><ref id="cit0234"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kramer</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>MD</given-names></string-name></person-group>. <article-title>Aluminium in allergen-specific subcutaneous immunotherapy&#8211;a German perspective</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>33</issue>):<fpage>4140</fpage>&#8211;<lpage>4148</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.05.063</pub-id>.<pub-id pub-id-type="pmid">24892252</pub-id></mixed-citation></ref><ref id="cit0235"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Souza</surname><given-names>JVD</given-names></string-name>, <string-name name-style="western"><surname>Moreira</surname><given-names>NDD</given-names></string-name>, <string-name name-style="western"><surname>Teixeira-Carvalho</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carneiro</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Siqueira</surname><given-names>FAM</given-names></string-name>, <string-name name-style="western"><surname>Vieira</surname><given-names>PMDA</given-names></string-name>, <string-name name-style="western"><surname>Giunchetti</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Moura</surname><given-names>SADL</given-names></string-name>, <string-name name-style="western"><surname>Fujiwara</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Melo</surname><given-names>MN</given-names></string-name></person-group>. et al. <article-title>Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund&#8217;s adjuvant, and monophosphoryl lipid a</article-title>. <source>PlLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>7</issue>):<fpage>e40745</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0040745</pub-id>.<pub-id pub-id-type="pmcid">PMC3400676</pub-id><pub-id pub-id-type="pmid">22829882</pub-id></mixed-citation></ref><ref id="cit0236"><label>236.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Whitehouse</surname><given-names>M</given-names></string-name></person-group>. <article-title>Oily adjuvants and autoimmunity: now time for reconsideration?</article-title><source>Lupus</source>. <year>2012</year>;<volume>21</volume>(<issue>2</issue>):<fpage>217</fpage>&#8211;<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0961203311429818</pub-id>.<pub-id pub-id-type="pmid">22235056</pub-id></mixed-citation></ref><ref id="cit0237"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vera-Lastra</surname><given-names>O</given-names></string-name></person-group>. et al. <article-title>Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld&#8217;s syndrome)</article-title>. <source>Lupus</source>. <year>2012</year>;<volume>21</volume>(<issue>2</issue>):<fpage>128</fpage>&#8211;<lpage>135</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0961203311429317</pub-id>.<pub-id pub-id-type="pmid">22235042</pub-id></mixed-citation></ref><ref id="cit0238"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Bruijn</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gerez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nauta</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Giezeman</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Palache</surname><given-names>B</given-names></string-name></person-group>. <article-title>Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>26</volume>(<issue>1</issue>):<fpage>119</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2007.10.051</pub-id>.<pub-id pub-id-type="pmid">18063446</pub-id></mixed-citation></ref><ref id="cit0239"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gjorup</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Skinh&#248;j</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Stoffel</surname><given-names>M</given-names></string-name></person-group>. <article-title>A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of engerix-B in healthy young adults</article-title>. <source>Scand J Infect Dis</source>. <year>2002</year>;<volume>34</volume>(<issue>8</issue>):<fpage>610</fpage>&#8211;<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00365540110080881</pub-id>.<pub-id pub-id-type="pmid">12238579</pub-id></mixed-citation></ref><ref id="cit0240"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lorent</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Quetin-Leclercq</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mingeot-Leclercq</surname><given-names>M-P</given-names></string-name></person-group>. <article-title>The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells</article-title>. <source>Org Biomol Chem</source>. <year>2014</year>;<volume>12</volume>(<issue>44</issue>):<fpage>8803</fpage>&#8211;<lpage>8822</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C4OB01652A</pub-id>.<pub-id pub-id-type="pmid">25295776</pub-id></mixed-citation></ref><ref id="cit0241"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waite</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Jacobson</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Ennis</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kammer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kensil</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21</article-title>. <source>Vaccine</source>. <year>2001</year>;<volume>19</volume>(<issue>28&#8211;29</issue>):<fpage>3957</fpage>&#8211;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0264-410X(01)00142-6</pub-id>.<pub-id pub-id-type="pmid">11427271</pub-id></mixed-citation></ref><ref id="cit0242"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alving</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Army Liposome Formulation (ALF) family of vaccine adjuvants</article-title>. <source>Expert Rev Vaccines</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>279</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2020.1745636</pub-id>.<pub-id pub-id-type="pmid">32228108</pub-id><pub-id pub-id-type="pmcid">PMC7412170</pub-id></mixed-citation></ref><ref id="cit0243"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wala</surname><given-names>S</given-names></string-name></person-group>. <article-title>Arthritis, a complex connective and synovial joint destructive autoimmune disease: animal models of arthritis with varied etiopathology and their significance</article-title>. <source>J Postgrad Med</source>. <year>2014</year>;<volume>60</volume>(<issue>3</issue>):<fpage>309</fpage>. doi:<pub-id pub-id-type="doi">10.4103/0022-3859.138799</pub-id>.<pub-id pub-id-type="pmid">25121375</pub-id></mixed-citation></ref><ref id="cit0244"><label>244.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Aguilar</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Vaccine adjuvants: current state and future trends</article-title>. <source>Immunol Cell Biol</source>. <year>2004</year>;<volume>82</volume>(<issue>5</issue>):<fpage>488</fpage>&#8211;<lpage>496</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.0818-9641.2004.01272.x</pub-id>.<pub-id pub-id-type="pmid">15479434</pub-id></mixed-citation></ref><ref id="cit0245"><label>245.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turley</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Rupp</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Wolfson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tussey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kavita</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Stanberry</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>A</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of a recombinant M2e&#8211;flagellin influenza vaccine (STF2. 4xM2e) in healthy adults</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>32</issue>):<fpage>5145</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.041</pub-id>.<pub-id pub-id-type="pmid">21624416</pub-id></mixed-citation></ref><ref id="cit0246"><label>246.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></string-name></person-group>. <article-title>Freeing vaccine adjuvants from dangerous immunological dogma</article-title>. <source>Expert Rev Vaccines</source>. <year>2008</year>;<volume>7</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14760584.7.1.7</pub-id>.<pub-id pub-id-type="pmid">18251687</pub-id></mixed-citation></ref><ref id="cit0247"><label>247.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rockman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dyson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Koernig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Becher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morelli</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Barnden</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>MLK</given-names></string-name>, <string-name name-style="western"><surname>Pearse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maraskovsky</surname><given-names>E</given-names></string-name></person-group>. et al. <article-title>Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>30</issue>):<fpage>3861</fpage>&#8211;<lpage>3868</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.03.032</pub-id>.<pub-id pub-id-type="pmid">24928062</pub-id></mixed-citation></ref><ref id="cit0248"><label>248.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baay</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bollaerts</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Verstraeten</surname><given-names>T</given-names></string-name></person-group>. <article-title>A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>29</issue>):<fpage>4207</fpage>&#8211;<lpage>4214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.004</pub-id>.<pub-id pub-id-type="pmid">29885773</pub-id></mixed-citation></ref><ref id="cit0249"><label>249.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Poggialini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pasqualini</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Trivisani</surname><given-names>CI</given-names></string-name>, <string-name name-style="western"><surname>Vagaggini</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dreassi</surname><given-names>E</given-names></string-name></person-group>. <article-title>Progress towards adjuvant development: focus on antiviral therapy</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>11</issue>):<fpage>9225</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms24119225</pub-id>.<pub-id pub-id-type="pmid">37298177</pub-id><pub-id pub-id-type="pmcid">PMC10253057</pub-id></mixed-citation></ref><ref id="cit0250"><label>250.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>H</given-names></string-name></person-group>. <article-title>Built-in adjuvants for use in vaccines</article-title>. <source>Eur J Med Chem</source>. <year>2022</year>;<volume>227</volume>:<fpage>113917</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113917</pub-id>.<pub-id pub-id-type="pmid">34688011</pub-id></mixed-citation></ref><ref id="cit0251"><label>251.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reiser</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Mosaheb</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Lisk</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Platt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wetzler</surname><given-names>LM</given-names></string-name></person-group>. <article-title>The TLR2 binding neisserial porin PorB enhances antigen presenting cell trafficking and cross-presentation</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>736</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-017-00555-4</pub-id>.<pub-id pub-id-type="pmid">28389664</pub-id><pub-id pub-id-type="pmcid">PMC5428659</pub-id></mixed-citation></ref><ref id="cit0252"><label>252.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lisk</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kuniholm</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Antos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Reiser</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Wetzler</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Toll-like receptor ligand based adjuvant, PorB, increases antigen deposition on germinal center follicular dendritic cells while enhancing the follicular dendritic cells network</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>1254</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.01254</pub-id>.<pub-id pub-id-type="pmid">32636846</pub-id><pub-id pub-id-type="pmcid">PMC7318107</pub-id></mixed-citation></ref><ref id="cit0253"><label>253.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mosaheb</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Reiser</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Wetzler</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Toll-like receptor ligand-based vaccine adjuvants require intact MyD88 signaling in antigen-presenting cells for germinal center formation and antibody production</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>225</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2017.00225</pub-id>.<pub-id pub-id-type="pmid">28316602</pub-id><pub-id pub-id-type="pmcid">PMC5334362</pub-id></mixed-citation></ref><ref id="cit0254"><label>254.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaur</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Salunke</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></string-name></person-group>. <article-title>Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics</article-title>. <source>Curr Opin Chem Biol</source>. <year>2022</year>;<volume>70</volume>:<fpage>102172</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cbpa.2022.102172</pub-id>.<pub-id pub-id-type="pmid">35785601</pub-id></mixed-citation></ref><ref id="cit0255"><label>255.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></string-name></person-group>. <article-title>Toll-like receptors and innate immunity</article-title>. <source>Nat Rev Immunol</source>. <year>2001</year>;<volume>1</volume>(<issue>2</issue>):<fpage>135</fpage>&#8211;<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.1038/35100529</pub-id>.<pub-id pub-id-type="pmid">11905821</pub-id></mixed-citation></ref><ref id="cit0256"><label>256.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>CC</given-names></string-name></person-group>. <article-title>Enhanced MHC-I antigen presentation from the delivery of ovalbumin by light-facilitated biodegradable poly (ester amide) s nanoparticles</article-title>. <source>J Mater Chem B</source>. <year>2018</year>;<volume>6</volume>(<issue>13</issue>):<fpage>1930</fpage>&#8211;<lpage>1942</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C7TB03233A</pub-id>.<pub-id pub-id-type="pmid">32254359</pub-id></mixed-citation></ref><ref id="cit0257"><label>257.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Treanor</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Strout</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kavita</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Ozer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tussey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>A</given-names></string-name></person-group>. <article-title>Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza&#8211;flagellin fusion vaccine (VAX125, STF2. HA1 SI)</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>31</issue>):<fpage>4897</fpage>&#8211;<lpage>902</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.001</pub-id>.<pub-id pub-id-type="pmid">21596084</pub-id></mixed-citation></ref><ref id="cit0258"><label>258.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mizel</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Bates</surname><given-names>JT</given-names></string-name></person-group>. <article-title>Flagellin as an adjuvant: cellular mechanisms and potential</article-title>. <source>J Immunol</source>. <year>2010</year>;<volume>185</volume>(<issue>10</issue>):<fpage>5677</fpage>&#8211;<lpage>5682</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1002156</pub-id>.<pub-id pub-id-type="pmid">21048152</pub-id><pub-id pub-id-type="pmcid">PMC3756556</pub-id></mixed-citation></ref><ref id="cit0259"><label>259.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mizel</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Graff</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ervin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Lively</surname><given-names>MO</given-names></string-name>, <string-name name-style="western"><surname>Hantgan</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>B</given-names></string-name></person-group>. et al. <article-title>Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates</article-title>. <source>Clin Vaccine Immunol</source>. <year>2009</year>;<volume>16</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00333-08</pub-id>.<pub-id pub-id-type="pmid">18987167</pub-id><pub-id pub-id-type="pmcid">PMC2620661</pub-id></mixed-citation></ref><ref id="cit0260"><label>260.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Treanor</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Tussey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hay</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kavita</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dark</surname><given-names>I</given-names></string-name></person-group>. et al. <article-title>Safety and immunogenicity of a recombinant hemagglutinin influenza&#8211;flagellin fusion vaccine (VAX125) in healthy young adults</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>52</issue>):<fpage>8268</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.10.009</pub-id>.<pub-id pub-id-type="pmid">20969925</pub-id></mixed-citation></ref><ref id="cit0261"><label>261.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aucouturier</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dupuis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deville</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ascarateil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ganne</surname><given-names>V</given-names></string-name></person-group>. <article-title>Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2002</year>;<volume>1</volume>(<issue>1</issue>):<fpage>111</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14760584.1.1.111</pub-id>.<pub-id pub-id-type="pmid">12908518</pub-id></mixed-citation></ref><ref id="cit0262"><label>262.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moreira</surname><given-names>LO</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>DeFreitas</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Qualls</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>El Kasmi</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Modulation of adaptive immunity by different adjuvant&#8211;antigen combinations in mice lacking Nod2</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>(<issue>46</issue>):<fpage>5808</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.08.038</pub-id>.<pub-id pub-id-type="pmid">18789992</pub-id><pub-id pub-id-type="pmcid">PMC2586078</pub-id></mixed-citation></ref><ref id="cit0263"><label>263.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Doorn</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Huckriede</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Hak</surname>, <given-names>E.</given-names></string-name></person-group><article-title>Safety and tolerability evaluation of the use of montanide ISA&#8482; 51 as vaccine adjuvant: a systematic review</article-title>. <source>Human Vaccines &amp; Immunotherapeutics</source>. <year>2016</year>;<volume>12</volume>(<issue>1</issue>):<fpage>159</fpage>&#8211;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2015.1071455</pub-id>.<pub-id pub-id-type="pmid">26378866</pub-id><pub-id pub-id-type="pmcid">PMC4962750</pub-id></mixed-citation></ref><ref id="cit0264"><label>264.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stephenson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>McManus</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Toth</surname><given-names>I</given-names></string-name></person-group>. <article-title>Schistosome vaccine adjuvants in preclinical and clinical research</article-title>. <source>Vaccines</source>. <year>2014</year>;<volume>2</volume>(<issue>3</issue>):<fpage>654</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines2030654</pub-id>.<pub-id pub-id-type="pmid">26344751</pub-id><pub-id pub-id-type="pmcid">PMC4494218</pub-id></mixed-citation></ref><ref id="cit0265"><label>265.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ciarambino</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Crispino</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Buono</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Giordano</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Trama</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Iodice</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Leoncini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Giordano</surname><given-names>M</given-names></string-name></person-group>. <article-title>Efficacy and safety of vaccinations in geriatric patients: a literature review</article-title>. <source>Vaccines</source>. <year>2023</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1412</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines11091412</pub-id>.<pub-id pub-id-type="pmid">37766089</pub-id><pub-id pub-id-type="pmcid">PMC10537287</pub-id></mixed-citation></ref><ref id="cit0266"><label>266.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>WHO</surname></string-name></person-group>. <article-title>Guidelines on the non-clinical evaluation of vaccine adjuvants and adjuvanted vaccines</article-title>. <publisher-loc>Geneva (Switzerland)</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="cit0267"><label>267.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Da Silva</surname><given-names>FT</given-names></string-name>, <string-name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yarzabal</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></string-name></person-group>. <article-title>Safety assessment of adjuvanted vaccines: methodological considerations</article-title>. <source>Hum Vaccin Immunother</source>. <year>2015</year>;<volume>11</volume>(<issue>7</issue>):<fpage>1814</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2015.1043501</pub-id>.<pub-id pub-id-type="pmid">26029975</pub-id><pub-id pub-id-type="pmcid">PMC4514270</pub-id></mixed-citation></ref><ref id="cit0268"><label>268.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gruber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></string-name></person-group>. <article-title>Overview of global regulatory toxicology requirements for vaccines and adjuvants</article-title>. <source>J Pharmacol Toxicol Methods</source>. <year>2012</year>;<volume>65</volume>(<issue>2</issue>):<fpage>49</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vascn.2012.01.002</pub-id>.<pub-id pub-id-type="pmid">22326278</pub-id></mixed-citation></ref><ref id="cit0269"><label>269.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Diseases, N.I.o.A.a.I.</collab></person-group><source><italic toggle="yes">2018 NIAID Strategic Plan For Research On Vaccine Adjuvants</italic></source>. <year>2018</year> [accessed 2014 Jan 17] <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niaid.nih.gov/sites/default/files/NIAIDStrategicPlanVaccineAdjuvants2018.pdf" ext-link-type="uri">https://www.niaid.nih.gov/sites/default/files/NIAIDStrategicPlanVaccineAdjuvants2018.pdf</ext-link>.</mixed-citation></ref><ref id="cit0270"><label>270.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>WHO</surname></string-name></person-group>. <article-title>Guidelines on clinical evaluation of vaccines: regulatory expectations</article-title>. <publisher-loc>Geneva (Switzerland)</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2017</year>.</mixed-citation></ref><ref id="cit0271"><label>271.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Plitnick</surname><given-names>LM</given-names></string-name></person-group>. <part-title>Global regulatory guidelines for vaccines</part-title>. In: <source>Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics</source>. <publisher-loc>West Point (PA)</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2013</year>. p. 225&#8211;41.</mixed-citation></ref><ref id="cit0272"><label>272.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Use, T.E.M.A.E.o.M.f.H.</collab></person-group><source>Guideline on adjuvants in vaccines</source>. <publisher-loc>London</publisher-loc>: <publisher-name>The European Medicines Agency Evaluation of Medicines for Human Use</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="cit0273"><label>273.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mestas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>CC</given-names></string-name></person-group>. <article-title>Of mice and not men: differences between mouse and human immunology</article-title>. <source>J Immunol</source>. <year>2004</year>;<volume>172</volume>(<issue>5</issue>):<fpage>2731</fpage>&#8211;<lpage>2738</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.172.5.2731</pub-id>.<pub-id pub-id-type="pmid">14978070</pub-id></mixed-citation></ref><ref id="cit0274"><label>274.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname><given-names>MVD</given-names></string-name>, <string-name name-style="western"><surname>Plunkett</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>M</given-names></string-name></person-group>. <article-title>Differential regulation of CD8+ T cell senescence in mice and men</article-title>. <source>Mech Ageing Dev</source>. <year>2001</year>;<volume>121</volume>(<issue>1&#8211;3</issue>):<fpage>69</fpage>&#8211;<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0047-6374(00)00198-6</pub-id>.<pub-id pub-id-type="pmid">11164461</pub-id></mixed-citation></ref><ref id="cit0275"><label>275.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>High</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Nikolich-Zugich</surname><given-names>J</given-names></string-name></person-group>. <article-title>Translational research in immune senescence: assessing the relevance of current models</article-title>. <source>Semin Immunol</source>. <year>2012</year>;<volume>24</volume>(<issue>5</issue>):<fpage>373</fpage>&#8211;<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2012.04.007</pub-id>.<pub-id pub-id-type="pmid">22633440</pub-id><pub-id pub-id-type="pmcid">PMC4018581</pub-id></mixed-citation></ref><ref id="cit0276"><label>276.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Domnich</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Arata</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Amicizia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Puig-Barber&#224;</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gasparini</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Panatto</surname><given-names>D</given-names></string-name></person-group>. <article-title>Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>4</issue>):<fpage>513</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.011</pub-id>.<pub-id pub-id-type="pmid">28024956</pub-id></mixed-citation></ref><ref id="cit0277"><label>277.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Young</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Parry</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Wilder-Smith</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>I-Cheng</surname><given-names>MC</given-names></string-name></person-group>. <article-title>Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>2</issue>):<fpage>212</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.013</pub-id>.<pub-id pub-id-type="pmid">27939013</pub-id></mixed-citation></ref><ref id="cit0278"><label>278.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>CD</given-names></string-name></person-group>. <article-title>B cell responses: cell interaction dynamics and decisions</article-title>. <source>Cell</source>. <year>2019</year>;<volume>177</volume>(<issue>3</issue>):<fpage>524</fpage>&#8211;<lpage>540</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2019.03.016</pub-id>.<pub-id pub-id-type="pmid">31002794</pub-id><pub-id pub-id-type="pmcid">PMC6538279</pub-id></mixed-citation></ref><ref id="cit0279"><label>279.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutmuller</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Garritsen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adema</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Regulatory T cells and toll&#8208;like receptors: regulating the regulators</article-title>. <source>Ann Rheum Dis</source>. <year>2007</year>;<volume>66</volume>(<issue>Suppl 3</issue>):<fpage>iii91</fpage>. doi:<pub-id pub-id-type="doi">10.1136/ard.2007.078535</pub-id>.<pub-id pub-id-type="pmid">17934105</pub-id><pub-id pub-id-type="pmcid">PMC2095279</pub-id></mixed-citation></ref><ref id="cit0280"><label>280.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutmuller</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><given-names>den Brok</given-names><surname>MH</surname></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><given-names>Bennink</given-names><surname>EJ</surname></string-name>, <string-name name-style="western"><given-names>Toonen</given-names><surname>LW</surname></string-name>, <string-name name-style="western"><given-names>Kullberg</given-names><surname>BJ</surname></string-name>, <string-name name-style="western"><given-names>Joosten</given-names><surname>LA</surname></string-name>, <string-name name-style="western"><surname>Akira</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><given-names>Netea</given-names><surname>MG</surname></string-name>, <string-name name-style="western"><surname>Adema</surname><given-names>GJ.</given-names></string-name></person-group><article-title>Toll-like receptor 2 controls expansion and function of regulatory T cells</article-title>. <source>J Clin Invest</source>. <year>2006</year>;<volume>116</volume>(<issue>2</issue>):<fpage>485</fpage>&#8211;<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI25439</pub-id>.<pub-id pub-id-type="pmid">16424940</pub-id><pub-id pub-id-type="pmcid">PMC1332026</pub-id></mixed-citation></ref><ref id="cit0281"><label>281.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duong</surname><given-names>VT</given-names></string-name>, <string-name name-style="western"><surname>Skwarczynski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Toth</surname><given-names>I</given-names></string-name></person-group>. <article-title>Towards the development of subunit vaccines against tuberculosis: the key role of adjuvant</article-title>. <source>Tuberculosis</source>. <year>2023</year>;<volume>139</volume>:<fpage>102307</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tube.2023.102307</pub-id>.<pub-id pub-id-type="pmid">36706503</pub-id></mixed-citation></ref><ref id="cit0282"><label>282.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perdomo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zedler</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>K&#252;hl</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Lozza</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Saikali</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sander</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Vogelzang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaufmann</surname><given-names>SHE</given-names></string-name>, <string-name name-style="western"><surname>Kupz</surname><given-names>A</given-names></string-name></person-group>. <article-title>Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis</article-title>. <source>MBio</source>. <year>2016</year>;<volume>7</volume>(<issue>6</issue>):<fpage>e01686</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1128/mBio.01686-16</pub-id>.<pub-id pub-id-type="pmid">27879332</pub-id><pub-id pub-id-type="pmcid">PMC5120139</pub-id></mixed-citation></ref><ref id="cit0283"><label>283.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lai</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Afkhami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haddadi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jeyanathan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments</article-title>. <source>Eur Respir Rev</source>. <year>2015</year>;<volume>24</volume>(<issue>136</issue>):<fpage>356</fpage>&#8211;<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1183/16000617.00002515</pub-id>.<pub-id pub-id-type="pmid">26028646</pub-id><pub-id pub-id-type="pmcid">PMC9487824</pub-id></mixed-citation></ref><ref id="cit0284"><label>284.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clements</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>EB</given-names></string-name></person-group>. <article-title><italic toggle="yes">T</italic>he mucosal vaccine adjuvant LT (R192G/L211A) or dmLT</article-title>. <source>mSphere</source>. <year>2018</year>;<volume>3</volume>(<issue>4</issue>). doi:<pub-id pub-id-type="doi">10.1128/mSphere00215-18</pub-id>.<pub-id pub-id-type="pmcid">PMC6060342</pub-id><pub-id pub-id-type="pmid">30045966</pub-id></mixed-citation></ref><ref id="cit0285"><label>285.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crothers</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>EB</given-names></string-name></person-group>. <article-title>Recent advances in enterotoxin vaccine adjuvants</article-title>. <source>Curr Opin Immunol</source>. <year>2023</year>;<volume>85</volume>:<fpage>102398</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coi.2023.102398</pub-id>.<pub-id pub-id-type="pmid">37976963</pub-id><pub-id pub-id-type="pmcid">PMC11258862</pub-id></mixed-citation></ref><ref id="cit0286"><label>286.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iwanaga</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Wanek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McCombs</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rangel-Moreno</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>EB</given-names></string-name></person-group>. et al. <article-title>Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling</article-title>. <source>Sci Immunol</source>. <year>2021</year>;<volume>6</volume>(<issue>63</issue>):<fpage>eabf1198</fpage>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abf1198</pub-id>.<pub-id pub-id-type="pmid">34516780</pub-id><pub-id pub-id-type="pmcid">PMC8796208</pub-id></mixed-citation></ref><ref id="cit0287"><label>287.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fujihashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kiyono</surname><given-names>H</given-names></string-name></person-group>. <article-title>Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly</article-title>. <source>Exp Gerontol</source>. <year>2014</year>;<volume>54</volume>:<fpage>21</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2014.01.006</pub-id>.<pub-id pub-id-type="pmid">24440991</pub-id><pub-id pub-id-type="pmcid">PMC3989367</pub-id></mixed-citation></ref><ref id="cit0288"><label>288.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>JQ</given-names></string-name>, <string-name name-style="western"><surname>Horvath</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Schmitz</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Sturtz</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Kalaidina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Thapa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alsoussi</surname><given-names>WB</given-names></string-name></person-group>. et al. <article-title>Germinal centre-driven maturation of B cell response to mRNA vaccination</article-title>. <source>Nature</source>. <year>2022</year>;<volume>604</volume>(<issue>7904</issue>):<fpage>141</fpage>&#8211;<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-022-04527-1</pub-id>.<pub-id pub-id-type="pmid">35168246</pub-id><pub-id pub-id-type="pmcid">PMC9204750</pub-id></mixed-citation></ref><ref id="cit0289"><label>289.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reed</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Orr</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>CB</given-names></string-name></person-group>. <article-title>Key roles of adjuvants in modern vaccines</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1597</fpage>&#8211;<lpage>1608</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.3409</pub-id>.<pub-id pub-id-type="pmid">24309663</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>